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Chapter 1 
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Introduction 
 
 
 
Peter Bult 
 
 
  

General introduction 
Breast cancer is the most frequent malignant tumour in women and the incidence is still 
rising. Nowadays, one in 8-9 women will get this disease, resulting in a total of approximately 
13.000 women a year in the Netherlands. Mainly due to a nation-wide breast cancer screening 
programme for women aged 50-75 years, more tumours are detected in an early stage and the 
incidence of (non-invasive) ductal carcinoma in situ has increased. 
Although the disease spectrum has changed, mainly due to the breast cancer screening 
patients still present with primary breast cancer in a high stage. 
In chapter 2 the highest clinical stage of primary breast cancer according to the UICC/TNM 
classification (cT4/pT4) is under study. 
In breast cancer many prognostic factors have been examined in order to predict outcome and 
select patients for adjuvant systemic therapy. In chapter 3 mitotic activity and histological 
grade of invasive breast carcinomas are discussed. 
After introduction of breast conserving surgery, axillary sparing surgery by using the sentinel 
lymph node (SN) procedure has been introduced. Chapter 4 and 5 are dealing with this 
subject.  
Although the incidence of breast cancer is rising, the breast cancer mortality is decreasing, 
probably due to the breast cancer screening and more effective (neo-) adjuvant systemic 
therapies. 
Prevention of breast cancer may be a different strategy in dealing with this disease. 
Prevention of breast cancer plays a role especially in women with high risk of getting breast 
cancer. High risk is based on family history (30% or more life time risk of breast cancer) or 
known BRCA1 or BRCA2 mutations (55-85% life time risk of breast cancer). With 
prophylactic simple mastectomy the risk of getting breast cancer is reduced to less than 10%. 
In chapter 6-9 prophylactic simple mastectomy for this high risk patient group is discussed. 
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Introduction to this thesis 
Patients with clinical T4 (cT4) breast cancer have a poor prognosis and most patients will die 
within 10 years of follow-up (1). Histopathological skin involvement without cT4 breast 
cancer is encountered rather frequently in daily clinical practice and leads to considerable 
discussions within the multidisciplinary breast cancer working group whether these patients 
should be treated like pT4 or pT1-3 patients. Histopathological skin involvement without cT4 
breast cancer is not a separate category in the UICC/TNM classification and is explicitly 
excluded from the pT4 category. T4 breast cancer according to the UICC/TNM classification 
is divided in four categories: T4a: extension to the chest wall, T4b: oedema (including peau 
d’orange), or ulceration of the skin of the breast, or satellite skin nodules confined to the same 
breast, T4c: both T4a and T4b, and T4d: inflammatory carcinoma (2). 
The question is whether a patient group with histopathological skin involvement without cT4 
breast cancer can be determined which has a worse prognosis compared to the patient group 
without skin involvement. 
In chapter 2, the prognostic significance of histopathological skin involvement without cT4 
breast cancer in consecutive breast cancer patients with long-term follow-up, not treated with 
adjuvant systemic therapy, is described. 
 
In order to predict overall survival (OS) and breast cancer specific survival (BCSS) of 
operable breast cancer patients a number of prognostic factors have been studied in the past. 
As a result, the lymph node status, tumour size, histological grade, oestrogen-receptor (ER) 
status, and age are established prognostic factors, and worldwide used in decision-making for 
selecting patients for adjuvant systemic therapy (3-6).  
Although histological grade is an independent prognostic factor, some groups have advocated 
the replacement of histological grade by the mitotic activity index (MAI) (7) or the volume 
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corrected mitotic index (M/V-index) (8, 9), as these would be better prognosticators than 
histological grade. 
The question is whether this can be confirmed in an independent breast cancer patient group. 
In chapter 3, the prognostic impact of the MAI and the M/V-index compared with that of the 
histological grade on survival is evaluated in a cohort of consecutive breast cancer patients 
who were not treated with adjuvant systemic therapy, with a median follow-up of more than 
10 years. 
 
Axillary lymph node status is still the most important prognostic indicator in primary breast 
cancer (6). To provide information about the axillary node status, axillary lymph node 
dissection (ALND) was long considered as the gold standard in breast cancer. However, 
because of the substantial morbidity associated with ALND and the reduced occurrence of 
nodal involvement, the role of ALND as part of a proper diagnostic work-up has been 
questioned. 
Sentinel lymph node (SN) mapping as an alternative way of axillary staging of breast cancer 
has been the subject of substantial research. The majority of published SN reports have 
focused on various methodological aspects like the use of different kind of tracers, the 
learning curve of the surgeons, and the pathological examination of the SN (10). As 
pathological work-up of SNs is usually done with serial sectioning and 
immunohistochemistry, this may lead to detection of more cases with isolated tumour cells 
and micrometastases. 
The question is whether finding more cases with isolated tumour cells and micrometastases is 
of prognostic significance. 
In chapter 4, a short summary of SN data in breast cancer at the time will be given. This 
chapter focuses on the impact of the SN procedure on the increased detection of axillary nodal 
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micrometastases and isolated tumour cells. The prognostic relevance of micrometastases and 
isolated tumour cells and their impact on stage migration and on decision making for adjuvant 
systemic therapy will be discussed. 
 
Based on figures from the pre-SN era, it was assumed that a completion ALND could be 
avoided in approximately 60% of patients with operable breast cancer by performing a SN 
biopsy (11). 
Obviously, a reliable examination of the SN by the pathologist is crucial, because a false-
negative finding may result in undertreatment both locally and systemically. Consequently, 
pathologists have intensified the examination of the SN by using serial sectioning and 
immunohistochemistry (IHC), whereas previously, the axillary lymph nodes were examined 
by haematoxylin and eosin (H&E) in one or two slides only. Unfortunately, internationally, 
there is no consensus on the SN pathology protocol to be used (12, 13). At present, therefore, 
various hospitals use different SN pathology protocols. So far, there are no data on whether 
differences in SN pathology protocols affect subsequent surgical treatment strategies. 
The hypothesis is that a more extensive pathology protocol will lead to more ALNDs because 
of the detection of more cases with isolated tumour cells and micrometastases. 
In chapter 5, prospectively collected clinical and pathologic data on breast cancer patients 
who underwent a SN procedure in four different hospitals in the eastern part of the 
Netherlands are presented. In the four involved hospitals, different pathology protocols 
existed and the effect on the numbers of completion ALNDs performed are presented and 
discussed. 
 
In women with high risk of developing breast cancer preventive options may be of great value 
in reducing the breast cancer prevalence and breast cancer deaths in these patients. The 
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decision regarding whether and when to undergo prophylactic mastectomy for hereditary 
breast cancer prevention is quite complex. A particular subject of debate is the utility of 
mastectomy for breast cancer prevention. Some studies have stressed the paradox of 
performing more extensive surgery for breast cancer prevention than for actual disease (14-
16). The gain in life expectancy may not be large (17, 18) and the effects of prophylactic 
mastectomy on quality of life are not precisely known (19, 20). Recent studies support the 
concept that mastectomy is effective for breast cancer prevention in women at high hereditary 
risk of breast cancer (21, 22). The effects of chemopreventive drugs, like tamoxifen, for the 
prevention of hereditary breast cancer are uncertain (23). 
Little is known about the early stages of breast cancer development in inherited forms of the 
disease. Identification of premalignant lesions in prophylactically removed breasts would add 
plausibility to the concept of breast cancer risk reduction by prophylactic mastectomy in 
women at high hereditary risk of breast cancer. 
The hypothesis is that precursor lesions, like ductal carcinoma in situ (DCIS), lobular 
carcinoma in situ (LCIS), atypical lobular hyperplasia (ALH), and atypical ductal hyperplasia 
(ADH) can be found in prophylactically removed breast, and in a higher frequency than in 
breasts of patients without a hereditary breast cancer risk. 
In chapter 6, a prospective study on prophylactic mastectomy specimens from women with a 
hereditary predisposition for breast cancer (i.e., women with a 30% to 85% lifetime risk of 
developing breast cancer) is presented, with special attention to the prevalence of high-risk 
histopathological lesions and to determine the variables related to, and predictive for, the 
presence of such high-risk lesions. 
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In Chapter 7, comments are given to a review (24), based on the data presented in chapter 6 
and two other studies presenting histopathological findings in prophylactic mastectomy 
specimen (25, 26). 
 
In chapter 8, a study is presented which is an extension of the data presented in chapter 6. 
This chapter focuses on the question if the prevalence of high-risk lesions differs between 
women with and without a BRCA mutation. 
 
In chapter 9, the methodology of examination of prophylactic mastectomy specimens is 
described in detail. 
 
 16  
With this thesis the broad spectrum of breast cancer is shown by discussing their established 
and proposed prognostic factors, and going from axillary sparing by using the sentinel node 
procedure to prophylactic mastectomy for breast cancer prevention in patients with a high 
hereditary risk. 
 17  
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Abstract 
Purpose: Clinical T4 (cT4) breast cancer patients with skin involvement have poor prognosis. 
Little is known about the prognostic impact of microscopic skin involvement without cT4 
breast cancer. We studied such a patient group with long-term follow-up. 
Patients and methods: Four hundred eighty-two patients with primary breast cancer 
diagnosed in the period of 1975-1986 and not treated with adjuvant systemic therapy were 
selected from 739 consecutive patients. 
Results: Median follow-up time was 141 months. Seven patients (1%) had cT4/pT4 breast 
cancer, thirty-three (7%) had microscopical skin involvement without cT4/pT4 breast cancer 
of whom 11 (33%) with dermal lymphatic involvement. In multivariate survival analyses 
breast cancers with non-cT4/pT4 skin involvement showed independent prognostic 
significance for overall survival (OS) (HR: 1.73 (95% CI: 1.16-2.59)) and breast cancer 
specific survival (BCSS) (HR: 2.13 (95% CI: 1.18-3.84)). However, when patients with 
dermal lymphatic involvement were excluded from the entire group of patients with non-
cT4/pT4 skin involvement, the prognosis of the remaining patients was similar to patients 
with comparable tumor characteristics but without skin involvement. On the other hand, for 
patients with tumors with non-cT4/pT4 skin involvement but with dermal lymphatic 
involvement the prognosis was as worse as that of patients with cT4/pT4 breast cancers with 
almost identical HRs for BCSS (4.73 (95% CI: 2.10-10.65) and 5.91 (95% CI: 2.40-14.59), 
respectively). 
Conclusion: Patients with clinically occult dermal lymphatic involvement have equally 
dismal prognosis as patients with cT4/pT4 breast cancer. Therefore, tumors with lymph vessel 
type skin involvement should be included in the cT4/pT4 category. 
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Introduction 
Clinical T4, pathologically confirmed (cT4/pT4), breast cancer patients with skin involvement 
have poor prognosis and many of them will die within 10 years of follow-up (1). Little is 
known about the prognostic impact and the optimal management of patients with microscopic, 
clinically occult, skin involvement, thus without a cT4/pT4 breast cancer (non-cT4/pT4 skin 
involvement). There is often considerable discussion within the multidisciplinary breast 
cancer working group on whether these patients should be treated like pT4, pT1-3, or, 
perhaps, as a completely separate group of patients. This uncertainty is based on the absence 
of data about the prognostic implication of this condition.  
T4 breast cancer according to the UICC/TNM classification is divided into four subgroups: 
T4a: extension to chest wall, T4b: edema (including peau d’orange), or ulceration of the skin 
of the breast, or satellite skin nodules confined to the same breast, T4c: both T4a and T4b, and 
T4d: inflammatory carcinoma (2). Microscopic, clinically occult skin involvement without 
cT4/pT4 breast cancer is not a separate category in the (UICC/TNM) classification. This type 
of tumor is included in the pT1-3 category and is explicitly excluded from the pT4 category. 
In present study, we evaluate the prognostic significance of clinically occult non-cT4/pT4 
skin involvement in breast cancer patients, not treated with adjuvant systemic therapy, with 
long-term follow-up.  
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Patients and methods 
Patients 
From 1975 through 1986 a total of 739 consecutive patients living in the city of Nijmegen 
with primary invasive breast cancer were treated in the Radboud University Nijmegen 
Medical Centre and the Canisius Wilhelmina Hospital, in Nijmegen, the Netherlands. 
Seventy-two (10%) cases were excluded from analyses because of various reasons (no 
histology of the primary tumor, histological slides not available, or of poor quality, etc). From 
the remaining 667 patients 121 patients (18%) received adjuvant systemic therapy and from 
26 patients (4%) it was unknown if adjuvant systemic therapy was given. Additionally, form 
the 520 patients who did not receive adjuvant systemic therapy, 36 patients (7%) had 
synchronous or metachronous bilateral breast cancer and from 2 patients skin involvement 
was unknown, leaving 482 patients for analyses.  
Patient characteristics are summarized in table 1. The median age at diagnosis of the 482 
patients was 62 years. Most patients (92%) were treated by modified radical mastectomy and 
266 patients (55%) received locoregional radiotherapy, 5 of the 7 cases with cT4/pT4 breast 
cancer and 20 (69%) of the 33 cases with microscopical skin involvement without cT4/pT4 
breast cancer.  
 
Pathology review 
One pathologist (PB) reviewed the histological slides and records of all cases.  
Histopathological skin involvement, including the skin of the nipple, was defined as direct 
extension of invasive tumor into the dermal connective tissue, or the presence of 
microscopical or macroscopical invasive satellite lesions, or involved lymph vessels in the 
dermal connective tissue, or some combinations of all of these (2). We assessed in addition 
whether the microscopical skin involvement was the manifestation of a cT4 tumor or a feature 
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without the presence of a cT4 tumor. The following pathological variables were determined: 
tumor size and type, tumor grade (based on the grading system of Elston and Ellis (3)), skin 
involvement, and axillary node status.  
 
Statistical analysis 
Only patients living in the city of Nijmegen were included in this study, because the follow-
up data (alive or not) could be retrieved with high reliability from the city archives. When a 
patient died, the medical record was retrieved from the archive and the cause of death was 
estimated, if necessary after consultation with the medical team involved. One patient died 
shortly after diagnosis and treatment, resulting in a follow-up of 0 months. All other patients 
had a follow-up of at least 2 months. Thirteen patients (3%) were lost during follow-up. All 
women who were lost during follow-up or were alive at the end of follow-up were right 
censored.  
Survival curves were computed using the Kaplan-Meier technique. P-values for differences 
between survival curves were calculated with the log-rank test.  
The prognostic impact of the variables was first studied by univariate analyses by estimation 
of the hazard rate ratio (HR) of having an event (death by any cause and death from breast 
cancer) per unit of time, along with its 95% confidence interval (CI) by applying the Cox 
proportional hazards method.  
Independence of prognostic variables was assessed by performing a multivariate Cox 
proportional hazards model. 
 28  
Table 1. Patient characteristics and pathological variables of the 482 cases. 
Patient characteristic  N (%) 
Age at diagnosis (years) Median: 62; range: 25-93 
25-35 
36-49 
50-74 
≥ 75 
482  (100) 
    9      (2) 
  75    (16) 
322    (67) 
  76    (16) 
Type of operation Mastectomy 
Breast conserving therapy 
Operation refused 
442    (92) 
  37      (8) 
    3      (1) 
Detection Screen-detected 
Non-screen-detected 
194    (40) 
288    (60) 
Adjuvant locoregional radiotherapy* None 
Given 
Unknown 
163    (34) 
266    (55) 
  53    (11) 
   
Pathological variable   
Tumor size (mm) Range: 1-100 482  (100) 
 ≤ 15  
>15  
≤ 20  
>20 
155    (32) 
327    (68) 
267    (55) 
215    (45) 
Histological tumor type Invasive ductal carcinoma 
Invasive lobular or mixed ductal/lobular carcinoma 
Other 
364    (76) 
  61    (13) 
  57    (12) 
Histological grade Well differentiated 
Moderately differentiated 
Poorly differentiated 
  62    (13) 
164    (34) 
256    (53) 
Histopathological skin involvement Absent 
Present 
442    (92) 
  40      (8) 
Type of skin involvement Clinically (cT4), confirmed by histopathological 
examination (pT4) 
Not clinically, only by histopathological examination (non-
cT4) 
    7      (1) 
 
33      (7) 
Type of skin involvement without 
cT4 breast cancer 
Lymph vessel invasion (with or without other types of skin 
involvement) 
Other types of skin involvement without lymph vessel 
invasion 
  11      (2) 
 
  22      (5) 
Number of positive lymph nodes 0 
1-3 
≥ 4 
Not examined histological 
238    (49) 
  64    (13) 
  17      (4) 
163    (34) 
*: Radiation of breast, or thoracic wall, or internal mammary chain, or axilla, or supraclavicular area, 
or combinations of these modalities. 
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Results  
Selected histopathological variables of the 482 breast cancer cases are summarized in table 1. 
The majority of the tumors was smaller than 2 cm (55%), of ductal type (76%), and poorly 
differentiated (53%). Twenty-five percent were node positive of those examined. 
Of the 482 breast cancer cases 40 had skin involvement, 7 associated with cT4 breast cancer 
(cT4/pT4 breast cancer) and 33 with skin involvement without cT4 breast cancer. 
Table 2 shows the histopathological characteristics of the 40 cases with skin involvement. Six 
of the seven patients with cT4/pT4 breast cancer showed a T4b stage. Of the 33 patients with 
histopathological skin involvement without cT4 breast cancer, most had direct extension of 
their tumor into the skin only (64%). Eleven patients (33%) had lymph vessel invasion in the 
skin, usually with another type of skin involvement (direct extension and/or microscopical 
satellites). 
 
Table 3. Type of skin involvement for the patients (N=40) with histopathological skin involvement. 
 
Type of skin involvement N (%) 
cT4/pT4  
T4b 6    (15)   
T4d 1      (3)   
  
Histopathological skin involvement without cT4 breast cancer  
Only direct extension into the skin 21  (53) 
Only microscopical satellites in the skin 1      (3) 
Only lymph vessel invasion in the skin 1      (3) 
Direct extension into and lymph vessel invasion in the skin 6    (15) 
Microscopical satellites and lymph vessel invasion in the skin 1      (3) 
Direct extension into, microscopical satellites, and lymph vessel invasion in the skin 3      (8) 
  
Total 40  (100) 
 
 
The prognostic impact of cT4/pT4 breast cancers and of breast cancers with non-cT4/pT4 skin 
involvement is shown in figures 1 and 2. For overall survival (Figure 1) the patients with 
cT4/pT4 breast cancers were doing poor and most of them died within 10 years after 
diagnosis (without adjuvant systemic therapy). The patients with breast cancers with non-
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cT4/pT4 skin involvement showed a survival curve in between the curves of patients without 
histopathological skin involvement and of patients with cT4/pT4 breast cancers (P<0.0001).  
As results might be confounded by the overall elderly age in the skin involvement group, the 
results of the BCSS is more informative showing even more distinct differences between the 
survival curves (Figure 2; P<0.0001). 
 
 
Figure 1. Kaplan-Meier curves for overall survival for the prognostic factors breast cancer without 
skin involvement, breast cancer with non-cT4/pT4 skin involvement (without and with dermal 
lymphatic involvement), and cT4/pT4 breast cancer. 
 
 
 
Figure 3 displays the prognostic results in time for BCSS for the four categories; breast 
cancers without skin involvement, breast cancers with non-cT4/pT4 skin involvement without 
and with dermal lymphatic involvement, and patients with cT4/pT4 breast cancers. Patients 
with non-cT4/pT4 lymphatic type skin involvement are doing as worse as the patients with 
cT4/pT4 breast cancers, whereas the patients with non-cT4/pT4 skin involvement without 
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dermal lymphatic involvement have the same BCSS as patients with tumors without skin 
involvement. The OS curves were comparable to those of BCSS (data not shown). 
 
Figure 2. Kaplan-Meier curves for breast cancer specific survival for the prognostic factors breast 
cancer without skin involvement, breast cancer with non-cT4/pT4 skin involvement (without and with 
dermal lymphatic involvement), and cT4/pT4 breast cancer. 
 
 
 
Table 3 summarizes the univariate and multivariate analyses for OS and BCSS of two models 
of skin involvement. Model 1 gives the results of the variables breast cancer with non-
cT4/pT4 skin involvement (including cases without and with dermal lymphatic involvement) 
and cT4/pT4 breast cancer compared to breast cancer without skin involvement. In 
multivariate analyses cT4/pT4 breast cancer was an independent predictor for BCSS with a 
HR of 5.65 (P=0.0002) and breast cancer with non-cT4/pT4 skin involvement showed a HR 
of 1.73 (P=0.008) for OS and 2.13 (P=0.039) for BCSS. 
In model 2 breast cancers with non-cT4/pT4 skin involvement were divided into a group 
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without and with dermal lymphatic involvement. Prognosis of patients with non-cT4/pT4 skin 
involvement and without dermal lymphatic involvement was not different from the prognosis 
of patients with tumors without skin involvement, with HRs  of 1.22 (P=0.446) for OS and 
1.31 (P=0.524) for BCSS in multivariate analyses. On the other hand, in multivariate 
analyses, the prognosis of the patients with non-cT4/pT4 skin involvement with dermal 
lymphatic involvement showed HRs for BCSS almost identical to those of cT4/pT4 breast 
cancers (4.73 and 5.91, respectively). 
Other independent variables for OS and BCSS were age at diagnosis (P<0.0001 and P=0.01, 
respectively), tumor size (P=0.003 and P=0.001), tumor grade (P=0.03 and P=0.003), and 
axillary node involvement (P<0.0001 for both) (data not shown). 
 
Figure 3. Kaplan-Meier curves for breast cancer specific survival for the prognostic factors breast 
cancer without skin involvement, breast cancer with non-cT4/pT4 skin involvement without dermal 
lymphatic involvement, breast cancer with non-cT4/pT4 skin involvement with dermal lymphatic 
involvement, and cT4/pT4 breast cancer. 
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Table 3. Hazard rate ratio’s for OS and BCSS based on univariate and multivariate analyses of 
cT4/pT4 and non-cT4/pT4 breast cancers. The latter’s with lymphatic and non-lymphatic type skin 
involvement. All compared to breast cancers without skin involvement. 
 
Prognostic variable                                      Overall survival  
 
     Breast cancer specific survival 
Univariate analyses     Multivariate analyses+ Univariate analyses     Multivariate analyses+ 
HR 
(95% CI)          
P*  HR 
(95% CI)            
P**  HR 
(95% CI)            
P*  HR 
(95% CI)            
P** 
Model 1: 
 
Non-cT4/pT4 breast 
cancer with skin 
involvement versus 
breast cancer without 
skin involvement 
  
cT4/pT4 breast cancer 
versus breast cancer 
without skin 
involvement 
 
 
1.81 
(1.22-2.68) 
 
 
 
 
4.89 
(2.31-10.39) 
0.0001   
 
1.73 
(1.16-2.59) 
 
 
 
 
1.90 
(0.85-4.27) 
0.019*** 
 
0.008 
 
 
 
 
 
0.12 
  
 
2.00 
(1.13-3.54) 
 
 
 
 
8.43 
(3.70-19.23) 
<0.0001   
 
2.13 
(1.18-3.84) 
 
 
 
 
5.65 
(2.29-13.90) 
0.0007*** 
 
0.039 
 
 
 
 
 
0.0002 
 
 
           
Model 2: 
 
Non-cT4/pT4 breast 
cancer with non-
lymphatic type skin 
involvement versus 
breast cancer without 
skin involvement 
 
Non-cT4/pT4 breast 
cancer with lymphatic-
type skin involvement 
versus breast cancer 
without skin 
involvement 
 
cT4/pT4 breast cancer 
versus breast cancer 
without skin 
involvement 
 
 
1.20 
(0.73-1.98) 
 
 
 
 
 
7.46 
(3.99-13.94) 
 
 
 
 
 
4.99 
(2.35-10.61) 
<0.0001   
 
1.22 
(0.74-2.04) 
 
 
 
 
 
4.66 
(2.46-8.85) 
 
 
 
 
 
2.02 
(0.90-4.54) 
<0.0001*** 
 
0.44 
 
 
 
 
 
 
<0.0001 
 
 
 
 
 
 
0.088 
  
 
1.07 
(0.47-2.43) 
 
 
 
 
 
8.30 
(3.77-18.28) 
 
 
 
 
 
8.60 
(3.77-19.61) 
<0.0001   
 
1.31 
(0.57-3.01) 
 
 
 
 
 
4.73 
(2.10-10.65) 
 
 
 
 
 
5.91 
(2.40-14.59) 
<0.0001*** 
 
0.53 
 
 
 
 
 
 
0.0002 
 
 
 
 
 
 
0.0001 
+: multivariate analyses performed on all 482 cases; HR: Hazard rate ratio; CI: confidence interval; 
P*: P-values of univariate proportional hazards method computed using the –2log likelihood ratio test; 
P**: P-values based on Wald-statistics for comparison with the reference group in the multivariate 
proportional hazards method; ***: P-values in the multivariate proportional hazards method minus 
covariate with >2 categories; P-value ≥ 0.05 is not significant. The variables age at diagnosis, tumor 
size, tumor grade, and axillary node status were included in both models (data not shown). 
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Discussion 
In the present study we found an independent prognostic power of microscopical skin 
involvement without cT4/pT4 breast cancer (non-cT4/pT4 skin involvement) for both OS and 
BCSS. However, when patients with dermal lymphatic involvement were excluded from the 
entire group of patients with non-cT4/pT4 skin involvement, the prognosis of the remaining 
patients was similar to patients with comparable tumor characteristics but without skin 
involvement. On the other hand, for patients with tumors with non-cT4/pT4 skin involvement 
but with dermal lymphatic involvement the prognosis was as worse as that of patients with 
cT4/pT4 breast cancers with almost identical HRs for BCSS (4.73 and 5.91, respectively) in 
multivariate analyses (Figure 3 & Table 3). 
In daily clinical practice the finding of microscopic skin involvement without cT4 breast 
cancer leads to considerable discussion within the multidisciplinary breast cancer working 
group on how to treat these patients. E.g. how to manage patients with small tumors close to 
and with direct extension into the skin or patients with dermal microscopic lymph vessel 
invasion but without clinical inflammatory cancer? Should these patients be treated with 
locoregional radiotherapy, adjuvant systemic treatment, or both, or is adjuvant treatment not 
necessary in the presence of otherwise favorable patient and tumor characteristics? According 
to the UICC/TNM classification these patients should be managed as having pT1-3 tumors 
(2). Data on the relevance of clinically occult skin involvement without cT4 breast cancer is 
remarkably scarce (4-7). 
Katz et al. (4) found histopathological skin involvement to be of importance for locoregional 
recurrence after mastectomy followed by doxorubicin-based chemotherapy, without 
locoregional radiotherapy in a cohort of 1031 stage II and stage IIIA patients. Patients with 
microscopical invasion of the skin (N=27) or nipple (N=59) experienced a locoregional 
recurrence rate of 32% and 50% after 10 years of follow-up. In patients with 1-3 positive 
lymph nodes, skin and nipple involvement were independent predictors of locoregional 
 35  
recurrence after 10 years of follow-up (38% and 47%, P=0.02 for both). The authors 
concluded that adjuvant irradiation might reduce locoregional recurrence in patients with 
microscopical skin or nipple involvement treated primarily by mastectomy and adjuvant 
systemic therapy. 
Güth et al. (5) examined two distinct groups of patients, one with pT4a-c breast cancer 
according to the UICC/TNM classification and the other with histopathological skin 
involvement but without cT4 breast cancer, and correlated the 3- and 5-years overall survival 
of these two groups of patients.  Patients with pT4a-c breast cancer (N=50) had a 5-years OS 
of 38%, compared to 84% for the patients with histopathological skin involvement without 
cT4 breast cancer (N=26). They concluded that, in agreement with the recommendation for 
UICC/TNM classification (2), histopathological skin involvement without cT4 breast cancer 
should not be classified as pT4 breast cancer. The role of lymph vessel invasion in the skin 
was not assessed. Further, of note, some patients received adjuvant or neoadjuvant systemic 
therapy, which may have biased the results.  
Lucas and Perez-Mesa (6) studied 58 patients with clinically inflammatory breast carcinoma 
and 15 patients with “occult” inflammatory cancer (dermal lymphatic invasion without 
clinical inflammation) in respect to 5-years follow-up. Both patient groups showed poor 
survival, although the “occult” inflammatory patient group did slightly better (5-years 
survival 4% and 17%, respectively). The authors concluded that either clinical or pathological 
criteria justify the use of the term “inflammatory breast carcinoma”.  
Recently, the relevance of non-uniform classification practices in breast cancer with non-
inflammatory skin involvement was highlighted by an international survey, in combination 
with a retrospective study in 182 patients (7). Patients with non-inflammatory 
histopathological skin involvement were divided into two categories. Patients with clinical 
skin signs (N=119) were compared to patients without clinical skin signs (N=63), all having a 
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follow-up of at least 5 years. The latter had a significantly better BCSS in comparison to the 
first group (P=0.002). If these patient groups, however, were divided based on the opinion of 
another 24 pathology departments, the statistical data would have been considerably distorted. 
This analysis underscores the need of a uniform classification of breast cancer skin 
involvement.   
In conclusion, we have shown that patients with breast cancers with clinically occult skin 
involvement (non-cT4/pT4 skin involvement), who were not offered adjuvant systemic 
therapy had poor prognosis. Patients with tumors with non-cT4/pT4 skin involvement but 
with dermal lymphatic involvement had a particularly dismal prognosis similar to that of 
patients with cT4/pT4 breast cancers. We therefore propose to include tumors with clinically 
occult dermal lymphatic involvement into the UICC/TNM cT4/pT4 category and that patients 
with this type of tumors should thus be treated as those with cT4/pT4 breast cancers. 
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Abstract 
We evaluated with up to 28 years follow-up, the prognostic value of the mitotic activity index 
(MAI) and the volume corrected mitotic index (M/V-index) compared with that of the 
histological grade in breast cancer patients not treated with adjuvant systemic therapy. 
Of 739 consecutive patients living in the city of Nijmegen, the Netherlands, 477 patients with 
primary unilateral breast cancer were not treated with adjuvant systemic therapy and eligible 
for the study.  
In multivariate survival analyses the MAI and M/V-index showed similar hazard ratios (HRs) 
compared to HRs of histological grade for overall survival (OS) (HR: 1.45, 1.48, and grade II 
versus grade I (GII/GI) 1.34, grade III versus grade I (GIII/GI) 1.53, respectively) and for 
breast cancer specific survival (BCSS) (HR: 1.27, 1.57, and (GII/GI) 1.57, (GIII/GI) 2.32, 
respectively). Other independent prognostic variables for OS and BCSS were age at 
diagnosis, tumour size, and number of positive lymph nodes. 
In the present study with long term follow-up, we compared the prognostic value of mitotic 
activity with that of histological grade and found no advantage for the mitotic activity in 
predicting either BCSS or OS and concluded that histological grade and the mitotic activity 
were equally informative in predicting patient outcome. 
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Introduction 
In order to predict overall survival (OS) and breast cancer specific survival (BCSS) of breast 
cancer patients a number of prognostic factors have been studied in the past. As a result, the 
lymph node status, tumour size, histological grade, oestrogen-receptor (ER) status, and age 
are established prognostic factors, and worldwide used in decision-making for selecting 
patients for adjuvant systemic therapy (1-4).  
Although histological grade proved to be an independent prognostic factor, some groups have 
advocated the replacement of histological grade by the mitotic activity index (MAI) (5) or the 
volume corrected mitotic index (M/V-index) (6, 7), as these would be better prognosticators 
than histological grade. These latter prognosticators have indeed proven to be able to divide 
primary breast cancer patients into groups with different prognosis. The MAI, the number of 
mitoses in ten consecutive high power fields (HPFs), can differentiate into a good prognosis 
group when the MAI is <10 and a poor prognosis group when the MAI is ≥ 10. This counts 
for the total group of breast cancer patients as well as for both the node-negative (N0) and 
node-positive (N+) subgroups (10-12). Also an intermediate prognosis group can be discerned 
when the MAI is divided in <10 (good), 10-20 (intermediate), and >20 (poor) (13). An 
alternative for the MAI is the M/V-index, the number of mitoses per mm2 tumour (7, 14-17). 
However, follow-up in most of the studies with these mitotic indices varies considerably and 
is usually relatively short. Besides, some of these studies did not include multivariate analyses 
to address the independent prognostic effect. 
In present study, based on the Nijmegen breast cancer archive, we had the opportunity to 
evaluate the prognostic impact of the MAI and the M/V-index compared with that of the 
histological grade on survival in a cohort of consecutive breast cancer patients who were not 
treated with adjuvant systemic therapy, with up to 28 years follow-up (median 12 years).  
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Patients and methods 
Patients 
In the period 1975-1986 a total of 739 consecutive primary invasive breast cancer patients, 
living in the city of Nijmegen, were treated in the Radboud University Nijmegen Medical 
Centre and the Canisius Wilhelmina Hospital, in Nijmegen, the Netherlands. Seventy-two 
cases (10%) were excluded from analyses because of various reasons (e.g. no histology of the 
primary tumour, poor quality of the histological slides, etc.).  From the remaining 667 patients 
121 patients (18%) received adjuvant systemic therapy and from 26 patients (4%) it was 
unknown if adjuvant systemic therapy was given. Adjuvant systemic therapy was gradually 
introduces during the inclusion period for N+ disease. None of the N0 patients received 
adjuvant systemic therapy. Additionally, from the 520 patients who did not receive adjuvant 
systemic therapy (neither chemotherapy, nor endocrine therapy), 36 patients (7%) had 
synchronous or metachronous bilateral breast cancer and 7 patients (1%) had T4 breast 
cancer, leaving 477 patients eligible for analyses.  
 
Table 1. Patient characteristics 
 
Variable  N (%) 
Age at diagnosis (years) Median: 61; range: 25-93 
25-35 
36-49 
50-74 
≥ 75 
477 (100) 
9         (2) 
76     (16) 
321   (67) 
71     (15) 
Type of operation Mastectomy 
Breast conserving therapy 
Operation refused 
437   (92) 
38       (8) 
2         (0) 
Detection Screen-detected 
Non-screen-detected 
195   (41) 
282   (59) 
Adjuvant locoregional radiotherapy& None 
Given 
Unknown 
162   (34) 
262   (55) 
53     (11) 
&: Radiation of breast, or thoracic wall, or internal mammary chain, or axilla, or supraclavicular area, 
or combinations of these modalities. 
 
 
 45  
Pathology review: 
One pathologist (PB) reviewed all cases, unaware of the follow-up data. For reviewing, the 
original pathology report, microscopical slides of the primary tumour (more than 12,000), 
and, if present, the surgical specimen X-rays were retrieved from the archive. The following 
pathological variables were evaluated: histological tumour type, largest pathological tumour 
diameter, and histological grade with estimation of tubule formation, nuclear pleomorphism, 
and mitotic count (based on the grading system of Elston and Ellis (2)), the MAI and M/V-
index (see below), oestrogen receptor (ER) status, and progesterone receptor (PgR) status 
(were biochemically assessed with the ligand binding assay, in fmol/mg protein [<10 fmol/mg 
protein: negative; ≥ 10 fmol/mg protein: positive] (18)), and number of positive axillary 
lymph nodes. 
 
Mitotic activity index (MAI) and volume corrected mitotic index (M/V-index) 
The MAI (5) in this study was determined as the number of mitoses in 10 consecutive HPFs  
(2.16 mm2), including clear prophase figures, but counting anaphase and telophase mitotic 
figures as one. The M/V-index used was a modification of that described by Haapasalo and 
Pesonen (19). The M/V-index was determined per 2 mm2 tumour area. The tumour volume 
percentage per HPF was subjectively estimated in rates of ten (e.g. 50%, 60%, till 100%). 
This tumour volume percentage was simultaneously recorded with the MAI. The M/V-index 
was calculated using the formula: M/V-index = 200 / [πr2 (∑110 MI/ ∑110 V)]. r = the radius of 
the circular microscopical field / HPF, MI = number of mitoses in a HPF, and V = volume 
fraction of the invasive carcinoma (in percentage) as estimated by the area of the invasive 
carcinoma in a HPF.  
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Table 2. Pathological variables of the 477 breast cancers  
 
Pathological variable  N (%) 
Tumour size (mm) Range: 1-85 477  (100) 
 ≤ 15  
>15  
≤ 20  
>20 
156    (33) 
321    (67) 
268    (56) 
209    (44) 
Histological tumour type Invasive ductal carcinoma 
Invasive lobular carcinoma 
Mixed invasive carcinoma (ductal/lobular) 
Tubular carcinoma 
Mucinous carcinoma 
Medullary carcinoma 
Other 
360    (75) 
60      (13) 
12        (3) 
9          (2) 
17        (3) 
3          (1) 
16        (3) 
Mitotic activity index Range: 1-989 477  (100) 
 ≤ 15 
>15 
131    (27) 
346    (73) 
M/V-index Range: 2-1476 477  (100) 
 ≤ 30 
>30 
131    (27) 
346    (73) 
Histological grade Well differentiated 
Moderately differentiated 
Poorly differentiated 
62      (13) 
163    (34) 
252    (53) 
Oestrogen receptor status* Positive 
Negative 
Unknown 
281    (59) 
87      (18) 
109    (23) 
Progesterone receptor status* Positive 
Negative 
Unknown 
201    (42) 
133    (28) 
143    (30) 
Number of positive lymph nodes& 0 
1-3 
≥ 4 
Not examined histological# 
238    (50) 
63      (13) 
15        (3) 
161    (34) 
M/V-index: Volume corrected mitotic index; *: In fmol/mg protein, <10 fmol/mg protein is negative, 
≥ 10 fmol/mg protein is positive; &: Based on histological examination; #: the axilla was treated with 
radiotherapy, instead of surgery. 
 
 
Statistical analysis 
Only patients living in the city of Nijmegen were included in this study, because the follow-
up data (alive or not) could be retrieved with high reliability from the city administration. 
When a patient died, the medical record was retrieved from the archive and the cause of death 
was determined. If necessary the medical doctors involved were consulted. One patient died 
shortly after diagnosis and treatment, resulting in a follow-up of 0 months. All other patients 
had a follow-up of at least 2 months. Thirteen patients (3%) were lost during follow-up. All 
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women who were alive at the end of follow-up or were lost during follow-up were right 
censored. 
Survival curves were computed using the Kaplan-Meier technique. Differences between 
curves were statistically tested using the log-rank test.  
The prognostic impact of the variables age at diagnosis, tumour size, MAI, M/V-index, 
histological grade, ER and PgR status, and number of positive lymph nodes, were first 
analysed univariately by estimation of the hazard rate ratio (HR) of having an event (death by 
any cause (OS) and death from breast cancer (BCSS)), along with its 95% confidence interval 
by applying the Cox proportional hazards method.  
Independence of prognostic variables was assessed by a multivariate Cox proportional 
hazards model in which the variables were included that proved to be of independent 
prognostic value in the univariate survival analysis. We compared a number of competing 
models for the modelling of OS and BCSS. All models included the univariately independent 
variables and the MAI, or M/V-index, or the histological grade. The Akaike’s Information 
Criterion (AIC) (20) was applied as a measurement of the prognostic influence of the MAI, or 
M/V-index, or histological grade in the multivariate models. The variable (the MAI, or M/V-
index, or histological grade) resulting in the lowest value of the AIC was considered the most 
powerful prognostic factor in de model. Finally, a multivariate Cox proportional hazards 
model was performed for OS and BCSS including the variable (the MAI, or M/V-index, or 
the histological grade) with the lowest value for the AIC in the model for BCSS. 
For the MAI the cut-off value of 15 in 2.16 mm2 was chosen and for the M/V-index 30 in 2 
mm2. 
We used the cut-off value of 15 mm for tumour size. 
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Results 
The median age at diagnosis of the 477 patients was 61 years. Most patients (92%) were 
treated with modified radical mastectomy. Adjuvant locoregional radiotherapy was given to 
262 patients (55%). The median follow-up time was 143 months (range: 0-339 months). 
Patient characteristics are summarized in Table 1.  
The pathological variables are summarized in table 2. The median tumour size was 20 mm. 
Most tumours were of invasive ductal type (75%) or invasive lobular type (13%). The median 
MAI was 34 and the median M/V-index was 64. Thirteen percent of the tumours were well 
differentiated, 34% moderately, and 53% poorly differentiated. Fifty-nine percent of tumours 
were ER and 42% PgR receptor positive. Part of the patients with clinically negative axillary 
lymph nodes the axilla was treated with radiotherapy instead of surgery. Of these 161 patients 
(34%) no histology of the axillary lymph nodes was available. 
 
Kaplan-Meier curves for overall survival: 
The prognostic impact of tumour size, histological grade, MAI, and number of positive lymph 
nodes for overall survival (OS) is presented in figures 1A-D, respectively. Patients with 
tumours of 15 mm or smaller had a better prognosis compared to those with tumours larger 
than 15 mm (Figure 1A; P<0.0001). Grade I tumours did much better than the Grade II and III 
tumours, and the intermediate group (grade II) lain close to and partly overlapped the survival 
curve of patients with grade III tumours (Figure 1B; P=0.0009). If the MAI was low (≤ 15) 
prognosis was better than when it was high (>15) (Figure 1C; P=0.0006). Histological N0 
patients showed a better survival compared to N+ patients. Within the N+ group the patients 
with 1-3 positive lymph nodes had a much better prognosis than the patients with ≥ 4 positive 
lymph nodes (Figure 1D; P<0.0001). 
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Figure 1. Kaplan-Meier curves for overall survival for tumour size (A), histological grade (B), MAI 
(C), and number of positive lymph nodes (D) 
 
        
 A                 B 
 
          
C                           D 
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Figure 2. Kaplan-Meier curves for breast cancer specific survival for tumour size (A), histological 
grade (B), MAI (C), and number of positive lymph nodes (D) 
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Kaplan-Meier curves for breast cancer specific survival: 
(Figures 2A-D) 
The difference between the BCSS curves for tumour size was comparable to that of OS 
(Figure 2A; P<0.001). For histological grade the three categories (grade I, II, and III) were 
more clearly separated from each other, especially when grade II and grade III are considered 
compared to OS (Figure 2B; P=0.001). The differences between the curves for the MAI were 
comparable with the differences between the survival curves for OS (Figure 2C; P=0.017). 
The BCSS curves for the number of positive lymph nodes showed more deviations between 
the curves for 0, 1-3, and ≥ 4 positive lymph nodes than in OS (Figure 2D; P<0.0001).  
The survival curves of the M/V-index for both OS and BCSS are highly comparable to the 
survival curves of the MAI (not shown). 
 
Table 3. Results of the univariate analyses of the prognostic variables related to overall survival and 
breast cancer specific survival 
 
Prognostic variable             Overall survival Breast cancer specific survival 
HR (95% CI) P* HR (95% CI) P* 
Age at diagnosis (years) 
25-35 versus 50-74 
36-49 versus 50-74 
≥ 75 versus 50-74 
 
1.83 (0.90-3.70) 
0.54 (0.38-0.76) 
2.70 (2.03-3.58) 
<0.0001 
 
 
3.36 (1.56-7.24) 
0.95 (0.61-1.46) 
0.62 (0.30-1.29) 
0.007 
Tumour size 
>15 mm versus ≤ 15 mm 
 
1.72 (1.35-2.18) 
<0.0001 
 
 
2.49 (1.64-3.77) 
<0.0001 
Mitotic activity index 
>15 versus ≤ 15 
 
1.53 (1.20-1.96) 
0.0007 
 
 
1.61 (1.09-2.40) 
0.02 
M/V-index 
>30 versus ≤ 30 
 
1.54 (1.20-1.96) 
0.0006 
 
 
1.96 (1.29-2.97) 
0.002 
Histological grade  
Moderate versus well  
Poor versus well 
 
1.51 (1.06-2.16) 
1.70 (1.21-2.39) 
0.01 
 
 
2.04 (1.02-4.07) 
3.00 (1.56-5.79) 
0.002 
Oestrogen receptor status@ 
Negative versus positive 
 
1.05 (0.78-1.40) 
0.76 
 
 
1.52 (1.00-2.31) 
0.05 
Progesterone receptor status@ 
Negative versus positive 
 
1.07 (0.82-1.39) 
0.64 
 
 
1.10 (0.72-1.68) 
0.64 
Number of positive lymph nodes& 
1-3 versus 0 
≥ 4 versus 0 
Unknown versus 0 
 
1.47 (1.06-2.04) 
2.72 (1.57-4.71) 
1.72 (1.35-2.18) 
<0.0001  
3.38 (2.07-5.53) 
6.24 (3.01-12.94) 
3.21 (2.14-4.82) 
<0.0001 
P*: P-values of univariate proportional hazards method computed using the –2log likelihood ratio test; 
M/V-index: Volume corrected mitotic index; @: In fmol/mg protein, <10 fmol/mg protein is negative, 
≥ 10 fmol/mg protein is positive; &: Based on histological examination. 
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Univariate and multivariate analyses: 
Table 3 summarizes the univariate survival analysis for OS and BCSS for age at diagnosis, 
tumour size, MAI, M/V-index, histological grade, ER status, PgR status, and number of 
positive lymph nodes.  
Except for ER and PgR status, all variables showed statistical significant differences for OS 
and BCSS.  
The results of the multivariate analysis for OS and BCSS for the independent prognostic 
variables age at diagnosis, tumour size, and number of positive lymph nodes with histological 
grade are presented in table 4. Age at diagnosis, tumour size, and the number of positive 
lymph nodes were independent predictors of OS and BCSS. Histological grade was nearly an 
independent predictor of OS (P=0.059) and a significant predictor of BCSS (P=0.012). 
 
Table 4. Results of the multivariate analyses of the significant prognostic variables for overall survival 
and breast cancer specific survival 
 
Prognostic variable            Overall survival Breast cancer specific survival 
HR (95% CI) P* HR (95% CI) P* 
Age at diagnosis (years) 
25-35 versus 50-74 
36-49 versus 50-74 
≥ 75 versus 50-74 
 
1.77 (0.85-3.66) 
0.52 (0.37-0.73) 
2.57 (1.93-3.42) 
<0.0001 
 
 
3.19 (1.45-7.01) 
0.88 (0.57-1.35) 
0.51 (0.25-1.06) 
0.012 
 
Tumour size 
>15 mm versus ≤ 15 mm 
 
1.55 (1.20-2.00) 
0.0009  
2.21 (1.42-3.45) 
0.0005 
Histological grade  
Moderate versus well  
Poor versus well 
 
1.34 (0.93-1.94) 
1.53 (1.06-2.20) 
0.059 
 
 
1.57 (0.77-3.19) 
2.32 (1.16-4.64) 
0.012 
 
Number of positive lymph nodes& 
1-3 versus 0 
≥ 4 versus 0 
Unknown versus 0 
 
1.41 (1.01-1.96) 
2.55 (1.45-4.47) 
1.72 (1.35-2.19) 
<0.0001  
3.05 (1.86-5.00) 
4.98 (2.38-10.42) 
3.58 (2.38-5.39) 
<0.0001 
+: Multivariate analyses performed on all 477 cases; HR: Hazard ratio; CI: Confidence interval; P*: P-
values overall test minus covariate with >2 categories; &: Based on histological examination. 
 
 
The results of multivariate survival analysis for OS and BCSS for the MAI, M/V-index, and 
histological grade, when they were included separately in the model (with age at diagnosis, 
tumour size, and number of positive lymph nodes), are summarized in table 5. 
For OS the MAI, M/V-index, and histological grade (poorly differentiated versus well 
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differentiated) were all independently associated with OS, with a HR of approximately 1.5. 
According to the AIC, the M/V-index was slightly more powerful variable than histological 
grade and practically equally powerful as MAI (AIC: 3658, 3663, and, 3659 respectively). 
For BCSS histological grade (poorly differentiated versus well differentiated) and the M/V-
index were independently associated with survival. According to the AIC, histological grade 
was a slightly more powerful variable compared to the MAI or M/V-index (AIC: 1523, 1529, 
and 1525, respectively). 
 
Table 5. Results from multivariate analyses for the prognostic variables MAI, M/V-index, and 
histological grade when included separately in the multivariate model (with age at diagnosis, tumour 
size, and number of positive lymph nodes) for overall survival and breast cancer specific survival with 
hazard rate ratios (HRs) with their 95% confidence intervals (CI) and the Akaike’s Information 
Criterion (AIC) for each model 
 
The prognostic variables MAI, M/V-
index, histological grade included in 
the multivariate model 
Overall survival+ Breast cancer specific survival+ 
HR (95% CI) P* AIC HR (95% CI) P* AIC 
MAI 
>15 versus ≤ 15 
 
1.45 (1.12-1.89) 
 
0.005 
3658.720  
1.27 (0.84-1.93) 
 
0.26 
1528.547 
M/V-index 
>30 versus ≤ 30 
 
1.48 (1.14-1.92) 
 
0.003 
3657.747  
1.57 (1.02-2.43) 
 
0.04 
1525.441 
Histological grade  
Moderate versus well  
Poor versus well 
 
1.34 (0.93-1.94) 
1.53 (1.06-2.20) 
0.12 
0.02 
3663.235  
1.57 (0.77-3.19) 
2.32 (1.16-4.64) 
 
0.22 
0.02 
1523.086 
+: Multivariate analyses performed on all 477 cases; P*: P-values based on Wald-statistics for 
comparison with the reference group in the multivariate proportional hazards method. 
 
The above described analyses were carried out also with dividing the MAI and M/V-index 
into three categories (≤ 15, 16-30, and >30 and ≤ 30, 31-60, and >60, respectively). These 
analyses did not show better results compared with the presented variables (data not shown).
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Discussion 
In present study, we have confirmed the independent prognostic relevance of the classical 
prognostic factors age, histological grade, tumour size, and number of positive lymph nodes 
with up to 28 years follow-up (median 12 years) of patients not treated with adjuvant systemic 
therapy. The prognostic value of histological grade in breast cancer patients has been long ago 
established (2). Some research groups, however, have advocated replacing the histological 
grade by the MAI or the M/V-index. In this study we evaluated the prognostic value of both 
the histological grade and the mitotic indices MAI and M/V-index for OS and BCSS in 477 
primary breast cancer patients. We demonstrated that, although the MAI and M/V-index were 
able to discriminate in good versus poor prognosis, they were not more informative than 
histological grade in predicting survival in patients with primary breast cancer. 
In a previous study we already demonstrated that the MAI was an independent prognostic 
factor for recurrence free survival (RFS), but not for OS (21). To obtain more robust data, we 
initiated this study with a longer follow-up and larger number of patients. In addition, we 
reviewed all cases pathologically, including the microscopic slides of the tumours and used 
BCSS instead of RFS as relevant disease outcome. 
As was shown by others (7-15) the MAI was a significant prognostic factor in univariate 
analysis. We could confirm the independent prognostic significance of the MAI in 
multivariate analysis for OS, but not for BCSS, in contrast to a number of other studies (5, 9, 
10, 12, 13, 15). With respect to the M/V-index we could confirm the findings of the group of 
Aaltomaa and co-workers (7, 14, 16, 17) who showed that the M/V-index was an independent 
prognostic factor for BCSS and was a better prognosticator than the MAI, but less powerful 
than histological grade. 
Histological grade is a widely used prognostic variable for decision making and management 
of patients with primary breast cancer and has been repeatedly been advised in Europe (3, 22, 
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23), whereas the use of the MAI is limited to some centres, most in the Scandinavian 
countries and in the Netherlands. From our study, it may now be concluded that both 
strategies are justified.  
 
In conclusion, our study with a long-term follow-up, confirms that OS and BCSS of breast 
cancer patients is independently predicted by the established prognostic factors of age at 
diagnosis, tumour size, histological grade, and lymph node status. We showed in addition, 
that the MAI and M/V-index were equally informative in predicting outcome as histological 
grade. 
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Summary 
Background Sentinel lymph node (SN) biopsy will increasingly replace axillary lymph node 
dissection (ALND) for staging in breast cancer. For daily practice, examination of the SN by 
serial sectioning (SS) and/or immunohistochemistry (IHC) is being promoted. Use of these 
techniques may result into stage migration due to the increased detection of micro-metastases. 
The consequence may be overshooting of patients with adjuvant therapy, as the prognostic 
relevance of (small) micro-metastases and isolated tumor cells is unclear. 
Methods The prognostic impact of micro-metastases is determined by reviewing ALND 
studies with a follow up of at least 5 years, including more than 100 patients, before the SN 
era. Furthermore, studies in which conventionally haematoxylin-eosin (H&E) negative SNs 
are investigated for occult metastases by SS and/or IHC are reviewed. 
Results In only one of eight studies, occult metastases were an independent risk factor for 
reduced survival. The outcome is dependent on the size of the nodal metastasis. IHC and SS 
as used in the SN procedure indeed induce a shift from pN0 to pN1a (according to TNM). 
Conclusion By the thorough pathologic examination of the SN, isolated tumor cells and 
micro-metastases are more frequently detected. We propose to classify small micro-
metastases (≤ 0.5 mm) in a separate pN1a(min) category (min for minimal) to prevent stage 
migration. As the prognostic relevance of isolated tumor cells and (small) micrometastases 
has not been proven, the value of adjuvant therapy can be questioned for patients with 
otherwise good prognostic factors.  
 
 65  
Introduction 
Axillary lymph node status is still the most important prognostic indicator in primary breast 
cancer (1). The incidence of axillary node involvement has decreased over time, partly due to 
population-based mammographic screening. In fact, nearly 70% of patients will nowadays be 
node-negative (N0) (2). To provide information about the axillary node status, axillary lymph 
node dissection (ALND) was long considered as the gold standard in breast cancer. However, 
because of the substantial morbidity associated with ALND and the reduced incidence of 
nodal involvement, the role of ALND as part of a proper diagnostic work-up has been 
questioned. 
Sentinel lymph node (SN) mapping as an alternative way of axillary staging of breast cancer 
has been the subject of substantial research. The majority of published SN reports have 
focused on various methodological aspects like the use of different kind of tracers, the 
learning curve of the surgeons and the pathological examination of the SN (3). 
In the present paper a short summary of SN data in breast cancer will be given. Subsequently, 
the study design and primary objectives of three recently activated trials will be discussed. 
The main topic of this article is, however, focused on the impact of the SN procedure on the 
increased detection of axillary nodal micro-metastases and isolated tumor cells. The 
prognostic relevance of micro-metastases and isolated tumor cells and their impact on stage 
migration and on decision making for adjuvant systemic therapy will be discussed. 
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The sentinel lymph node 
The SN is defined as the first node(s) that drains the primary tumor. Based on this concept, it 
has been evaluated whether the status of the SN can accurately predict the axillary nodal 
status. In a recent meta-analysis, 11 studies were reported including a total of 912 patients 
with breast cancer, in whom SN dissection was routinely followed by ALND (4). Overall in 
84% of the patients the SN could be identified, with highest identification in 97% of patients 
by the use of albumin radiocolloid, with injection around the tumor site and in a clinically 
negative axilla. The SN (based on H&E staining) was positive in 33% of patients and in 
approximately one-half this was the only positive axillary node. The false-negative rate was 
5%, that is, the percentage of cases with a negative SN while in fact the ALND was positive. 
In general, it can be concluded that SN mapping is a reliable method to retrieve information 
about the axillary status, and thus has the potential to replace ALND with respect to staging. 
 
 67  
What is the value of a complete ALND in addition to staging? 
At the 6th International Conference on Adjuvant Therapy of Primary Breast Cancer it was 
stated that ‘while axillary dissection is considered the proper staging procedure for breast 
cancer, its impact on curability of the disease is unclear, especially in patients with clinically 
N0 disease who are given adjuvant therapy (1). 
In the NSABP-B-04 trial, patients with clinically N0 disease were randomized to radical 
mastectomy (with ALND), or to simple mastectomy (without ALND) but with regional 
irradiation, or to simple mastectomy without irradiation. In this last group ALND was only 
performed as second stage procedure for patients with an axillary recurrence (5). A 10-year 
axillary recurrence rate of 18% was seen if the axilla was left untreated in clinically lymph 
node negative patients, despite the observation that 40% of patients randomized to the ALND 
arm did have lymph node metastases. Moreover, delayed development of clinically positive 
axillary lymph nodes requiring a delayed ALND did not have a negative impact on survival. 
The authors concluded that variations in local-regional treatment in clinical node-negative 
patients were not important in determining survival. However, the conclusion of the NSABP 
trial was highly criticized (6). Firstly, 35% of the patients assigned to simple mastectomy in 
fact had a limited axillary dissection. Secondly, no information was provided with respect to 
what proportion of patients did not require an ALND because of distant metastases. And, 
thirdly, in order to have a 90% chance of detecting a 7% difference 2000 patients are needed. 
Together with conflicting reports of others (7,8), daily clinical practice didn’t change. 
Moreover, ALND was still important for axillary staging. However, with the introduction of 
the SN staging, the question focuses once again on whether there is still a place for ALND 
with respect to therapy. 
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Therapy based on SN findings 
Three large randomized trials have recently been activated which address again some major 
topics concerning local-regional therapy, depending on SN findings. 
 
Prospective validation of a negative SN 
In the NSABP-B-32 trial, 4000 patients with clinically node-negative breast cancer will be 
included. In one arm, patients will have SN dissection immediately followed by ALND. In the 
other arm, the SN is intra-operatively examined: if the SN is negative, then no further surgery 
is performed, while if the SN is positive, a conventional ALND will be performed 
immediately. The NSABP trial is primarily testing whether there is excess morbidity (local 
failure in axilla, decreased disease-free and overall survival) when a SN biopsy is used as the 
only axillary staging procedure if the SN is histologically negative by routine pathologic 
evaluation (given that some SN negative patients, estimated to be 10%, will have disease in 
unresected non-SNs). A secondary aim of the study is to evaluate the clinical significance of 
occult micro-metastases utilizing the same clinical endpoints.  
 
The value of ALND in case of a positive SN 
The trials of the American College of Surgeons Oncology Group (ACOSOG, Z-0010 and Z-
0011) are primarily testing the utility of ALND in the setting of a positive SN. There is no 
stratification on this study with regard to the size of the metastases identified in the SN. In 
other words, a patient with a 2 cm metastasis could get randomized to observation and a 
patient with a 2 mm metastasis could get randomized to an ALND. The Z-0010 trial is a 
registration trial (no randomization). Patients with positive SNs will be offered participation 
in Z-0011 (ALND vs. observation) whereas patients with negative SNs will be observed; 
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however, their nodes will be further examined pathologically similar to NSABP B-32 with a 
goal of determining whether occult micro-metastases impact survival and local recurrence. 
 
Prospective comparison of ALND versus axillary radiotherapy in the case of a positive SN 
In a trial of the European Organization for Research and Treatment of Cancer (EORTC) 3000 
patients with a clinically negative axilla but positive SN will be randomized to ALND or 
axillary radiotherapy. This is an equivalence study, in which it is hypothesized that both 
treatment modalities will result in the same degree of regional control and survival.  
It is important to realize that in all these trials it is allowed to give systemic adjuvant treatment 
with respect to conventional criteria, like nodal status and primary tumor characteristics. This 
may be of special relevance for the ACOSOG trial in which only half of the patients will 
undergo axillary treatment. 
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Pitfalls of serial sectioning and immunohistochemistry 
As local-regional and also systemic therapy will be based on the SN classification a correct 
pathologic examination is crucial. Conventionally, a lymph node examination is based on 
H&E staining of one or two sections through the largest diameter of the lymph node. 
However, it is increasingly advocated to use in addition SS and immunohistochemistry (IHC) 
in the case of an H&E negative SN. The use of SS and IHC has already been tested in H&E 
negative nodes of complete ALND specimens, before the SN era. Studies with a follow up of 
at least 5 years and including more than 100 patients are shown in Table 1 (9-16). 
Occult metastases were detected in 9-31% of originally node-negative cases. As can be 
expected, the detection rate was dependent on the interval of the SS with a 9% detection rate 
at 2 mm interval (9) and 17% detection rate with 24/48 µ interval (10). In other words, the 
probability of detecting a micro-metastasis of a particular size is directly dependent of the 
serial section interval (the histology cutting schema) (17,18). IHC in addition to serial sections 
simply aids the pathologist in identifying small metastases that are cytologically similar in 
appearance and size to sinus histiocytes in the lymph nodes.  
These studies have been reviewed (19), with the conclusion that it has consistently been 
demonstrated that these small metastases have important prognostic implications and 
therefore could be important in making therapeutic decisions. 
However, some serious objections can be made against this conclusion. Firstly, in their review 
the P-values sometimes referred to results obtained in the univariate analysis, while in fact the 
results were non-significant in the multivariate analysis when primary tumor size and grade 
were taken into account (15,16). Secondly, although some subgroup analyses demonstrated 
significant differences, this was in three studies not the case for the whole study population 
(12-14). Thirdly, the size of the occult metastases was not fully appreciated, while this is 
clearly of major importance. 
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Table 1. Detection of occult metastases in H&E node-negative breast cancer (ALND) 
 
Author  
(Ref. 9-16) 
Methodb No. node- 
negative 
Occult (%)c Disease free survival 
(occult vs. no occult) 
Overall survival 
(occult vs. no occult) 
Friedman SS (2 mm) 456 9 NS NS 
Wilkinson SS (24/48 µ) 525 17 (79% <2 mm) NS NS 
Bettelheima SS (12 per node) 921 9 5-yr DFS: 58% vs. 74%d 5-yr OS: 79% vs. 88%d 
Cotea IHC 736 20 NSe NSe 
Hainsworth IHC 343 12 (76% <2 mm) NSf NSf 
Trojani IHC 150 14 NSg NSg 
Nasser SS (150 µ) +IHC 159 31 (62% ≤ 0.2 mm) NSh NS 
McGuckin SS (300 µ) +IHC 208 25 (53% ≤ 0.25 mm) 10-yr DFS: 65% vs. 85%d NSi 
a: For the International (Ludwig) Breast Cancer Study Group: partly the same cohort of patients. 
b: SS: serial sectioning (intervals) stained with H& E; IHC: immunohistochemistry. 
c: Percentage of metastases not detected with conventional H& E, but with additional pathologic 
examination found (percentage of micro-metastases as defined in that specific study with upper 
diameter). 
d: Significant for the whole patient population, in the multivariate analysis independent of primary 
tumour size and grade. 
e: Only significant for subgroup of postmenopausal patients: 10-yr DFS: 49% versus 65%; 10-yr OS: 
62% versus 79%. 
f: Only significant if two or more nodes were involved: 5-yr DFS: 54% versus 84%; 5-yr OS: 70% 
versus 85%. 
g: Only significant in subgroup of ductal carcinoma: 10-yr DFS: 80% versus 90%; 10-yr OS: 85% 
versus 90%. 
h: Only significant in the univariate analysis for occult metastases larger than 0.2 mm: 10-yr DFS: 
51% versus 68%. 
i: Only significant in the univariate analysis: 10-yr OS: 70% versus 90%. 
NS: not significant in the multivariate analysis, for the total study population. 
 
With respect to this latter aspect, it should be pointed out that ‘occult’ is not necessarily 
synonymous for ‘micro’, with the cut-off point of the latter ranging from 0.2 to 2.0 mm 
(13,15). Huvos, Hutter and others first proposed the 2 mm cut point for micro-metastases 
(20). This was later substantiated by the NSABP; however their data suggested 1.3 mm might 
be a better cut point for clinical relevance (21). 
As far as size was reported, a substantial number of occult metastases were in fact macro-
metastases. This is noteworthy, as the survival outcome has been demonstrated to be 
dependent on the size of the nodal metastases (12,13,15,16). These larger occult metastases 
may have confounded the survival outcome in these studies with respect to the impact of 
micro-metastases. 
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The importance of size can also be demonstrated by the following. The International Ludwig 
Breast Cancer Study Group performed two separate important studies in conventionally node-
negative cases. In the first, the nodes of 921 cases were re-examined by SS and H&E staining 
(11), and in the second, nodes from 736 of these 921 patients were also examined by IHC at 
one single section (12). In the first, SS revealed only 9% occult metastases, but with a 
significant survival disadvantage for these patients. In the latter, IHC demonstrated 20% 
occult metastases, yet without an impact on survival outcome for all 736 patients (although 
the subgroup of postmenopausal patients had a significant worse outcome). These at first 
glance conflicting data should focus attention once again toward the impact of size on final 
outcome. The authors reported that for cases with a low to moderate number of tumor cells 
detected by IHC (1-100 cells), tumor was detected by SS and H&E in only 25% of cases (11). 
However, even for cases with >100 cells detected by IHC, 35% were negative on SS by 
routine H&E staining. Furthermore, they reported that the 10 year disease-free survival for 
patients with lymph nodes showing no tumor cells, 1-100 tumor cells or more than 100 tumor 
cells, as identified by IHC was 63% (95% CI 59-67), 57% (49-66), and 40% (18-62), 
respectively. One may conclude that by the use of IHC more frequently smaller micro- 
metastases or even isolated tumor cells will be detected, that are possibly clinically irrelevant 
with respect to survival. This may also explain, why in one of two studies in which both SS 
and IHC were used no difference in survival was seen for the whole study population (15). 
SS and/or IHC of the entire axillary dissection specimen are time-consuming and costly, and 
due to the continuing debate concerning its prognostic relevance, it never became standard 
practice, thereby leaving the micro-metastases dilemma to a theoretical one.  
However, with the introduction of the SN procedure a scrupulous examination of this one (or 
few) node(s) by SS and/or IHC became yet feasible. Even more, it has been promoted by 
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some for routine daily practice, as subsequent anti-breast cancer therapy may be solely based 
on this SN finding (22). 
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The pathologic examination of the SN 
In the studies reported in Table 2, the SN was originally classified as N0 in about two third of 
operated patients (23-29). In the majority of studies, occult metastases were detected in 9-23% 
of originally H&E node-negative cases with higher rates for the combined use of SS and IHC, 
which is in line with the older ALND studies. 
In one study an exceptional high conversion rate was seen of 52% (24/46 patients), with 
micro-metastases in 83% of T1a patients (28). Although this high rate may somehow be 
related to the rather high percentage of originally classified N0, it clearly reflects the small SS 
interval (250 µ) at which the entire lymph node was investigated. In a pilot study of these 
authors, they detected 23% occult metastases with SS at 500 µ (27). Their conclusion was that 
it is very unlikely that all tumor cells detected in the SN with such an extensive examination 
will be of clinical relevance (28). This highlights the pitfall associated with SS and IHC. The 
authors further reported that of 24 patients with occult metastases, 12 had isolated tumor cells 
and 12 had colonies of several thousand malignant cells (size of 1-2 mm), hypothesizing that 
colonies of cells may be clinically significant and individual cells possibly not. 
 
Table 2. Occult SN metastases detected with serial sectioning (SS) and/or immunohistochemistry 
(IHC) in tumor-free SNs by routine H&E 
 
Author 
(Ref. 23-29) 
Method of re-examination of the SN No. H&E node- 
negative cases * 
Occult (%) 
 
Turner IHC 70 (68) 14 
Offodile IHC 25 (62) 12 
Czerniecki IHC 29 (71) 10 
Weaver Two additional sections for H&E + IHC at one level per block 214 (72) 9 
Jannink SS (500 µ) + IHC 13 23 
Dowlatshahi SS (250 µ) + IHC 46 (88) 52 
Cserni SS (49 levels) + IHC 21 (42) 19 
*Between brackets: percentage of patients that were node-negative as part of the complete study 
population. 
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Weaver et al., tested in an excellent designed study the hypothesis underlying the SN concept, 
that is, that tumor cells that gain access to lymphatic channels drain into one or a few lymph 
nodes first before they spread to other lymph nodes (26). Thus, the concept would predict that 
metastases, both occult and non-occult, are more likely to be identified in the SN than in non-
SNs. They indeed observed that (with two additional sections and IHC) occult metastases 
were detected in the SN in 8.9% of patients, compared with occult non-SN metastases in 3.2% 
of patients. Another interesting observation of this group was that deeper sections and IHC 
stains of the SN would only reduce the overall incidence rate of residual axillary lymph node 
metastases (i.e., false-negative rate) from 13.3 to 11.1% (26). Thus, only a small proportion of 
false-negatives can be prevented by a more thorough SN examination. 
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Micro-metastases in the SN versus all ALNs 
The incidence of axillary node metastases in SN versus ALND specimens is also compared 
prospectively (30). In a non-randomized fashion patients were entered in the period 1990-
1994. Patients in the ALND group were enrolled early in the study, before a reliable technique 
for SN was established. The SN group included only those patients in whom the biopsy was 
successful and the procedure was followed by completion ALND. The nodes in the ALND 
specimen were examined at 1-2 levels with H&E staining, while the SN was examined at 6-8 
levels by IHC. In the ALND group 29% of patients had a lymph node metastases compared to 
42% of patients in the SN group. Micro-metastasis (≤ 2 mm) was the sole focus of tumor cells 
in the axillary lymph nodes from 3% of all ALND patients compared to 16% of all SN 
patients. 
In conclusion, due to the SN procedure a substantial proportion of patients who are 
conventionally considered to be node negative will shift into the group of node positive 
patients, due to the presence of only micro-metastases. 
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Classification of micro-metastases and isolated tumor cells 
How are micro-metastases classified according to TNM? TNM does not recommend standard 
pathology protocols. However, it is proposed to distinguish micro-metastasis from isolated 
tumor cells (31). Micro-metastasis is defined as arrest and implantation of tumor cells in the 
organ involved, with extravasation, proliferation, and, often, a stromal reaction with a defined 
size of ≤ 2 mm. Thus, micro-metastases can be diagnosed only by histological examination 
and are classified as pN1a. In cases in which isolated tumor cells are found, the symbol ‘i+’ is 
used in parentheses after pN0, with in the case of SN biopsy the additional symbol ‘sn’, and 
classified as pN0(i+) (sn) (31). TNM provides no solution how to classify multiple locations 
of isolated tumor cells or multiple locations of micro-metastases. 
By the EORTC Breast Cancer Group it is recommended to slice SN paraffin blocks in at least 
three sections at 0.5 mm (500 micron) intervals (32). From each section at least two slides 
should be made: one for H&E staining and one for IHC with cytokeratins. This pathology 
protocol is now also recommended for daily practice in The Netherlands (33). This extensive 
examination of the SN will cause a stage migration. 
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Treatment and classification dilemma in daily practice 
Obviously, some of the patients with micro-metastases or isolated tumor cells in the SN will 
have macro-metastases in the remaining axillary lymph nodes or will have large or poorly 
differentiated primary tumors for which cases adjuvant systemic treatment would have been 
indicated anyhow. However, yet for a substantial number of patients the introduction of the 
SN procedure, by its thorough pathologic examination, may have the unexpected ‘side-effect’ 
of increased administration of adjuvant systemic treatment. The number of patients affected 
regarding change in therapy may be estimated to be 5-15% of all newly diagnosed breast 
cancer patients (30). 
The prognostic relevance of micro-metastases can be questioned, however, the use of 
adjuvant therapy is generally accepted for this situation. But, as long as the prognostic 
relevance of isolated tumor cells has not been validated prospectively, adjuvant therapy 
should in our opinion not be administered to patients classified as pN0(i+) with otherwise 
good prognostic factors. 
In addition, we propose a modified pathology classification based on the size of the lymph 
node micro-metastasis, with small micro-metastases being classified separately to prevent an 
undesired stage migration. Such a classification based on nodal metastasis size will be 
feasible for routine daily clinical practice. Furthermore, it is biologically appropriate, since it 
has been demonstrated that there is a linear correlation between size of nodal metastases and 
survival (12,15,16). 
All proposed limits of the size of the nodal metastases are in fact arbitrary until a survival 
analysis can be conducted on controlled data. 
It may be argued to define the limit at 0.5 mm, as in many (European) countries it is 
recommended to examine the SN at 0.5 mm intervals (with unreliable detection of micro- 
metastases smaller than 0.5 mm). For this latter group of patients the use of adjuvant therapy 
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should also be re-considered. If agreed that adjuvant therapy is not indicated for this 
subgroup, the underdetection of these small micro-metastases will not be of relevance. In 
other words, we would like to propose a modified pN classification, by adding pN1a(min) (for 
minimal micro-metastasis).  
•pN0(i+) in the case of isolated tumor cells. 
•pN1a(min) (mm) for micro-metastasis ≤ 0.5 mm, with size between brackets. 
•pN1a (mm) for micro-metastasis >0.5 to ≤ 2 mm, size between brackets. 
We propose to report the maximum size of lymph node metastasis in addition to the 
categorical TNM pathologic node classification, as was also recommended by the College of 
American Pathologists (34). 
The American Joint Commission on Cancer (Breast Committee) has recently proposed that 
micro-metastases 0.2 mm in greatest size or smaller should be considered as pN0(itc) and that 
metastases larger than 0.2 mm but not larger than 2.0 mm in greatest dimension be considered 
micrometastases pN1(mcm). It is not known at present whether this proposal will be accepted 
by UICC (unpublished and obtained through communication of one of the referees of this 
manuscript with Dr. Singletary, chair of the AJCC breast committee). The general philosophy 
is similar to that proposed by us and discussed by others (35,36). 
Although, the limit (0.5 or 0.2 mm) is arbitrary, it should be recognized that the histology 
cutting schema should directly correlate with it. If the SN is cut into 2 mm slices, the 
examination of four sections taken at 0.5 mm interval ensures detection of all metastases 
larger than 0.5 mm, but metastases of 0.2 mm in size will be detected in only 40% of cases 
(17). For the reliable detection of metastases larger than 0.2 mm 10 sections would be needed. 
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Conclusions 
As the SN hypothesis is supported by growing amounts of data, a SN biopsy will increasingly 
replace ALND for axillary staging. With the introduction of the SN procedure, an 
examination of the SN by SS and/or IHC is being promoted for routine daily practice. This 
scrupulous examination will lead to the detection of more and smaller micro-metastases and 
isolated tumor cells. This implicates that the (disputed) prognostic relevance of larger occult 
metastases as seen in some older studies can not simply be translated to the SN findings. 
To prevent an undesired stage migration, we make a plea for an additional classification 
pN1a(min), if only very small micro-metastases are detected, to discriminate this from pN1a. 
Questions that need to be addressed to are, whether the presence of SN metastases and 
especially the presence of solely SN micro-metastases or isolated tumor cells justify an 
additional complete ALND. Patients with small breast cancers (smaller than 1 or 2 cm), SN 
micro-metastases ≤ 2 mm and no lymphovascular invasion may not require completion 
ALND (37–39). Stratification for isolated cells versus micro- versus macro-metastases in the 
ongoing large randomized trials should be performed to sort this out. 
For daily practice we should only consider patients with pN1a as suitable candidates for 
adjuvant systemic treatment, as this is generally accepted. We suggest to follow prospectively 
good risk pN0(i+) or pN1a(min) patients to address the independent prognostic impact of 
isolated tumor cells and small micro-metastases. Thus, without prospective validation, 
adjuvant therapy outside the setting of a clinical trial should in our opinion not be offered to 
this group of patients. In this way, the number of patients treated with adjuvant therapy will 
be kept more or less unchanged compared to the pre-SN era. 
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Summary 
Background Internationally, there is no consensus on the pathology protocol to be used to 
examine the sentinel lymph node (SN). At present, therefore, various hospitals use different 
SN pathology protocols of which the effect has not been fully elucidated. We hypothesized 
that differences between hospitals in SN pathology protocols affect subsequent surgical 
treatment strategies. 
Methods Patients from four hospitals (A-D) were prospectively registered when they 
underwent a SN biopsy. In hospitals A, B, and C, three levels of the SN were examined 
pathologically, whereas in hospital D, at least seven additional levels were examined. In the 
absence of apparent metastases with hematoxylin and eosin examination, 
immunohistochemical examination was performed in all four hospitals.  
Results In total, 541 eligible patients were included. In hospital D, more patients were 
diagnosed with a positive SN (P<0.001) as compared with hospitals A, B, and C, mainly 
because of increased detection of isolated tumor cells. This led to more completion axillary 
lymph node dissections in hospital D (66.3% of patients (P<0.0001), compared with 29.0% in 
hospitals A, B , and C combined). Positive non-SNs were detected in 13.9% of patients in 
hospital D, compared with 9.7% in hospitals A, B, and C (P=0.70). That is, in 52.4% of 
patients in hospital D, a negative completion axillary lymph node dissection was performed,  
compared with 19.3% of patients in hospitals A, B, and C combined. 
Conclusions Differences in SN pathology protocols between hospitals do have a substantial 
effect on SN findings and subsequent surgical treatment strategies. Whether ultrastaging and, 
thus, additional surgery can offer better survival remains to be determined.  
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Introduction 
The axillary lymph node status is still the most important prognostic factor in primary breast 
cancer. During recent years, the sentinel lymph node (SN) procedure was shown to be a 
reliable strategy to replace axillary lymph node dissection (ALND) in selected patients with 
primary breast cancer (1). On the basis of figures from the pre-SN era, it was assumed that a 
completion ALND could be avoided in approximately 60% of patients with operable breast 
cancer by performing a SN biopsy (2). 
Obviously, a reliable examination of the SN by the pathologist is crucial, because a false-
negative finding may result in undertreatment both locally and systemically. Consequently, 
pathologists have intensified the examination of the SN by using serial sectioning and 
immunohistochemistry (IHC), whereas previously, the axillary lymph nodes were examined 
by hematoxylin and eosin (H&E) in one or two slides only. In the past decade, a lot of 
research focused on this topic, and this was summarized in an excellent review. It was shown 
that an intensified examination of the SN results in a significantly increased detection of 
isolated tumor cells and micrometastases (3). Unfortunately, internationally, there is no 
consensus on the SN pathology protocol to be used (4,5). At present, therefore, various 
hospitals use different SN pathology protocols. 
So far, there are no data on whether differences in SN pathology protocols affect subsequent 
surgical treatment strategies. In our region, we prospectively collected clinical and pathologic 
data on breast cancer patients who underwent a SN procedure. In the four involved hospitals, 
different pathology protocols existed. Therefore, we decided to test the hypothesis that 
differences in SN pathology protocols between hospitals would lead to different numbers of 
completion ALNDs performed, of which the relevance was aimed to be determined. 
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Patients and methods 
Patients from four hospitals (A, B, C, and D) were prospectively registered when they 
underwent a SN biopsy because of a cytological or histological proven invasive breast cancer 
with a clinical tumor size of ≤5 cm. Patients were excluded from a SN biopsy when there was 
clinical proof of axillary lymph node metastases, multifocality in the primary breast tumor, or 
radiotherapy of the breast or axilla in the past; when patients had received neoadjuvant 
systemic therapy; or when the SN was not detectable. The ethics committee approved the 
investigational protocol. 
The prospectively collected data included the lymph node status with the number of nodes 
examined, the number of positive nodes, the size of metastases, classification according to the 
tumor-node-metastasis categories defined in the 6th edition of the TNM Classification of 
Malignant Tumors (6), and the detection method (H&E/IHC). These items were separately 
registered for SNs and non-SNs. Also, primary tumor characteristics (localization, tumor size, 
histology, histological grade, lymph and/or blood vessel invasion, and hormone receptor 
status), patient characteristics (age), and information on the surgical procedure (SN biopsy 
with or without ALND, lumpectomy or mastectomy, and various combinations) were 
collected. 
The surgical procedure was, in all four hospitals, in accordance to the Dutch guidelines for 
treatment of breast cancer (7). SN localization was performed by using the combined 
technique of blue dye and radioisotope in all patients. In the presence of isolated tumor cells, 
micrometastases, or macrometastases in the SN, a completion ALND was recommended. The 
pathology procedure for the SN examination is also described in the Dutch guidelines for 
treatment of breast cancer. However, in these guidelines, only the minimal criteria are 
described. Pathologists are advised to examine the SN with H&E at, at least, three levels of 
the paraffin block, with IHC to be used in case of doubt. These minimal recommendations 
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actually led to quite different local pathology protocols. In hospitals A, B, and C, three levels 
of the SN were pathologically examined. In hospital D, at least 7 additional levels were 
examined (at least 10 levels in total). In the absence of apparent metastases with H&E 
examination, IHC examination was performed in all four hospitals. 
All lymph nodes in the ALND specimen were examined. In hospital B, at least three levels 
were examined with H&E and IHC. In hospital D, the nodes were examined at least at two 
levels with H&E, and in hospitals A and C they were examined at one level. In hospitals A, C, 
and D, IHC examination was used only when H&E examination was not conclusive. 
According to the international tumor-node-metastasis classification (2002), isolated tumor 
cells, micrometastases, and macrometastases were classified as follows: Isolated tumor cells 
[pN0(i+)] were defined as solitary tumor cells or tumor cell clusters ≤0.2 mm. 
Micrometastases [pN1mi ] were >0.2 mm and maximally 2.0 mm. Macrometastases were 
>2.0 mm. For the SN findings, ‘‘SN’’ was added [pN(SN)]. In this article we added pN1+, 
which refers to pN1a and higher pN-positive stages. 
The results of the four hospitals concerning SN findings, performance of completion ALND, 
and non-SN findings after a positive SN finding were compared by using χ2 tests. The 
differences in detecting a positive SN among the four hospitals were corrected for patient and 
primary tumor characteristics with a logistic regression analysis. P<0.05 was considered 
statistically significant. 
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Results 
Patient Characteristics 
Five hundred eighty-seven patients were prospectively included. In 28 patients, there was no 
invasive tumor component, in 13 patients the SN was not detectable, 4 patients received 
neoadjuvant systemic therapy, and 1 patient had already a proven axillary lymph node 
metastasis before surgery. These 46 (7.8%) patients were excluded, leaving 541 patients in 
our prospective database. Of the 541 eligible patients, 198 patients had surgery in hospital A, 
153 patients in hospital B, 104 patients in hospital C, and 86 patients in hospital D. Patient 
and primary tumor characteristics per hospital are listed in Table 1. 
 
Table 1. Patient and primary tumor characteristics per hospital 
 
Patient/tumor characteristics Hospital A (N = 198) Hospital B (N = 153) Hospital C (N = 104) Hospital D (N = 86) 
Age (y) 
<36 
36 to <50 
50 to <60 
60 to <70 
≥70 
Tumor size (cm)a 
≤1.0 
1.1-2.0 
2.1-3.0 
3.1-4.0 
4.1-5.0 
>5.0 
Histological gradeb 
I 
II 
III 
Hormone-receptor statusc 
ER+ and/or PgR+ 
ER- and PgR- 
Lymph and/or blood vessel 
invasion 
No 
Yes 
 
7 (3.6) 
43 (21.7) 
67 (33.8) 
43 (21.7) 
38 (19.2) 
 
29 (14.9) 
84 (43.1) 
58 (29.7) 
15 (7.7) 
6 (3.1) 
3 (1.5) 
 
35 (17.9) 
100 (51.0) 
61 (31.1) 
 
182 (91.9) 
16 (8.1) 
 
 
177 (89.4) 
21 (10.6) 
 
5 (3.3) 
29 (19.0) 
39 (25.5) 
40 (26.1) 
40 (26.1) 
 
46 (30.5) 
70 (46.4) 
25 (16.6) 
8 (5.3) 
1 (.6) 
1 (.6) 
 
66 (43.7) 
63 (41.7) 
22 (14.6) 
 
126 (82.4) 
27 (17.6) 
 
 
144 (94.1) 
9 (5.9) 
 
2 (1.9) 
27 (26.0) 
34 (32.7) 
26 (25.0) 
15 (14.4) 
 
19 (18.6) 
54 (52.9) 
23 (22.6) 
4 (3.9) 
1 (1.0) 
1 (1.0) 
 
31 (29.8) 
45 (43.3) 
28 (26.9) 
 
85 (81.7) 
19 (18.3) 
 
 
92 (88.5) 
12 (11.5) 
 
1 (1.2) 
18 (20.9) 
33 (38.4) 
18 (20.9) 
16 (18.6) 
 
25 (29.1) 
33 (38.4) 
16 (18.6) 
7 (8.1) 
3 (3.5) 
2 (2.3) 
 
26 (31.3) 
34 (41.0) 
23 (27.7) 
 
74 (89.2) 
9 (10.8) 
 
 
50 (58.1) 
36 (41.9) 
Data are n (%). ER, estrogen receptor; PgR, progesterone receptor. a In seven patients, the pathologic 
tumor size was missing. b In seven patients, the histological grade was missing. c In three patients, 
hormone receptor status was missing. 
 
Differences in SN Findings Among the Four Hospitals 
Three hundred thirty-eight (62.5%) patients of the total of 541 eligible patients had a negative 
SN, and 203 (37.5%) a positive SN. In 54 (10.0%) of 541 patients, the SN contained isolated 
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tumor cells, in 53 (9.8%) patients it contained micrometastases, and in 96 (17.7 %) patients it 
contained macrometastases. 
There was a significant difference in detecting a positive SN among the four hospitals 
(P<0.0001). In hospital D, more patients were diagnosed with a positive SN as compared with 
hospitals A, B, and C (P<0.001). 
Of note, when looking at patient and primary tumor characteristics, there were overall no 
large differences among the four hospitals that might have contributed to the difference in SN 
findings (Table 1). However, there was a remarkable difference in the documented presence 
of lymph and/or blood vessel invasion. Lymph and/or blood vessel invasion was seen more 
frequently in hospital D.  
The higher incidence of a positive SN in hospital D compared with hospital A remained 
significant (P<0.001) when corrected, with a logistic regression analysis, for patient and 
primary tumor characteristics. Similarly, with correction for patient and primary tumor 
characteristics, the higher incidence of a positive SN in hospital D compared with hospital B 
remained significant (P<0.001), whereas the higher incidence of a positive SN in hospital D 
compared with hospital C could be partly explained by the presence of lymph and/or blood 
vessel invasion, now resulting in borderline significance for the difference in detecting a 
positive SN between these two hospitals (P=0.06). 
The higher incidence of a positive SN in hospital D was mainly the result of isolated tumor 
cells being far more often documented in patients in this hospital (P<0.0001; Table 2). The 
detection rate of micrometastases and macrometastases in hospital D (32.6% was not 
significantly different from the detection rate in hospitals A and C (24.2% and 39.4% 
respectively) and was only slightly higher than in hospital B (20.9%, P=0.05). 
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Table 2. Sentinel lymph node (SN) status distributed per hospital 
 
pN(SN) Hospital A (N = 198) Hospital B (N = 153) Hospital C (N = 104) Hospital D (N = 86) 
pN0(SN) 
pN0(i+)(SN) 
pN1mi(SN) 
pN1+ (SN)a 
134 (67.7) 
16 (8.1) 
16 (8.1) 
32 (16.1) 
117 (76.5) 
4 (2.6) 
13 (8.5) 
19 (12.4) 
59 (56.7) 
4 (3.9) 
10 (9.6) 
31 (29.8) 
28 (32.5) 
30 (34.9) 
14 (16.3) 
14 (16.3) 
Data are n (%). a pN1+: pN1a and higher pN-positive stages. 
 
 
Completion ALND in the Four Hospitals 
Differences in SN findings led to large differences in the numbers of completion ALNDs 
performed. In hospital D, a completion ALND after a positive SN was performed in 66.3% of 
patients, in 31.8% of patients in hospital A, in 21.6% of patients in hospital B, and in 34.6% 
of patients in hospital C (P <0.0001). One patient in hospital A, 3 patients in hospital B, 5 
patients in hospital C, and 1 patient in hospital D did not undergo a completion ALND despite 
documented isolated tumor cells or micrometastasis in the SN. In three patients there was no 
full completion ALND performed, but there were non-SNs removed during the SN procedure; 
all were negative. 
 
Non-SN Findings in the Four Hospitals 
The number of patients per hospital with positive non-SNs after a positive SN result is shown 
in Table 3 and Fig.1. In hospital D, positive non-SNs were detected in 13.9% of all patients 
who underwent a SN biopsy, compared with 9.6% in hospital A, 9.8% in hospital B, and 9.6% 
in hospital C (P=0.70). When analyzing the number of patients with positive non-SNs after 
completion ALND performed in case of a positive SN, we found a trend for fewer positive 
non-SNs in hospital D (12 [21.1%] of 57), compared with 19 (30.2%) of 63 in hospital A, 15 
(45.5%) of 33  in hospital B, and 10 (27.8%) of 36 in hospital C (P=0.11). 
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Table 3. Number of patients who underwent a sentinel lymph node (SN) biopsy and completion 
axillary lymph node dissection (ALND) per hospital 
 
Hospital Positive SN, 
na  (%) 
 
SNsb 
ALND performed, 
na  (%) 
Positive non-SNs, 
na  (%) 
 
Non-SNsb 
Positive non-SNs, 
na  (% of ALND) 
A (n =198) 
B (n =153) 
C (n =104) 
D (n =86) 
64 (32.3) 
36 (23.5) 
45 (43.3) 
58 (67.4) 
1.6 
1.7 
1.9 
1.9 
63 (31.8) 
33 (21.6) 
36 (34.6) 
57 (66.3) 
19 (9.6) 
15 (9.8) 
10 (9.6) 
12 (13.9) 
9.6 
8.6 
11.4 
18.0 
19 (30.2) 
15 (45.5) 
10 (27.8) 
12 (21.1) 
a Number of patients. b Mean number of lymph nodes removed per patient. 
 
 
Figure 1. Results of patients who underwent a sentinel lymph node (SN) biopsy and completion 
axillary lymph node dissection (ALND) per hospital. 
 
 
The incidence of non-SN metastases was related to the size of the SN metastasis. For instance, 
in hospital A the SN contained isolated tumor cells in 16 patients. All 16 underwent a 
completion ALND, and of these 16 patients, 2 (12.5%) patients had positive non-SNs. Non-
SN metastases occurred in 4 (26.7%) of the 15 patients with micrometastases in the SN. Of 
the 32 patients with macrometastases in the SN, non-SN metastases occurred in 13 (40.6%) 
patients. In hospital D, the SN contained isolated tumor cells in 30 patients. All 30 patients 
underwent a completion ALND, and of these 30 patients, 4 (13.3%) patients had positive non-
SNs. Non-SN metastases occurred in 4 (30.8%) of the 13 patients with micrometastases in the 
SN. Of the 14 patients with macrometastases in the SN, 4 (28.6%) patients had positive non-
SNs in hospital D. This indicates also for this hospital that the incidence of non-SN 
0
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metastases was related to the size of the SN metastasis, although this was less strong related 
compared with hospital A (see for more detailed information per hospital Figs. 2-4). 
 
Figure 2. Status of nonsentinel lymph nodes (non-SNs) removed during completion axillary lymph 
node dissection (ALND) in cases with isolated tumor cells in the sentinel lymph node. In hospital A, 
16 of 16; in B, 1 of 4; in C, 1 of 4; and in D, 30 of 30 cases with isolated tumor cells underwent a 
completion ALND. 
 
 
Figure 3. Status of nonsentinel lymph nodes (non-SNs) removed during completion axillary lymph 
node dissection (ALND) in cases with micrometastasis in the sentinel lymph node. In hospital A, 15 of 
16; in B, 13 of 13; in C, 8 of 10; and in D, 13 of 14 cases with micrometastasis underwent a 
completion ALND. 
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Discussion 
This is the first study ever reported that analyzed the effect of different SN pathology 
protocols on decision making for a completion ALND in breast cancer patients. We 
prospectively compared the policies in four large hospitals in the eastern part of The 
Netherlands. In agreement with recommendations of the European Organization for Research 
and Treatment of Cancer (8), the guidelines in The Netherlands advise to examine the paraffin 
block of the SN at, at least, three levels. We observed that these minimal recommendations 
actually led to substantial differences among the hospitals. In one hospital (D), the SN was 
routinely examined at, at least, 10 levels, whereas the other 3 hospitals routinely examined the 
SN at 3 levels. With similar eligibility criteria for a SN biopsy, the detection frequency of 
isolated tumor cells was 34.9% in hospital D, compared with 8.1% in hospital A, 2.6% in 
hospital B, and 3.9% in hospital C. The detection frequency of micrometastasis was 16.3% in 
hospital D, compared with 8.1% in hospital A, 8.5% in hospital B, and 9.6% in hospital C.  
Other authors have found, on the basis of a study of 1959 patients, a detection frequency of 
isolated tumor cells of 2.9% and a detection frequency of micrometastasis of 8.9% (9). Viale 
et al. (10) found a detection frequency of micrometastasis of 12.9% on the basis of a study of 
4351 patients, but no distinction was made between isolated tumor cells and micrometastasis. 
As in agreement with the guidelines, a completion ALND was recommended in case of a 
tumor-positive SN. An ALND was performed in 66.3% of patients in hospital D, compared 
with 31.8% of patients in hospital A, 21.6% of patients in hospital B, and 34.6% of patients in 
hospital C (P<0.0001). The European Working Group for Breast Screening Pathology 
evaluated aspects of the practice of SN pathology in breast cancer via a questionnaire-based 
survey. The questionnaire revealed that the pathologic examination of SNs throughout Europe 
varies considerably and is not standardized. Some countries have set up national guidelines, 
but many institutions have developed their own guidelines for SN processing, which are more 
 100  
intensive than the national guidelines recommended as a minimum and which are frequently 
determined by the institution’s research strategy (4,5). The European Working Group for 
Breast Screening Pathology recommended techniques that identify metastases >2 mm as a 
minimum standard (levels taken 1 mm apart should be sufficient for this), because 
macrometastases have proven prognostic relevance and all should be identified. Uniform 
reporting of additional findings may also be important, because micrometastases and isolated 
tumor cells may in the future be shown to have clinical relevance (step sections taken 200 or 
250 µm apart are ideal for this purpose) (11). The value of more detailed examination with 
IHC is controversial. Klevesath et al. (12) concluded that all metastatic deposits identified by 
IHC were either micrometastasis or isolated tumor cells, and until the prognostic significance 
of these deposits has been determined, IHC may be of limited value in the histopathologic 
examination of the SN. 
When looking at large trials, we see the same variety. For example, in the important 
randomized trial by Veronesi et al. (13), approximately 15 pairs of sections were cut at 50- 
µm intervals in each half of the SN, amounting to approximately 60 sections per SN to be 
examined, whereas in a recent study by Colleoni et al. (9), no details concerning the 
pathology protocol were mentioned. This shows that, apparently, the influence of pathology 
protocols on surgical strategies is underestimated. Looking at our study results, we found that 
differences in pathology protocols do, however, have a large effect on surgical treatment 
strategies. 
The occurrence of SN metastases is associated with the primary tumor size and with 
lymphovascular invasion. These are the most powerful variables that are independently 
predictive of positive SN biopsy results (14). Tan et al. (15) showed in their series the same 
results for the occurrence of SN macrometastases. Lack of progesterone receptors is inversely 
associated with the prevalence of SN metastases (10). 
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Figure 4. Status of nonsentinel lymph nodes (non-SNs) removed during completion axillary lymph 
node dissection (ALND) in cases with macrometastasis in the sentinel lymph node. In hospital A, 32 
of 32; in B, 19 of 19; in C, 27 of 31; and in D, 14 of 14 cases with macrometastasis underwent a 
completion ALND. 
 
All patients in our study were prospectively registered and considered eligible to undergo a 
SN procedure on the basis of similar criteria. Indeed, we did not observe gross differences 
among the four hospitals in patient and primary tumor characteristics that could have 
contributed otherwise to the outcome parameters. Lymph and/or blood vessel invasion was 
seen more frequently in hospital D, but the higher incidence of a positive SN in hospital D 
compared with hospitals A and B remained significant when corrected for lymphovascular 
invasion (P<0.001). The higher incidence of a positive SN in hospital D compared with 
hospital C could be partly explained by the presence of lymph and/or blood vessel invasion, 
but this still resulted in borderline significance for the difference between these hospitals 
(P=0.06). Therefore, although there were some differences in primary tumor characteristics, 
as shown in Table 1, this does not explain the differences in SN findings between hospitals. 
The differences in pathology protocols between hospitals A, B, and C versus hospital D do 
explain the differences in SN findings. 
The big central issue is whether patients in hospital D are overtreated or whether patients in 
hospitals A, B, and C are undertreated. In agreement with the guidelines, a completion ALND 
was recommended in case of a tumor-positive SN. In hospital D, an ALND was performed in 
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66.3% of patients who underwent a SN biopsy, with positive non-SNs in 13.9% of the 
originally included patients. In contrast, in hospitals A, B, and C taken together, an ALND 
was performed in 29.0% of patients who underwent a SN biopsy, with positive non-SNs in 
9.7% of the originally included patients. That is, in 52.4% of patients in hospital D, a negative 
completion ALND was performed, compared with in 19.3% of patients in hospitals A, B, and 
C combined. The question is whether the additional 4.2% increased detection of non-SN 
disease outweighs the 37.3% additional performance of a completion ALND. That is, the 
number needed to treat is nine patients to detect one patient with non-SN disease. 
In breast cancer, it may require considerable time before small metastases left behind become 
clinically manifest as regional recurrences or the source of distant metastases. Also, the use of 
adjuvant systemic therapy has been demonstrated to decrease the risk of locoregional 
recurrence. Currently, most node-negative patients undergo either adjuvant chemotherapy or 
hormone therapy because of their patient and primary tumor characteristics (16,17). This may 
protect against the outgrowth of regional tumor cells that may be left behind. 
Smidt et al. (18) found an incidence of 0.46% axillary recurrence after a negative SN biopsy, 
after a median follow-up of 26 months (one patient after 4 months and one patient after 27 
months). Pathologically each half of the SN was step-sectioned at 500-µm intervals at three 
levels. Zavagno et al. (19) found in their series of 479 patients no clinical axillary recurrence 
after a median follow-up of 35.8 months. For definitive SN examination, two sections were 
cut from a paraffin block at three levels, each 40 µm apart. Also, at Memorial Sloan-Kettering 
Cancer Center, a low relapse rate was found. With a median follow-up of 31 months, axillary 
recurrence occurred in 10 (0.25%) of 4008 patients (20). Final pathologic examination of a 
frozen section-negative SN included two sections from each of two levels 50 µm apart. 
Longer follow-up is necessary to answer the question properly (21). The patients in the 
cohorts of the four hospitals will be observed with longer follow-up to get a definitive answer 
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on axillary recurrence rates. Large (randomized) prospective trials such as National Surgical 
Adjuvant Breast and Bowel Project B32 and American College of Surgeons Oncology Group 
Z10 may provide clinical evidence for the formulation of policies on axillary sparing after a 
positive SN biopsy result. The National Surgical Adjuvant Breast and Bowel Project B32 
compares SN resection with conventional ALND in clinically node-negative breast cancer 
patients. An objective, among others, of American College of Surgeons Oncology Group Z10 
is to estimate the prevalence and the prognostic significance of SN micrometastases detected 
by IHC. 
To this end, we conclude that there are differences in SN pathology protocols between 
hospitals that do lead to differences in SN findings. These differences have a large effect on 
subsequent surgical treatment strategies. The question is whether the additional 4.2% 
increased detection of non-SN disease outweighs the 37.3% additional performance of a 
completion ALND. Longer follow-up will have to decide whether ultrastaging and, thus, 
additional surgery can offer better survival. 
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Summary 
Purpose Women with a hereditary predisposition for breast cancer have an extremely high 
risk of developing invasive breast carcinoma, and many women consider prophylactic 
mastectomy to avoid this risk. The use of prophylactic mastectomy is still debated. 
Identification of frequent premalignant lesions in mastectomy specimens would support the 
preventive concept of prophylactic mastectomy. 
Patients and Methods We performed a prospective study of breast specimens from 67 women 
at extremely high genetic risk of breast cancer, with or without previous breast cancer, who 
were undergoing prophylactic mastectomy (66% were carriers of a BRCA1 or BRCA2 
mutation). Breast specimens were studied by radiographic and macroscopic examination of 5-
mm tissue slices, with subsequent histology of suspicious lesions and random samples from 
each quadrant of the breast and the nipple area. 
Results In 57% of the women, one or more different types of high-risk histopathologic lesions 
were present: 37% atypical lobular hyperplasia, 39% atypical ductal hyperplasia, 25% lobular 
carcinoma-in-situ, and 15% ductal carcinoma-in-situ. A 4-mm invasive ductal carcinoma was 
found in one woman with ductal carcinoma-in-situ. None of these lesions was detected at 
palpation or mammography, which were performed before the mastectomy. The presence of 
high-risk lesions was independently related to age older than 40 years (odds ratio, 6.6; P = 
0.01) and to bilateral oophorectomy before prophylactic mastectomy (odds ratio, 0.2; P = 
0.02). 
Conclusion Many women at high risk of hereditary breast cancer develop high-risk 
histopathologic lesions, especially after the age of 40 years. Surveillance does not detect such 
high-risk histopathologic lesions. 
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Introduction 
The decision regarding whether and when to undergo prophylactic mastectomy for hereditary 
breast cancer prevention is quite complex. A particular subject of debate is the utility of 
mastectomy for breast cancer prevention. Some studies have stressed the paradox of 
performing more extensive surgery for breast cancer prevention than for actual disease (1-3). 
The gain in life expectancy may not be large (4,5) and the effects of prophylactic mastectomy 
on quality of life are not precisely known (6,7). A decision model estimated that the gain in 
life expectancy for a 30-year-old woman who carries a BRCA1 or BRCA2 mutation from 
bilateral prophylactic mastectomy is 3 to 5 years (5). Recent studies support the concept that 
mastectomy is effective for breast cancer prevention in women at high hereditary risk of 
breast cancer (8,9). The effects of chemopreventive drugs, like tamoxifen, for the prevention 
of hereditary breast cancer are uncertain (10). The expected efficacy is low (11) especially for 
women carrying a BRCA1 mutation, because most invasive breast cancers in BRCA1 mutation 
carriers are estrogen receptor-negative (12). 
Little is known about the early stages of breast cancer development in inherited forms of the 
disease. For instance, it is not known whether women with a hereditary risk of breast cancer 
are prone to develop high-risk histopathological lesions. Identification of premalignant lesions 
in prophylactically removed breasts would add plausibility to the concept of breast cancer risk 
reduction by prophylactic mastectomy in women at high hereditary risk of breast cancer. 
We performed a prospective study on prophylactic mastectomy specimens from women with 
a hereditary predisposition for breast cancer (i.e., women with a 30% to 85% lifetime risk of 
developing breast cancer). The aim of this study was to assess whether women at high 
hereditary risk for breast cancer have high-risk histopathologic lesions and to determine the 
variables related to, and predictive for, the presence of such high-risk lesions. 
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Patients and methods 
Patients 
Prophylactic mastectomy was performed between 1989 and 2001 in women, with and without 
previous breast cancer, who were at high hereditary risk. Prophylactic mastectomy of the 
contralateral breast was performed in women who had previous breast cancer. Bilateral 
mastectomy was performed in women who did not have previous breast cancer but were at 
high genetic risk. Individuals were included who had been tested for germline BRCA1 or 
BRCA2 mutations that were associated with breast and/or ovarian cancer in their families. Six 
women were included because of familial clustering of breast cancer, without testing the 
presence of a BRCA mutation. The lifetime risk of breast cancer in BRCA mutation carriers is 
55% to 85% (13) and the lifetime risk of breast cancer in the group of hereditary breast cancer 
patients (patients whose breast cancer is not a result of BRCA1 or BRCA2) is at least 30%, 
based on the model of Claus et al. (14). Medical records were reviewed for family history, 
breast cancer-related risk factors (age, oophorectomy, previous breast cancer, menarche, 
duration of oral contraceptives, age at first pregnancy, and parity), physical examinations, and 
radiological examinations. 
 
Specimens 
The handling of 65 of 67 specimens was based on the correlated radiographic and pathologic 
technique developed by Egan (15) which has been routinely performed in our pathology 
department for many years. The method is described in detail elsewhere (16). The specimens 
were cooled and sliced in serial sections with approximately 5-mm intervals. Radiographs 
were made from the tissue slices. Suspicious lesions and randomly selected areas from each 
quadrant and the nipple were sampled, with a mean number of 19 samples per specimen. A 
review of the pathology report, histologic slides, and the simple mastectomy specimen 
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radiographs was conducted. Atypical lobular hyperplasia (ALH), atypical ductal hyperplasia 
(ADH), and lobular carcinoma-in-situ (LCIS) were classified according to the criteria of Page 
et al. (17,18). Ductal carcinoma-in-situ (DCIS) was classified according to the criteria of 
Holland et al. (19). 
 
Statistical Analysis 
Continuous variables were compared by t tests, categorical variables, with the use of cross 
tables and Pearson’s χ2 test. Only one breast from each patient was taken into evaluation. To 
evaluate whether it is possible to predict histologic abnormalities with a combination of 
baseline characteristics, we performed multivariate logistic regression analyses. In these 
analyses, histopathology was defined as the dependent variable. Odds ratios, with their 95% 
confidence intervals, were calculated as a measure of the predictive power of each 
characteristic, independent of the other characteristics in the model. Based on the outcome of 
the multivariate analysis, we calculated the probability of histologic abnormalities for each 
woman. Subsequently, these probabilities were used to construct a receiver operating 
characteristic (ROC) curve to visualize the predictive power of the combination of the 
variables. The area under the ROC curve quantified this predictive power. 
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Results 
Patient Characteristics 
Two groups of women were studied. Women in one group had a unilateral prophylactic 
mastectomy, contralateral to a previous breast cancer (n = 26), with a mean time interval 
between breast cancer diagnosis and prophylactic mastectomy of 1 ± 4 years. Women in the 
second group had a bilateral prophylactic mastectomy, without previous breast cancer (n = 
41). Chemopreventive drugs such as tamoxifen were not used by any of the women included. 
High-risk histopathologic lesions were found in both breasts of 13 of 41 women who had 
undergone bilateral mastectomy (aged 27 to 52 years; six BRCA mutation carriers). In seven 
of 41 women, only one breast was affected, and in 21 of 41 women, neither breast had high-
risk lesions. High-risk lesions were found in 18 of 26 women who had undergone unilateral 
mastectomy. In case of bilateral mastectomy, the breast with the most severe lesions was 
taken into evaluation. The mean age of the women with bilateral prophylactic mastectomy 
was significantly lower than in the group of women with previous breast cancer who 
underwent unilateral prophylactic mastectomy (37 ± 7 years and 45 ± 9 years, respectively; P 
< 0.001). There were significantly more BRCA mutation carriers in the group of women who 
had undergone bilateral prophylactic mastectomy than in the group of women who had 
undergone unilateral prophylactic mastectomy (80% and 42%, respectively; P = 0.01). Other 
risk factors (Table 1) were not significantly different between the groups with bilateral or 
unilateral mastectomy (data not shown). Prophylactic oophorectomies were only performed in 
the group of women carrying a BRCA mutation. 
Table 1 summarizes the baseline characteristics of women who underwent prophylactic 
mastectomy. In 44 of 67 women, a BRCA mutation was found (38 BRCA1 and six BRCA2 
mutations). To exclude overt malignancy, palpation was performed by a skilled practitioner 
the day before mastectomy, mammography was done in all patients (3 ± 3 months before the 
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mastectomy), and 27 of 67 patients underwent magnetic resonance imaging (MRI) of the 
breasts (3 ± 2 months previous to the mastectomy). In all women, palpation, mammography, 
and MRI were without signs of breast cancer. In Table 1, the characteristics of the groups, 
with and without high-risk histopathologic lesions, are listed. Compared with patients without 
high-risk lesions, patients with high-risk lesions were, on average, 6 years older (P < 0.01), 
less likely to have had a previous oophorectomy (18% v 34%, respectively; P < 0.05), and had 
less chance of carrying a BRCA mutation (50% v 86%, respectively; P < 0.01). 
 
Table 1. Prevalence of breast cancer-related risk factors in patients undergoing prophylactic 
mastectomy with and without high-risk histopathologic lesions 
 
  
 
N = 67 (%) 
No High-Risk 
Lesions, n = 
29 (%) 
High-Risk 
Lesions, n = 38 
(%) 
 
 
P* 
Genetic risk factors     
BRCA mutation carrier 44 (66) 25 (86) 19 (50) 0.002 
Youngest family member breast cancer (years) 38 ± 10 37 ± 10 39 ± 10 ns (0.49) 
Youngest family member ovarian cancer (years) 51 ± 7 51 ± 8 51 ±  6 ns (0.92) 
Nongenetic risk factors     
Age at prophylactic mastectomy (years) 39 ± 8 37 ± 7 43 ± 11 0.008 
Prophylactic oophorectomy 29 (43) 17 (58) 12 (32) 0.030 
Oophorectomy before mastectomy 17 (25) 10 (34) 7 (18) ns (0.13) 
Previous breast cancer 26 (38) 8 (28) 18 (47) ns (0.10) 
Age at previous breast cancer (years) 42 ± 10 35 ± 5 47 ±  9 0.002 
Age at menarche (years) 13.0 ± 1.5 13.4 ± 1.4 12.9 ± 1.6 ns (0.23) 
Parity 2.1 ± 1.2 2.2 ± 1.1 1.9 ± 1.3 ns (0.43) 
Age at first pregnancy (years) 27.0 ± 4.1 26.9 ± 4.7 27.3 ± 3.5 ns (0.31) 
Duration of oral contraceptive (years) 9.2 ± 6.2 9.7 ± 7.0 8.8 ± 7.3 ns (0.73) 
Body mass index (kg/m2 ) 23.8 ± 5.3 24.0 ± 4.3 23.1 ± 6.4 ns (0.53) 
Breast specimen weight (g) 567 ± 338 551 ± 342 590 ± 354 ns (0.66) 
Nodular breasts at palpation 13 (19) 4 (14) 9 (24) ns (0.24) 
Difficult interpretable mammography 23 (34) 11 (38) 12 (32) ns (0.66) 
NOTE. 
Abbreviation: ns, not significant. 
Data are presented as mean ± SD, or as number with the percentage between brackets. *Indicates the 
significance of the difference between the group with and without high-risk lesions. 
 
 
Histopathologic Findings 
Table 2 summarizes the histopathologic findings. One or more high-risk lesions was found in 
57% of the patients, with ALH in 37%, ADH in 39%, LCIS in 25%, and DCIS in 15% of the 
women. Table 2, which also gives the histopathologic findings and main risk factors of 
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women younger and older than 40 years of age, shows that there were significantly more 
lesions in the group aged 40 years and older.  
 
Table 2. Histopathologic findings and relevant risk indicators of patients younger versus older than 40 
years of age 
 
  
N = 67 (%) 
< 40 years, 
n = 37 (%) 
≥ 40 years, 
n = 30 (%) 
 
P* 
Overall presence of high-risk lesions 38 (57) 16 (43) 22 (73) 0.01 
ALH 25 (37) 8 (22) 17 (57) 0.003 
ADH 26 (39) 10 (27) 16 (53) 0.03 
LCIS 17 (25) 4 (11) 13 (43) 0.002 
DCIS 10 (15) 3 (8) 7 (23) 0.08 
Oophorectomy before mastectomy 17 (25) 5 (14) 12 (40) 0.013 
BRCA mutation carrier 44 (66) 29 (78) 15 (50) 0.015 
Previous breast cancer 26 (39) 7 (19) 19 (63) 0.000 
NOTE. 
Data are presented as the actual number, with the percentage between brackets. 
*Indicates the significance of the difference between the group older and younger than 40 years. 
 
 
Table 3 presents the results of the multivariate logistic regression analysis. Age older than 40 
years and oophorectomy had a significant predictive value for the presence or absence of 
histologic abnormalities in the mastectomy specimens. Previous breast cancer did not add any 
predictive value. This multivariate regression analysis was also performed separately for the 
groups with and without previous breast cancer, giving comparable predictive values (data not 
shown). The presence of BRCA1 or BRCA2 mutations was not included in the model, because 
this variable was highly correlated with oophorectomy. We used the model to calculate the 
probability for each woman to have histologic abnormalities. Subsequently, we considered 
this probability as a diagnostic test for histologic abnormalities, and we evaluated its 
predictive value with an ROC curve. The area under the curve was 0.72 (95% confidence 
interval, 0.58 to 0.83). Thus, age and previous oophorectomy have limited predictive ability 
that is not sufficient to predict abnormalities with any certainty. This is also demonstrated in 
Table 4, which presents the distribution of patients according to these characteristics. High-
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risk lesions were present at appreciable frequency in all subgroups; however, some clear 
differences were evident. High-risk histopathologic lesions were detected in almost 50% (16 
of 37 women) of the women younger than age 40 years. Among 29 BRCA mutation carriers, 
only one of five women had high-risk lesions after oophorectomy, compared with 10 of 24 
women without previous oophorectomy. Similarly, five of eight women whose families were 
negative for BRCA mutations had high-risk lesions. None of them had undergone an 
oophorectomy. A higher frequency of lesions and the same effect of oophorectomy was 
observed in women older than age 40 years. Among women from families with strong genetic 
predisposition but with no demonstrable BRCA mutation, almost all of them (14 of 15 
women) had at least one high-risk histopathologic lesion on careful examination of the 
mammary gland. None of these women had undergone an oophorectomy. In contrast, the 
majority of older BRCA mutation carriers (12 of 15 women) had undergone an oophorectomy. 
In this group, only 50% were found to have high-risk lesions. These data confirm that age and 
oophorectomy (or possibly BRCA mutation status) influence the risk of having high-risk 
histopathologic lesions of the mammary gland. 
 
Table 3. Multivariate regression analysis of factors predicting the presence of high-risk pathologic 
findings 
 
 Odds Ratio 95% CI P 
Age ≥ 40 years 6.6 1.5-28.6 0.011 
Oophorectomy before mastectomy 0.2 0.04-0.8 0.02 
Previous breast cancer 1.2 0.4-4.2 0.7 
Abbreviation: CI, confidence interval. 
 
Ten women had DCIS at the time of prophylactic mastectomy. These women were of special 
interest because DCIS has an extremely high risk of subsequent invasive cancer. Two of the 
women had undergone an oophorectomy. The mean age of the group of women with DCIS 
was 45 years (range, 29 to 62 years). DCIS was moderate or high grade in seven of 10 
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women, with a mean size of 9 mm (range, 2 to 40 mm). Four of 10 women carried a BRCA 
mutation, and 50% had previous breast cancer. Clinical breast examination was performed in 
all of these women the day before mastectomy. Mammography was done, on average, 3 
months before the mastectomy (maximum, 6 months). Clinical breast examinations and 
mammograms did not disclose any signs of malignancy. In four of 10 patients, mammography 
was combined with MRI, which was also unremarkable. In seven of 10 women with DCIS, 
microcalcifications were visible on postsurgery x-rays of the specimen, and in two cases, 
these microcalcifications led to the diagnosis of DCIS. ADH, ALH, or LCIS was present in 
most of these women with DCIS. A 4-mm invasive ductal carcinoma was found in one 52-
year-old woman with DCIS who underwent a bilateral prophylactic mastectomy. In 
retrospect, this invasive carcinoma was not identified on mammography or MRI of the breast, 
which was performed 2 months before the mastectomy. In addition to this invasive carcinoma 
and DCIS, both breasts showed ADH and ALH, and LCIS was diagnosed in the contralateral 
breast. 
 
Table 4. Distribution of patients with and without high-risk histopathologic lesions, according 
to age, BRCA mutation, previous breast cancer, and previous oophorectomy 
 
 High-Risk Lesions No High-Risk Lesions 
 Age < 40 Years Age ≥ 40 Years Age < 40 Years Age ≥ 40 Years 
 BRCA+ BRCA- BRCA+ BRCA- BRCA+ BRCA- BRCA+ BRCA- 
Previous breast cancer         
Oophorectomy 0 0 4 0 1 0 2 0 
No oophorectomy 1 1 1 11 2 2 0 1 
No previous breast cancer         
Oophorectomy 1 0 2 0 3 0 4 0 
No oophorectomy 9 4 1 3 12 1 1 0 
 
 121  
Discussion 
Women with a hereditary predisposition for breast cancer are prone to develop high-risk 
lesions in their breasts. In our study, these lesions included ADH, ALH, LCIS, or DCIS, and 
they were present in 73% of the women aged 40 years and older. The high prevalence of 
lesions in our study may be explained by a careful macroscopic examination of the breast 
specimens combined with specimen radiograms and a large number of excisions. This 
combined procedure made possible the detection of small foci of microcalcifications or small 
distortions, and it allowed the detection of normally occult lesions such as carcinoma-in-situ 
or atypical hyperplasia. 
High-risk histopathologic lesions were found in both breasts of 13 of 41 women who had 
undergone mastectomy. In seven of 41 women, one breast was affected, and in 21 of 41 
women, neither breast had high-risk lesions. It is therefore clear that development of high-risk 
lesions tended to occur simultaneously in both breasts. Moreover, even within a single breast, 
there was a strong tendency for multiple lesions to occur. Thus, one would expect that high-
risk lesions should be particularly frequent in women with a previous history of cancer of the 
contralateral breast. This was indeed the case with high-risk lesions, which were present in 18 
of 26 breast specimens examined. These data indicate that although the genetic factor 
determines high relative risk, the actual occurrence of high-risk histopathologic lesions is a 
result of other systemic factors that are unrelated to the gene. We examined factors that might 
influence the development or detection of high-risk lesions, such as age, previous breast 
cancer, and previous oophorectomy. Of these factors, only age correlated positively, as would 
be expected. However, there was a strong negative correlation between the occurrence of 
high-risk lesions and previous oophorectomy. We cannot exclude that the inverse relation 
between high-risk lesions and previous oophorectomy was caused by selection, as all women 
who underwent a prophylactic oophorectomy were BRCA mutation carriers. The presence of a 
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BRCA mutation was significantly lower in the group with high-risk lesions than in the group 
without high-risk lesions. The lower prevalence of high-risk lesions in women who carried a 
BRCA mutation may indicate a different pathophysiology in the progression of precancerous 
lesions to invasive cancer than in the group without such a mutation. A relation between 
oophorectomy and a decreased breast cancer risk is supported by Rebbeck and colleagues, 
who showed that breast cancer risk was reduced by almost 50% after bilateral prophylactic 
oophorectomy in BRCA1 mutation carriers. These authors speculated that the decreased 
production of sex hormones after oophorectomy is responsible for the reduction in breast 
cancer risk (20). Turner et al. (21) showed that relapses of breast cancer in BRCA mutation 
carriers were mostly new primary tumors, although in the general population, relapses were 
most often recurrences of the previous tumor. This supports our findings of frequent 
synchronous and metachronous high-risk lesions in women who are at high hereditary risk for 
breast cancer. In addition, we found these lesions to exist more frequently in high-risk women 
without a BRCA mutation than in women with a BRCA mutation. This indicates that all 
women at high hereditary risk for breast cancer are prone to develop multiple lesions, 
independent of whether they do or do not carry a BRCA mutation. 
DCIS was present in 10 of 67 women. This finding is of great concern because, as in the 
general population, unresected DCIS strongly increases the risk of subsequent invasive breast 
cancer from 30% to 50% after 10 years (22). Therefore, DCIS should be resected completely 
to prevent invasive breast cancer. In our study, DCIS was not detected by either palpation or 
mammography before mastectomy. In four of the 10 patients with DCIS, MRI of the breasts 
was performed, which also failed to detect the DCIS lesions. Most women with DCIS were 
older than 40 years of age. Although the occurrence of high-risk lesions, such as DCIS, was 
strongly related to age and correlated negatively to previous oophorectomy, the predictive 
value of these variables was not sufficient to predict abnormalities with any certainty. 
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Therefore, age and oophorectomy cannot be used to counsel women who are at high 
hereditary risk about whether or when to perform prophylactic mastectomy. We concluded 
that clinical breast examination, mammography, and breast cancer risk factors are insufficient 
to predict the presence of high-risk histopathologic lesions. 
In addition to regular surveillance, current risk reduction strategies for women at hereditary 
risk for breast cancer include prophylactic mastectomy, oophorectomy (or both), and 
chemoprevention. The effects of tamoxifen, currently the most important chemopreventive 
drug, have been questioned with respect to its efficacy for BRCA1 mutation carriers (11,12). 
Breast cancers that arise in carriers of BRCA1 mutations are commonly estrogen receptor-
negative, unlike tumors associated with BRCA2 mutations, indicating that the effect of 
tamoxifen might be selective for distinct genotypes. The results of our study support the 
concept of early prophylactic mastectomy or prophylactic oophorectomy to reduce the genetic 
risk of breast cancer. 
The fact that an occult carcinoma was present in only one of 67 patients in our study might 
indicate that surveillance is as effective as prophylactic mastectomy. However, in our study, 
all 10 DCIS cases were missed by surveillance, and it was recently shown by Meijers-
Heijboer at al. (9) that surveillance is less effective than prophylactic mastectomy in 
preventing breast cancer deaths. 
This study lacks a control group of women without hereditary risk. This is because women 
who undergo an operation for breast reduction have only part of their breasts removed, and 
these women, for the most part, belong to a younger age group. Fortunately, healthy women 
who are of the same age group as our patients only rarely come for autopsy. Despite the 
absence of this control group, the high prevalence of DCIS and other high-risk lesions in the 
prophylactically removed breasts strongly supports the relevance of prophylactic mastectomy 
in women who are at high hereditary risk for breast cancer. 
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The occurrence of lesions found in the study population is much higher than that reported in 
the literature (23-27). In 25 women with a family history of breast cancer, Khurana et al. (23) 
reported ADH in 8%, ALH in 4%, and DCIS in 4% of the women. In the general population, 
ALH and ADH represent a relatively uncommon diagnosis, constituting less than 5% of all 
benign breast biopsies (17,28). Dupont et al. (29) showed that women with ADH or ALH and 
a family history of breast cancer have an 11-fold increased risk of developing breast cancer. 
The reported prevalence of LCIS in the general population is variable, ranging from 0.5% to 
3.6% (30,31). Controversy exists with regard to the natural course of LCIS. Specifically, there 
is disagreement about whether LCIS is a precursor of invasive disease or merely a marker of 
subsequent invasive carcinoma risk. In women diagnosed with LCIS, approximately 30% will 
develop an invasive carcinoma (32), most often of the ductal type (33). LCIS is most likely a 
risk indicator for breast cancer, but it is not itself a true precursor for invasive disease in most 
patients. 
For women carrying a BRCA mutation, the risk of breast cancer begins to increase before the 
age of 25 years, with a steep increase after age 40 years. The cumulative risk of developing 
breast cancer before the age of 40 years is approximately 15%, whereas the risk of developing 
breast cancer before the age of 50 years is 40% to 50% (13,34). In our study, all types of high-
risk lesions showed a higher prevalence in the group of women aged 40 years and older. 
Multivariate regression analysis showed that age is independently related to the occurrence of 
high-risk lesions. This indicates that there is a time-dependent development of lesions, 
probably under the influence of genetic susceptibility, which precedes the occurrence of 
invasive breast cancer.  
In conclusion, this study shows that the majority of women at high hereditary risk of breast 
cancer have high-risk histopathologic lesions in one or both breasts. Although not all lesions 
will develop into invasive carcinoma, they may predict the occurrence of subsequent invasive 
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breast cancer elsewhere in the breast. The risk for developing (contralateral) invasive 
carcinoma is high for patients with hereditary predisposition (35). The high rate of high-risk 
lesions found in our study helps to explain this risk. 
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In reply: 
Adem et al. (J Clin Oncol 2004;22:1159-1161) review three studies on breast pathology in 
patients with hereditary breast cancer. They conclude that the available data support their 
previous claim that breast cancer progression from benign breast disease to invasive cancer is 
more rapid in BRCA mutation carriers (1). They list the following arguments: 1) A low 
prevalence (2-2.5%) of high-risk lesions in prophylactically removed breasts from BRCA-
mutation carriers, and 2) a high incidence of cancer in BRCA-mutation carriers. This model 
may be true. On the other hand, our study (2) and the Memorial Sloan-Kettering Cancer 
Center study (3) found a much higher prevalence of high-risk lesions (43% and 46%, 
respectively). Both these studies used more extensive breast tissue sampling protocols and 
therefore achieved higher sensitivity. Thus, the hypothesis that BRCA mutation carriers have a 
higher prevalence of high-risk lesions cannot be discarded. In fact, our data and that from the 
Memorial Sloan-Kettering Cancer Center study seem to favor increased incidence of lesions 
over rapid progression (2,3). 
 
Table 1. Histopathologic findings in prophylactic mastectomy specimen of patients with and without a 
BRCA mutation 
 
 BRCA 
Carrier 
 
Non-Carrier 
 
P* 
No. of Patients 44 23  
Overall presence of high-risk lesions, % 43 82 0.002 
ALH, % 20 50 0.000 
ADH, % 25 65 0.001 
LCIS, % 14 48 0.002 
DCIS, % 9 30 0.010 
Abbreviations: ALH, atypical lobular hyperplasia; ADH, atypical ductal hyperplasia; LCIS, lobular 
carcinoma in situ; DCIS, ductal carcinoma in situ. 
* Indicates the significance of the difference between the group with and without a BRCA mutation. 
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We agree that future studies are required to resolve whether progression or incidence of high-
risk lesions is more important or whether other factors are involved. We note that irrespective 
of the underlying biologic model, the data argue for prophylactic removal of the breasts in 
BRCA1 and BRCA2 mutation carriers (4). We also note that the prevalence of high-risk 
lesions was even higher in non-BRCA linked high-risk families in our study (Table 1). Thus 
the absence of a mutation in the BRCA1 or BRCA2 genes in such a family should not be taken 
to indicate low risk. 
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Abstract 
Purpose To assess the occurrence of high-risk epithelial lesions in women of breast cancer 
families with and without a BRCA mutation. 
Patients and methods Prospective study of women at very high risk of breast cancer 
undergoing prophylactic mastectomy (68 BRCA1 mutation carriers, 14 BRCA2 mutation 
carriers and 24 non-BRCA mutation carriers). 
Results The prevalence of high-risk lesions is equal in women with a BRCA1 or a BRCA2 
mutation, but is higher in non-BRCA mutation carriers: all lesions 43% versus 71% (P=0.02), 
atypical lobular hyperplasia 26% versus 67% (P=0.001), atypical ductal hyperplasia 17% 
versus 42% (P=0.01), lobular carcinoma in situ 15% versus 29% (P=0.10) and ductal 
carcinoma in situ 9% versus 17% (P=0.25). The presence of high-risk lesions is related to 
absence of a BRCA mutation and to age over 40 years. 
Conclusion Women with an autosomal dominant family history for breast cancer, with and 
without a BRCA mutation are prone to develop high-risk epithelial lesions, especially over 40 
years. 
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Introduction 
Little is known about the early stages of breast cancer development in women with a strong 
family history. This applies equally to those testing negative for a BRCA mutation and to 
those carrying a BRCA1 or a BRCA2 mutation. There might be differences in breast cancer 
development between BRCA1 and BRCA2 mutation carriers because the features of fully 
developed invasive breast cancers from BRCA1 and BRCA2 mutation carriers are different 
(1-3). Women with hereditary predisposition to breast cancer are prone to develop epithelial 
lesions that indicate a high risk of subsequent invasive breast cancer (4-6). These high-risk 
lesions include atypical lobular hyperplasia (ALH), atypical ductal hyperplasia (ADH), 
lobular carcinoma in situ (LCIS), and ductal carcinoma in situ (DCIS) (4,7). 
The options for women with a deleterious germline mutation in BRCA1 or BRCA2 to handle 
their high risk are either regular surveillance or prophylactic mastectomy. Bilateral 
prophylactic mastectomy in healthy women with a BRCA mutation is associated with a 90% 
reduction in breast cancer incidence (8,9). When applied at young age, around or before the 
age of 40 years, this may lead to a significant survival advantage (10). This procedure is much 
less accepted for women who appeared to be negative for a BRCA mutation even though they 
have an apparent autosomal dominant family history for breast cancer (11-14). Especially 
women with breast cancer at young age and a strong family history but without a BRCA 
mutation may want to opt for contralateral prophylactic mastectomy. While cancer-free 
survival is the ultimate test of effectiveness, a first indication may be gleaned from examining 
mastectomy specimens. 
Information is lacking on whether the prevalence of high-risk lesions differs between women 
with and without a BRCA mutation. In a previous study by our group, of women at high 
hereditary risk of breast cancer, the prevalence of a BRCA mutation was lower in the group 
with high-risk lesions compared to the group without high-risk lesions (4). At that time the 
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group that was tested negative for a mutation was not strictly defined and the groups with a 
BRCA1 or a BRCA2 mutation were too small to be studied separately. In the present study, 
we investigated the differences in prevalence of high-risk epithelial lesions in women with an 
exceptionally strong family history for breast cancer with and without a BRCA mutation, who 
chose for prophylactic mastectomy because of their high risk for breast cancer. These results 
may be relevant for breast cancer prevention in women with an autosomal dominant family 
history for breast cancer. 
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Patients and methods 
Patient characteristics 
Women at high hereditary risk of breast cancer, who underwent prophylactic mastectomy 
between 1989 and 2004 with and without previous breast cancer, were included. In case a 
woman had previous breast cancer, prophylactic mastectomy of the contralateral breast was 
performed. All women had extensive genetic counselling and were shown to have a strong 
family history for breast cancer, often in combination with ovarian cancer, suggestive for 
autosomal dominant transmission of the disease, occurring in consecutive generations and at 
young age. All women had been tested for germline BRCA1 or BRCA2 mutations associated 
with breast and/or ovarian cancer in their family. Analysis was done of the entire open 
reading frames and all exon boundaries by a combination of protein truncation testing (PTT) 
of the exons 11 and denaturing gradient gel electrophoresis (DGGE) of the boundary of the 
exons 11 and of all coding exons. Multiple ligation probe amplification (MLPA) was used to 
test for exon deletions. Whenever a BRCA mutation had been identified in the family, healthy 
relatives were tested for that specific mutation. The lifetime risk of breast cancer in BRCA 
mutation carriers is 55–85% (15), and the estimated lifetime risk of breast cancer in the group 
without a BRCA1 or BRCA2 mutation in our study is more than 30%, based on the model of 
Claus et al. (16). Medical records of all patients were reviewed for family history and breast 
cancer related risk factors (such as age, menarche, parity, and duration of oral contraceptives, 
salpingo-oophorectomy, and previous breast cancer). Patients with a BRCA-unclassified 
variant were not included. 
Inclusion of patients was limited to those who chose for prophylactic mastectomy because of 
their high lifetime risk for breast cancer. Prior to mastectomy all patients had physical breast 
examination and mammography (some in combination with an MRI), without suspicion for 
pathology. 
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The data from 59 out of the presented 106 patients were described previously (4). From the 
previously described cohort of 67 women, 8 non-BRCA mutation carriers were excluded in 
this study because BRCA mutation detection was not performed or with the currently 
available techniques. 
 
Figure 1. Prevalence of breast cancer-related risk lesions in patients with a BRCA1, a BRCA2 
mutation, or non-BRCA mutation carriers. 
 
 
ALH, atypical lobular hyperplasia; ADH, atypical ductal hyperplasia; LCIS, lobular carcinoma in situ; 
DCIS, ductal carcinoma in situ. 
* indicates significant difference from BRCA mutation carriers (p < 0.05). 
 
Specimens 
The handling of the specimens was based on the correlated radiographic and pathology 
technique developed by Egan (17), and which has been routinely performed in our pathology 
department for many years (18).The specimens were cooled and sliced in serial sections with 
approximately 5-mm intervals. Radiographs were made from these tissue slices. Suspicious 
lesions and randomly selected areas from each quadrant and the nipple were sampled, with a 
mean number of 18 ± 5 samples per specimen (range 7-39). One pathologist (PB) conducted a 
review of the pathology report, the histological slides, and the simple mastectomy specimen 
radiographs. Atypical lobular hyperplasia (ALH), atypical ductal hyperplasia (ADH), and 
lobular carcinoma in situ (LCIS) were classified according to the criteria of Page et al. 
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(19,20). Ductal carcinoma in situ (DCIS) was classified according to the criteria of Holland et 
al. (21). 
Quality and consistency of the procedure over time were tested by comparison of the 
prevalence of high-risk lesions in the group with a mastectomy (n = 59) performed between 
1989 and 2001 versus the group (n = 47) with a mastectomy performed between 2001 and 
2004. The number of samples and the prevalence of the various high-risk lesions between the 
older and the latter group were not different (data not shown). 
 
Table 1. Breast cancer related risk factors (percentages or mean with standard deviation) in patients 
undergoing prophylactic mastectomy with and without a BRCA mutation 
 
 All, N = 106 (%) BRCA, N = 82 (%) Non-BRCA, N = 24 (%) p-Valuea 
Histopathology     
Overall presence of high-risk lesions 49 43 71 0.015
ALH 35 26 67 0.000
ADH 23 17 42 0.011
LCIS 18 15 29 0.10
DCIS 10 9 17 0.25
    
Genetic risk factors     
Youngest patient with breast cancer in the family 38 ± 8 36 ± 9 41 ± 6 0.045
Youngest patient with ovarian cancer in the family 50 ± 8 50 ± 8 50 ± 1 0.9
Families with ovarian cancer 35 41 13 0.007
    
Non-Genetic risk factors     
Age at prophylactic mastectomy (years) 41 ± 9 40 ± 9 44 ± 8 0.06
Mastectomy years after breast cancer (years) 2.7 ± 4.6 3.3 ± 5.2 1.8 ± 3.4
Previous breast cancer 45 35 79 0.000
Age at previous breast cancer (years) 43 ± 9 42 ± 9 44 ± 7 0.40
    
Hormonal risk factors     
Oophorectomy >1 year before mastectomy 18 23 –
Age at oophorectomy 43 ± 8 43 ± 7 –
Postmenopausal 43 46 30 0.17
Menarche 13.3 ± 1.6 13.2 ± 1.6 13.6 ± 1.6 0.40
Parity 1.9 ± 1.2 1.9 ± 1.2 1.8 ± 1.2 0.90
ALH, atypical lobular hyperplasia; ADH, atypical ductal hyperplasia; LCIS, lobular carcinoma in situ; 
DCIS, ductal carcinoma in situ. a, difference between BRCA and non-BRCA group. 
 
 
Statistical analysis 
From every patient only one breast was evaluated. If bilateral prophylactic mastectomy was 
performed, the breast was selected having the highest frequency (in descending order) of: 
DCIS, LCIS, ADH, and ALH, respectively. This order is based on the related risk for a 
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woman with two breasts to develop breast cancer. Descriptive data are reported as mean ± 
standard deviation for continuous variables and as percentages for categorical variables. 
Group comparisons were tested for statistical significance using t-tests for continuous 
variables, and cross tables with Pearson χ2 tests for categorical variables. Independent values 
of predictors for high-risk lesions were calculated using a multivariate logistic regression 
model. The following factors were entered in the model: non-BRCA versus BRCA mutation 
carrier, previous oophorectomy versus no previous oophorectomy, previous breast cancer 
versus no previous breast cancer, and age at mastectomy older than 40 years versus younger 
than 40 years. Because none of our patients in the non-BRCA-group had a previous 
oophorectomy, we combined these two variables into a categorical new variable with three 
groups: BRCA mutation carrier without previous oophorectomy (the reference group), BRCA 
mutation carrier with oophorectomy, and non-BRCA mutation carriers without previous 
oophorectomy. Odds ratios with corresponding 95% confidence intervals were calculated in 
order to estimate the association with high-risk lesions. Also, predicted probabilities for high-
risk lesions for different combinations of predictors were calculated from the multivariable 
model results. 
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Results 
Histological findings in women with a BRCA1 or a BRCA2 mutation 
Eighty-two patients with a deleterious BRCA mutation underwent prophylactic mastectomy 
(68 BRCA1 mutation carriers and 14 BRCA2 mutation carriers). The total prevalence of all 
high-risk lesions in BRCA1 and BRCA2 mutation carriers was 44% versus 36% (P=0.56), 
with ALH in 26% versus 21% (P=0.69), ADH in 18% versus 14% (P=0.70), LCIS in 16% 
versus 7% (P=0.38) and DCIS in 9% versus 7% (P=0.83), respectively. 
Risk factors for breast carcinoma were documented at the time of mastectomy. The youngest 
family member with breast cancer in the BRCA1 families was approximately 9 years younger 
than in the BRCA2 families (44 ± 9 years and 35 ± 9 years, respectively (P=0.02)). The 
youngest family member with ovarian cancer was 11 years older in the BRCA1 families; 52 ± 
7 versus 41 ± 7 years for BRCA2 (P=0.006), and a comparable proportion of families with 
ovarian cancer (43% versus 36%, P=0.5). No other differences in risk factors between the 
group with a BRCA1 or a BRCA2 mutation were found (data not shown). 
In order to enable comparison between BRCA mutation carriers and the non-BRCA group, 
the data from BRCA1 and BRCA2 mutation carriers were combined. In these 82 BRCA 
mutation carriers, the prevalence of high-risk lesions was equal among women with and 
without a prophylactic oophorectomy, being 47% (9/19) and 41% (26/63) (P=0.64), 
respectively. 
 
Histological findings in women with and without BRCA mutation 
The presence of high-risk lesions was positively correlated with age (correlation coefficient 
0.28, P=0.004). Comparison of all women with and without high-risk lesions showed that 
women with high-risk lesions were older 44 ± 9 years versus 39 ± 8 years (P=0.003). Women 
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over 40 years of age had a higher prevalence of high-risk lesions than younger women: 60% 
(33/55) versus 38% (20/52) (P=0.03). 
Table 1 summarises the histological lesions and other risk factors for breast cancer in women 
with and without a BRCA mutation. A higher prevalence of histological high-risk lesions was 
found among patients not carrying a BRCA mutation (Figure 1). The two groups appeared to 
be different in some aspects: women from the non-BRCA group had relatively more often 
previous breast cancer (P<0.0001), never had a prophylactic oophorectomy, were slightly 
older (P=0.06), and less often had a relative with ovarian cancer (P=0.007) (Table 1). 
When grouped according to their mutation carrier status, previous breast cancer and previous 
oophorectomy did not appear to play a significant role in the prevalence of high-risk lesions 
(Table 2). The prevalence of high-risk lesions was comparable in the groups with and without 
previous breast cancer, in BRCA mutation carriers 44% (13/29) and 41% (22/53), 
respectively (P=0.77), and in the non-BRCA group 68% (13/19) and 80% (4/5), respectively. 
The average number of years between breast cancer diagnosis and preventive mastectomy 
was 2.7 ± 4.6 years. 
 
Table 2. Breast cancer-related risk factors (percentages or mean with standard deviation) in patients 
undergoing prophylactic mastectomy with and without high-risk lesions 
 
 BRCA-positive  BRCA-negative 
 No high-risk 
lesions,  
N = 47 (%) 
High-risk 
lesions, N = 35 
(%) 
p 
No high-risk 
lesions,  
N = 7 (%) 
High-risk 
lesions, 
N = 17 (%) 
p 
Genetic risk factors       
Youngest patient with breast cancer in the family 36 ± 8 36 ± 10 0.9 36 ± 5 43 ± 6 0.014 
Youngest patient with ovarian cancer in the family 52 ± 8 47 ± 9 0.1 – 2 families  
       
Non-genetic risk factors       
Age at prophylactic mastectomy (years) 39 ± 8 43 ± 10 0.03 40 ± 6 46 ± 8 0.11 
Age <40 year at prophylactic mastectomy 60 46 0.21 57 18 0.053 
Previous breast cancer 34 37 0.77 86 76 0.61 
Age at previous breast cancer (years) 38 ± 8 47 ± 9 0.01 40 ± 6 46 ± 7 0.087 
       
Hormonal risk factors       
Oophorectomy >1 year before mastectomy 21 26 0.64 – –  
Age at oophorectomy 41 ± 6 46 ± 8 0.02 31 jr 55 jr  
Postmenopausal 40 54 0.21 – 41 0.06 
Menarche 13.0 ± 1.5 13.4 ± 1.8 0.6 14.2 ± 1.3 13.4 ± 1.6 0.31 
Parity 1.8 ± 1.2 1.2 ± 1.3 0.7 1.7 ± 1.2 1.9 ± 1.3 0.8 
Oral anti-conceptive use (years) 11 ± 8 11 ± 7 0.2 9 ± 9 5 ± 4 0.2 
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Table 3. Risk factors for high-risk lesions in prophylactic mastectomy specimens: multivariable 
adjusted odds ratio’s with 95% confidence intervals of various predictors 
 
 Odds ratio 95% CI p 
BRCA mutation without previous oophorectomy Ref   
BRCA mutation with previous oophorectomy 0.80 0.25–2.55 0.71 
Non-BRCA without previous oophorectomy 3.13 1.05–9.32 0.04 
No previous breast cancer Ref   
Previous breast cancer 0.78 0.32–1.89 0.58 
Age at mastectomy under 40 year Ref   
Age at mastectomy older than 40 year 2.44 0.96–5.88 0.06 
 
Table 3 presents the results of the multivariate logistic regression analysis. Non-BRCA 
mutation carrier status and age over 40 years had significant independent predictive value for 
the presence of high-risk lesions in the mastectomy specimen. This analysis supports the 
previously drawn conclusion that preventive oophorectomy does not affect the presence of 
high-risk lesions in BRCA mutation carriers. Using the regression coefficients from the 
logistic regression analysis, we calculated the predicted probability for each woman to have 
histological abnormalities. This is shown in Table 4. Women at high familial risk for breast 
cancer not carrying a BRCA mutation over 40 years of age have the highest predicted 
probability of approximately 80% for the presence of high-risk lesions in their breast. For a 
woman over 40 years with a BRCA mutation this risk is approximately 55%. 
 
Table 4. Predicted probability for the presence of high-risk lesions in prophylactic mastectomy 
specimen related to mutation status, breast cancer history, age and oophorectomy history 
 
BRCA mutation Previous breast cancer Age under 40 years Previous oophorectomy Probability for high-risk lesions 
+ – + – 0.36 
+ + + – 0.30 
+ – – – 0.58 
+ + – – 0.51 
+ – + + 0.31 
+ + + + 0.26 
+ – – + 0.52 
+ + – + 0.46 
– – + – 0.64 
– + + – 0.58
– – – – 0.81
– + – – 0.78
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Table 5 presents the data of 12 patients who appeared to have DCIS at, what was planned to 
be, a preventive mastectomy, the so-called occult DCIS. One of these patients also had an 
invasive ductal cancer. DCIS was moderate or high grade in 9 of 11 women, with a mean size 
of 10 mm [range 2-40 mm]. The age of these patients was 44 ± 9 years, seven being over the 
age of 40 years. Five DCIS patients were BRCA1 mutation carriers, two a BRCA2 mutation 
carrier and five from the non-BRCA group. The large majority of DCIS cases had other high-
risk lesions too: 6/12 (50%) ALH, 7/12 (58%) ADH, and 4/12 (33%) LCIS. Six patients 
(50%) with DCIS had previously been diagnosed with breast cancer in the contralateral 
breast. 
 
Table 5. Patient characteristics with occult DCIS in prophylactically removed breasts 
 
ID nr BRCA 
mutation 
DCIS size 
(mm) 
DCIS 
grade ADH ALH LCIS Invasive 
Mastect 
age Oophor. 
BC 
age 
8 BRCA1 2 3  Yes Yes  35  35 
76 BRCA1 6 2     43   
11 BRCA1 11 2     51   
98 BRCA1 15 3 Yes    39  39 
64 BRCA1 40 2     29   
120 BRCA2 4 3  Yes Yes  56  56 
10 BRCA2 13 2 Yes Yes  Yes 52 Yes  
40 Non-BRCA 2 3     51   
37 Non-BRCA 3 1 Yes Yes Yes  53  54 
30 Non-BRCA 4 2 Yes Yes Yes  42  41 
29 Non-BRCA 6 1 Yes Yes   30   
3 Non-BRCA 10 3 Yes Yes   48  48 
DCIS, ductal carcinoma in situ; ADH, atypical ductal hyperplasia; ALH, atypical lobular hyperplasia; 
LCIS, lobular carcinoma in situ; invasive, invasive ductal cancer; Mastect., mastectomy, Oophor., 
oophorectomy 1 year or more previous to mastectomy, BC, previous breast cancer. 
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Discussion 
We here show that women with an autosomal dominant family history for breast cancer that is 
not caused by a BRCA1 or BRCA2 mutation have an even higher prevalence of epithelial 
high-risk lesions than mutation carriers. Furthermore, the presence of high-risk lesions is 
associated with age; especially at age over 40 years a large number of women with and 
without a BRCA mutation have epithelial high-risk lesions. These epithelial lesions may 
predict the occurrence of subsequent invasive breast cancer (5,6,22-24). 
After initial diagnosis of breast cancer in a BRCA1 or BRCA2 mutation carrier, the risk of 
developing cancer in the opposite breast is approximately 30% in 10 years (26), increasing to 
40% in 10 years when breast cancer occurred before the age of 40 (27). Data concerning the 
risk of cancer in the opposite breast of women with an autosomal dominant family history for 
breast cancer without a BRCA mutation are lacking. Most likely the risk of a second primary 
breast cancer in these women greatly depends on the age of breast cancer diagnosis, as well as 
on family history. The optimal management of patients with breast cancer and an autosomal 
dominant family history for breast cancer is still controversial. Simple mastectomy is an 
effective way to prevent breast cancer (8,9). However, it is unknown whether contralateral 
prophylactic mastectomy leads to survival advantage (13,14). The prognosis of the treated 
breast cancer may greatly influence survival of patients with contralateral prophylactic 
mastectomy. Especially young women who had breast cancer with characteristics indicating a 
good prognosis and a high genetic risk of a second primary breast cancer may benefit from 
prophylactic contralateral mastectomy. 
Most women in the non-BRCA group have sought genetic counselling because of a 
combination of breast cancer at a relatively young age and an autosomal dominant family 
history, suggestive for autosomal dominant transmission of the disease. Most likely the non-
BRCA group has a heterogeneous genetic origin, consisting of women carrying a yet 
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unknown BRCA mutation, or a combination of several less potent susceptibility genes. They 
considered contralateral preventive mastectomy more acceptable than life long surveillance 
with an expected high risk of a second primary breast cancer within 10-12 years (25). 
Although prophylactic mastectomy can be an option for these women, it is not the only 
option. Improved surveillance with advanced technologies such as MRI may be able to detect 
cancers at an early stage (11). In theory chemoprevention, for example with tamoxifen, may 
be an option, in spite of the fact that for hereditary cancer the preventive effect of tamoxifen is 
still uncertain (11). Especially for women with a BRCA1 mutation, the effectiveness of 
chemoprevention is questioned, because breast cancers from most BRCA1 mutation carriers 
do not have ER/PR receptor activity. In the present study 36% of the BRCA mutation carriers 
were positive for ER/PR receptor activity, this percentage was higher, 70%, in the non-BRCA 
group. No statistical difference was found for the presence of high-risk lesions between the 
group with and without ER/PR receptor activity. However, this conclusion may be influenced 
by the small sample size. 
It is important to realise that for women with an autosomal dominant family history but 
without a personal history of breast cancer and no detectable BRCA mutation, alternative 
options instead of preventive mastectomy should be considered, because risk status cannot 
adequately be measured and the ability to modify this risk by mastectomy is not sufficiently 
known. 
The higher prevalence of high-risk lesions in the non-BRCA group cannot be explained by a 
lower incidence of previous oophorectomy as compared to BRCA mutation carriers. 
Previously it was shown that breast cancer risk, in premenopausal BRCA1 mutation carriers, 
reduces after bilateral prophylactic oophorectomy (28). The decreased production of sex 
hormones after oophorectomy may be responsible for this reduction in breast cancer risk. An 
earlier study by our group suggested that oophorectomy relates to a lower occurrence of high-
 153  
risk histological lesions (4). It was discussed that this relation might have been caused by 
selection as all women who underwent oophorectomy were BRCA mutation carriers, but at 
that time groups where too small to be analysed separately. In the present study, we did not 
find a relation between oophorectomy and prevalence of high-risk lesions in a large group of 
BRCA mutation carriers. Therefore, oophorectomy cannot explain the lower prevalence of 
high-risk lesions in BRCA mutation carries as compared to the non-BRCA group. This 
indicates that previous oophorectomy should not be taken to indicate low-risk of epithelial 
lesions in women at high risk of hereditary cancer. 
Controversies exist regarding the role of ductal carcinoma in situ (DCIS) in both BRCA1 and 
BRCA2 mutation carriers (29,30). From our data we can conclude that BRCA1 and BRCA2 
mutation carriers are equally prone to develop high-risk lesions in their breasts, with a 
considerable proportion having occult DCIS. The data from a recent study among DCIS 
patients show that the prevalence of BRCA mutations among DCIS patients is similar to that 
found in patients with invasive breast cancer (31), and suggest that DCIS belongs to the 
spectrum of inherited breast cancer. As a consequence, in family-histories, DCIS can be 
considered as equal to the breast-cancer affected status, when considering familial at-risk 
status for BRCA (32-34). 
The prevalence of high-risk lesions in BRCA mutation carriers from our study is comparable 
to that reported by a study from the Memorial Sloan-Kettering Cancer Center in 24 BRCA 
mutation carriers (7). This study also showed that the prevalence of high-risk lesions in 
BRCA mutation carriers is much higher than in women without a genetic predisposition (7). 
In contrast to our data and those from Memorial Sloan-Kettering, the Mayo Clinic reported a 
low prevalence (2–2.5%) of high-risk lesions in prophylactically removed breasts from BRCA 
mutation carriers with no major difference in the prevalence of precursor lesions between 28 
BRCA mutation carriers and their matched controls (35). Apart from differences in ethnic 
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background, the number of sampling slices between the three studies may explain some of 
this difference. A mean of seven slices was examined in the Mayo Clinic study compared to 
14 in the Memorial Sloan-Kettering study and 18 in the present study. This may have added to 
the lower prevalence of high-risk lesions found in the Mayo Clinic study. 
A limitation of our study is the lack of a control group of women without familial breast 
cancer risk. Irrespective of this, the comparisons between BRCA1 and BRCA2 mutation 
carriers are not affected by this, as are the comparisons between woman at high genetic risk 
due to BRCA mutations and the high genetic risk group without BRCA mutation. The 
reported prevalence of undiagnosed DCIS in a review of autopsy studies, using various 
techniques, of women with an age range between 15 and 80 years is approximately 9% (range 
0–15%) (36). For LCIS this prevalence is less extensively studied and reported to range 
between approximately 1% and 3% (6). On average, the prevalence of these lesions reported 
in our study is higher than that reported in the general population. 
The data of this study indicate that women with an autosomal dominant family history of 
breast cancer should be considered prone to develop high-risk epithelial lesions in their 
breasts, especially at age over 40 years. Prophylactic mastectomy can prevent progression 
towards invasive carcinoma. It is unknown whether this may lead to survival advantage in the 
group without a BRCA mutation. 
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Introduction 
BRCA1 and BRCA2 mutation carriership is associated with a highly increased risk of 
developing breast carcinoma. For women carrying a BRCA mutation the risk of breast cancer 
begins to increase before the age of 25, with a steep increase after the age of 40 years. The 
cumulative risk of developing breast cancer before the age of 40 years is ≈15%, while the 
cumulative risk of developing breast cancer before the age of 50 is 40-50% (Ford et al., 
1998). The life time risk of invasive breast cancer is 60-80%. Very little is known regarding 
the early stages of breast cancer development in the inherited forms of the disease. Women 
with hereditary predisposition to breast cancer are prone to develop epithelial lesions that 
indicate a high risk of subsequent invasive breast cancer (Dupont and Page, 1985; 
Hoogerbrugge et al., 2003). These high-risk lesions include atypical lobular hyperplasia 
(ALH), atypical ductal hyperplasia (ADH), lobular carcinoma-in-situ (LCIS), and ductal 
carcinoma-in-situ (DCIS) (Kauff et al., 2003). These epithelial lesions may predict the 
occurrence of subsequent invasive breast cancer (Singletary, 1994). 
Women with a clear autosomal dominant family history for breast cancer that is not caused by 
a BRCA1 or BRCA2 mutation also have a prevalence of epithelial high-risk lesions, which is 
at least as high as that of mutation carriers. The presence of high-risk lesions is associated 
with age; especially at the age over 40 years a large number of women with and without a 
BRCA mutation have high-risk epithelial lesions. Previous oophorectomy should not be taken 
to indicate low-risk of epithelial lesions in women at high risk of hereditary cancer 
(Hoogerbrugge et al., 2006).   
The options for women with a deleterious germ-line mutation in BRCA1 or BRCA2 to handle 
their high risk are either regular surveillance or prophylactic mastectomy. Bilateral 
prophylactic mastectomy in healthy women with a BRCA mutation is associated with a 90% 
reduction in breast cancer incidence (Meijers-Heijboer et al., 2001; Rebbeck et al., 2004). 
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When applied at young age, at or before the age of 40 years, this may lead to a significant 
survival advantage (van Roosmalen et al., 2002). This procedure is much less accepted for 
women who appeared to be negative for a BRCA mutation even though they have an apparent 
autosomal dominant family history for breast cancer (Lostumbo et al., 2004). Especially 
women with breast cancer at young age and a strong family history but without a BRCA 
mutation may want to opt for contralateral prophylactic mastectomy. 
After initial diagnosis of breast cancer in a BRCA1 or BRCA2 mutation carrier, the risk of 
developing cancer in the opposite breast is ≈30% in 10 years (Metcalfe et al., 2004), 
increasing to 40% in 10 years when breast cancer occurred before the age of 40 (Verhoog et 
al., 2000). Data concerning the risk of cancer in the opposite breast of women with an 
autosomal dominant family history for breast cancer without a BRCA mutation are lacking. 
Most likely the risk of a second primary breast cancer in these women greatly depends on the 
age of the breast cancer patient, as well as on family history. The optimal management of 
patients with breast cancer and an autosomal dominant family history for breast cancer is still 
controversial. Simple mastectomy is an effective way to prevent breast cancer (Meijers-
Heijboer et al., 2001). However, it is unknown whether contralateral prophylactic mastectomy 
leads to survival advantage (Lostumbo et al., 2004). The stage and thereby the prognosis of 
the treated breast cancer may greatly influence survival of patients with contralateral 
prophylactic mastectomy. Especially young women who had breast cancer with 
characteristics indicating a good prognosis and a high genetic risk of a second primary breast 
cancer may benefit from contralateral prophylactic mastectomy. Most likely these patients 
have a heterogeneous genetic origin, consisting of women carrying a yet unknown BRCA 
mutation, or a combination of several less potent susceptibility genes (Easton et al., 2007). 
Although prophylactic mastectomy can be an option for these women, it is not the only 
option. Improved surveillance with advanced technologies such as magnetic resonance 
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imaging (MRI) may be able to detect cancers at an early stage (Kriege et al., 2004). In theory 
chemoprevention, for example with tamoxifen, may be an option (Bramley et al., 2006). It is 
important to realize that for women with an autosomal dominant family history but without a 
personal history of breast cancer and no detectable BRCA mutation, alternative options instead 
of preventive mastectomy should be considered, because risk status cannot adequately be 
measured and the ability to modify this risk by mastectomy is not sufficiently known.  
Careful examination of prophylactically removed breasts by the pathologist is important to 
exclude occult invasive carcinoma. Additionally, identification of premalignant lesions in 
prophylactically removed breasts supports the decision of prophylactic mastectomy in women 
at high hereditary risk of breast cancer. 
In general practice, sampling of the mastectomy specimen is performed by macroscopical 
examination and palpation, before and after manual slicing of the specimen. Excisions are 
taken at least from the nipple and the four quadrants of the breast, and from suspicious areas. 
Special attention should be paid to changes in color and to palpable lesions not seen on the 
radiograms or not apparent with inspection. For example, ochreous colored fat tissue may 
indicate an invasive carcinoma and point-shaped necrosis is suspicious for comedo type 
DCIS. Specimen radiography can guide this sampling of the mastectomy specimen (Egan, 
1982; Holland et al., 1985; Hoogerbrugge et al., 2003, 2006). Resolution of the specimen 
radiograms is much higher than that of mammography. Therefore, small architectural 
distortions, small densities (Figures 1 and 2), and tiny microcalcifications (Figures 3 and 4) in 
the breast tissue, skin, or fascia can be detected and subsequently sampled for 
histopathological examination.  
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Figure 1. Specimen radiograms of a right breast without (A) and with (B) pathological findings. A 
small partly speculated density is seen (short arrow), besides an intramammary lymph node (long 
arrow). 
 
A 
 
B 
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Figure 2. Magnified radiograms of Figure 1 with a small partly speculated density (arrow), 
representing invasive ductal carcinoma (IDC), with occult surrounding ductal carcinoma in situ 
(DCIS). 
 
  
A      B
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Materials 
1. Measuring staff. 
2. Scale. 
3. Indian ink. 
4. Waterproof felt pen. 
5. Sutures. 
6. Surgical needles. 
7. Refrigerator which cools down to 32 degrees Fahrenheit (0 degrees Celsius). 
8. Meat slicing machine. 
9. Old mammograms or hard plastic pads. 
10. Digital camera. 
11. Digital radiography/mammography machine. 
12. Software to retrieve the digital radiograms from the radiology/hospital database. 
13. Software to annotate the digital radiograms; to add pathology data to the digital images. 
14. Software to return the annotated digital radiograms to the radiology/hospital database. 
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Methods 
The following procedure of mastectomy handling is partly based on the description of Egan 
(1982). 
Handling of the mastectomy specimen 
1. The excised simple mastectomy specimen should arrive at the pathology department 
within 1 h after removal to prevent autolysis of the tissue. 
2. At the pathology department the whole specimen is weighed and measured immediately. 
3. The excised skin is measured. 
4. The fascia is inked with Indian ink. 
5. The specimen is inspected and palpated for lesions. If a palpable lesion is found, this 
lesion is cut from the fascia side in medial-lateral direction. If a solid lesion is found the 
lesion is measured and the aspect of the lesion is described. A tissue slice is taken for 
direct formalin fixation and one or more small tissue fragments of this lesion are frozen in 
liquid nitrogen. If the resection margins other than the fascia are involved or suspected for 
involvement these are also inked with Indian ink. 
6. The artificial fascia defect is closed with sutures. 
7. The lateral and medial parts of the skin are marked with a waterproof felt pen with a “L” 
and “M”, respectively. 
8. The mastectomy specimen is placed in the refrigerator for overnight cooling to stiffen the 
breast and fat tissue. 
9. The next morning the specimen is palpated. If the tissue is stiff, the specimen can be 
processed. If the tissue is still soft, the specimen is put in a freezer and turned up side 
down every 15 min and every time the issue is inspected. If the tissue is stiff it can be 
processed further. Special attention should be paid to prevent the tissue to be frozen. 
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Figure 3. Specimen radiograms of a right breast without (A) and with (B) pathological findings. 
 
 
A 
 
B 
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Figure 4. Magnified radiograms of Figure 3 with tiny microcalcifications (arrow), pointing towards a 
part of an area of ductal carcinoma in situ (DCIS). 
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10. The breast specimen is sliced on a meat slicing machine form cranial to caudal in 5 mm 
thick slices. 
11. The slices are placed on old mammograms or hard plastic pads in sequence from cranial to 
caudal, as if looking at the tissue from feet to head. 
12. Digital radiograms of the slices are made on a digital radiography/mammography machine 
in sequence from cranial to caudal and stored in the hospital database. 
13. The radiograms are retrieved from the hospital database. 
14. All radiograms are numbered in sequence from cranial to caudal. 
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15. The radiograms are marked; cranial and caudal is added to the first and the last 
radiograms, respectively. Lateral and medial is added to all radiograms. 
16. The tissue (breast, fascia, and skin) is inspected and palpated and the findings are 
correlated with the radiograms and vice versa. 
17. Tissue sampling is performed from the nipple and the four quadrants and areas which are 
aberrant in the breast tissue, fascia, and skin (palpable lesions, discolorations e.g. ochreous 
colored fat tissue, point shaped necrosis, architectural tissue distortion, densities, 
microcalcifications, retraction of the skin or fascia, and thickened skin or fascia), and 
(intramammary) lymph nodes. The number of tissue samples can vary considerably from 
specimen to specimen depending on the size and weight of the specimen, the amount of 
fibrose (which might hamper the judgment of the radiograms leading to more tissue 
samples), the amount and distribution of microcalcifications, etc. 
18. The total number of samples should be ≈18 (range 7-39). 
19. The tissue excisions are marked on the digital radiograms. 
20. The tissue excisions are processed to paraffin blocks, and from the paraffin blocks 4 
micron thick slices are cut for hematoxylin and eosin staining. 
21. In the pathology report all aberrant findings are described, with special attention to the 
premalignant lesions (ALH, ADH, LCIS, and DCIS) and eventual invasive carcinoma. If 
an invasive carcinoma is present, all relevant aspects of the tumor are reported (e.g., tumor 
type, tumor size, histological grade, vessel invasion, skin invasion, invasion of the fascia, 
estrogen receptor and progesterone receptor status, HER-2/neu status, surgical resection 
margins, status of (intramammary) lymph nodes and pTNM stage). If DCIS is present the 
type of DCIS, the histological grade, the size of the lesion, and resection margins are 
reported. 
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22. Eventually, the histopathological findings can be added to the digital specimen radiograms 
and these annotated specimen radiograms can be returned to the hospital database. 
23. The pathological findings are presented in a multidisciplinary meeting with pathologists, 
radiologists, medical oncologists, radiotherapists, and surgeons where the (annotated) 
specimen radiograms are compared with the preoperative radiological examinations. 
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Figure 5
(B), E-cadherin immunohistochemistry (C), ductal carcinoma in situ; cribriform (D) and solid (E), and 
atypical ductal hyperplasia (F).
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Classification of premalignant lesions 
Lobular carcinoma-in-situ (LCIS) 
Lobular carcinoma-in-situ can be divided in two main groups, classical LCIS, which is most 
frequently found, and pleomorphic LCIS. Classical LCIS is defined as a proliferation of small 
and often loosely cohesive cells originating in the terminal duct-lobular unit, with or without 
pagetoid involvement of terminal ducts, and with completely distended duct-lobular units. 
The lobular architecture is maintained. The cells are loosely cohesive and regularly dispersed. 
The cells are monomorphic, small, round, polygonal, or cuboidal, with a high nuclear-
cytoplasmic ratio and frequently intracytoplasmic lumina (Tavassoli and Devilee, 2003) 
(Figure 5A). These cells are also referred to as type A cells (Simpson, et al., 2003; Lakhani et 
al., 2006). Pleomorphic LCIS has the same architecture as the classical type of LCIS, 
however, the cells show mild to moderate enlarged and pleomorphic nuclei with more 
abundant cytoplasm. These cells are also referred to as type B cells (Simpson, et al., 2003; 
Lakhani et al., 2006). 
 
Atypical lobular hyperplasia (ALH) 
Atypical lobular hyperplasia is defined as a proliferation of small and often loosely cohesive 
cells originating in the terminal duct-lobular unit, with or without pagetoid involvement of 
terminal ducts, but without completely distended duct-lobular units (Tavassoli and Devilee, 
2003) (Figure 5B). The cells of ALH are of type A cells as described under classical LCIS 
(Simpson, et al., 2003). The cells of LCIS and ALH characteristically lack expression of E-
cadherin, an intercellular adhesion molecule of epithelial cells (Gamallo et al., 1993) (Figure 
5C). 
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Ductal carcinoma-in-situ (DCIS) 
Ductal carcinoma in situ is defined using the classification of Holland et al. (1994), which is 
based on cytonuclear and architectural differentiation. Three categories are defined; well, 
intermediately, and poorly differentiated DCIS. 
Well differentiated DCIS is composed of cells with monomorphic, regularly spaced nuclei 
containing fine chromatin, inconspicuous nucleoli, and few mitoses. The cells show 
pronounced polarization with orientation of their apical border towards intercellular spaces 
usually resulting in rigid cribriform (Figure 5D), micropapillary, and clinging patterns, 
although solid growth may also occur. Necrosis is uncommon. Calcifications, when present, 
are usually psammomatous. 
Poorly differentiated DCIS is composed of cells with very pleomorphic, irregularly spaced 
nuclei, with coarse, clumped chromatin, prominent nucleoli, and frequent mitoses. 
Architectural differentiation is absent or minimal. The growth pattern is solid or pseudo-
cribriform and pseudo-micropapillary (without cellular polarization). Necrosis is usually 
present. Calcifications, when present, are usually amorphous. 
Intermediately differentiated DCIS is composed of cells showing some pleomorphism but not 
so marked as in the poorly differentiated group, and mitoses are less numerous as in the 
poorly differentiated group. These is, however, always evidence of polarization around 
intercellular spaces, although this is not so pronounced as in the well-differentiated group. 
Solid growth can also be seen (Figure 5E). Necrosis can be present. Calcifications, when 
present, can be psammomatous and amorphous.  
 
Atypical ductal hyperplasia (ADH) 
Atypical ductal hyperplasia is used in the spectrum of ductal hyperplasia, ADH, and well 
differentiated DCIS, and is defined as a lesion exhibiting some, but not all features of well 
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differentiated DCIS (Page and Rogers, 1992; Pinder and Ellis, 2003). ADH is formed by a 
uniform population of small or medium-sized, round, cuboidal, or polygonal hyperchromatic 
cells, which are regularly arranged. The nuclei are evenly distributed and may form a rosette-
like pattern. Only single small nucleoli are seen. Mitoses, particularly abnormal forms, are 
rarely found. Geometric spaces are present and, in cribriform type, the cells are arranged at 
right angles to the bridges formed (Figure 5F). Rigid punched-out lumina are not seen. 
Micropapillary ADH is also recognized and a solid pattern may very rarely be seen. Small 
foci of necrosis may rarely be identified in ADH, and do not indicate that the process should 
be classified as DCIS. 
In case of doubt between classification as ADH or DCIS, ADH is diagnosed. 
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Results and discussion 
The prevalence of DCIS and LCIS lesions reported in studies with women at high genetic risk 
for breast cancer is higher than that reported in the general population. The reported 
prevalence of undiagnosed DCIS in a review of autopsy studies, using various techniques, of 
women with an age range between 15-80 years is ≈9% (range 0-15%) (Welch and Black, 
1997). For LCIS this prevalence is less extensively studied and reported to range between ≈1-
3% (Singletary, 1994).  
Controversies exist regarding the role of DCIS in both BRCA1 and BRCA2 mutation carriers 
(Sun et al., 1996).  From our series we concluded that BRCA1 and BRCA2 mutation carriers 
are equally prone to develop high-risk lesions in their breasts, with ≈8% having occult DCIS 
(Hoogerbrugge et al., 2006) (Table 1). The data from recent studies among DCIS patients 
show that the prevalence of BRCA mutations among DCIS patients is similar to that found in 
patients with invasive breast cancer (Claus et al., 2005; Hwang et al., 2007), suggesting that 
DCIS belongs to the spectrum of inherited breast cancer. As a consequence, in family-
histories, DCIS can be considered as equal to the breast-cancer affected status, when 
considering familial at-risk status for BRCA. 
 
Table 1. High risk epithelial lesions in various groups of patients with a prophylactic mastectomy 
because of a clear autosomal dominant family history for breast cancer (Hoogerbrugge et al., 2006). 
 BRCA1 BRCA2 non-BRCA 
(N) (68) (14) (24) 
    
Overall presence of high-risk lesions 44% 36% 71% 
ALH 26% 21% 67% 
ADH 18% 14% 42% 
LCIS 16% 7% 29% 
DCIS 9% 7% 17% 
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The natural course of LCIS is not entirely clear. There is disagreement about whether LCIS is 
a precursor of invasive disease or merely a marker of subsequent invasive carcinoma risk. In 
women diagnosed with LCIS, ≈30% will develop an invasive carcinoma (Hutter, 1984), 
mostly of the ductal type (Rosen et al., 1980). It seems that LCIS is merely a risk-indicator for 
breast cancer, not a true precursor for invasive disease in most patients. This seems true for 
breast cancer developing in BRCA1 mutation carriers, as ILC is less frequently found in these 
patients than in sporadic breast cancer patients (1-16% versus 5-25%, respectively). For 
BRCA2 mutation carriers, however, this is less obvious, as the frequency of ILC is the same as 
in sporadic breast cancer patients (9-29% and 5-25%, respectively) (Honrado et al., 2006). So, 
at least a part of the invasive breast carcinomas (mean ≈15%) originates from LCIS and LCIS 
is thus the precursor of the invasive cancer. Atypical ductal hyperplasia and ALH are also 
associated with an increased risk of a subsequent invasive carcinoma. The risk is ≈4-5 times 
that of the general population for both ADH and ALH. 
We found a high prevalence of high-risk epithelial lesions in BRCA mutation carriers and 
women at high genetic risk tested negative for such a mutation (43% and 71%, respectively). 
The prevalence was highly correlated with age. Women over 40 years of age had a higher 
prevalence of high-risk lesions than younger women: 60% versus 38%, respectively 
(Hoogerbrugge et al., 2006). This finding is in concordance with the steep increase of the risk 
of breast cancer after the age of 40 years with a cumulative risk of developing breast cancer 
before the age of 50 of 40-50% (Ford et al., 1998). These findings highly suggest that 
invasive breast cancer in BRCA mutation carriers and in women at high genetic risk who are 
tested negative for such a mutation is preceded by premalignant lesions as in sporadic breast 
cancer. 
In conclusion, extensive pathological examination of a prophylactically removed breast in 
BRCA mutation carriers and in women at high genetic risk tested negative for such a mutation 
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is necessary to exclude an occult invasive carcinoma, and may add plausibility to the concept 
of breast cancer risk reduction by prophylactic mastectomy when premalignant lesions are 
detected. Specimen radiography can be very helpful for adequate sampling of the specimen. 
Especially on high resolution radiograms, lesions that are likely to be missed by conventional 
examination can easily be detected. Nevertheless, a substantial number of premalignant high-
risk epithelial lesions can only be identified by examination of “blind” tissue samples of the 
breast specimen. 
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Summarizing discussion 
_____________________________________________ 
 

In chapter 2 the prognostic impact of histopathological skin involvement without cT4 breast 
cancer was evaluated in 482 breast cancer patients not treated with adjuvant systemic therapy 
and with long-term follow-up (median follow-up: 141 months). 
Seven patients (1%) had cT4 breast cancer confirmed by histopathological examination 
(cT4/pT4). Thirty-three patients (7%) showed histopathological skin involvement without cT4 
breast cancer (non-cT4/pT4 skin involvement), of whom 11 (33%) had dermal lymphatic 
involvement. In multivariate survival analyses breast cancers with non-cT4/pT4 skin 
involvement showed independent prognostic significance for overall survival and breast 
cancer specific survival (BCSS). However, when patients with dermal lymphatic involvement 
were excluded from the entire group of patients with non-cT4/pT4 skin involvement, the 
prognosis of the remaining patients was similar to patients with comparable tumour 
characteristics but without skin involvement. On the other hand, for patients with non-
cT4/pT4 skin involvement but with dermal lymphatic involvement the prognosis was as 
worse as that of patients with cT4/pT4 breast cancers with almost identical HRs for BCSS 
(4.73 (95% CI: 2.10-10.65) and 5.91 (95% CI: 2.40-14.59), respectively). 
cT4 breast cancer according to the UICC/TNM classification includes tumour extension to 
chest wall, edema (including peau d’orange), satellite nodules, or ulceration of the skin, or 
inflammatory carcinoma. Microscopic, clinically occult skin involvement without cT4 breast 
cancer is not a separate category in the (UICC/TNM) classification. This type of tumour is 
included in the pT1-3 category and is explicitly excluded from the pT4 category. 
We confirmed the strong prognostic significance of cT4/pT4 breast cancer as defined by the 
UICC/TNM classification. However, histopathological skin involvement without cT4 breast 
cancer, but with lymph vessel invasion in the skin is of similar prognostic significance. This 
type of tumour may represent a precursor of the full-blown T4d inflammatory carcinoma, 
characterized by massive lymph vessel invasion in the dermis, with equally poor prognosis. 
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In the contrary, tumours with skin involvement by direct extension or microscopical satellite 
lesions but without dermal lymphatic involvement have the same, more favourable prognosis 
as tumours with no skin involvement.  
In daily clinical practice the finding of microscopical skin involvement without cT4 breast 
cancer leads to considerable discussion within the multidisciplinary breast cancer working 
group on how to treat these patients. E.g. how to manage patients with small tumours close to 
and with direct extension into the skin or patients with dermal microscopic lymph vessel 
invasion but without clinical inflammatory cancer? Should these patients be treated with loco-
regional radiotherapy, adjuvant systemic treatment, or both, or is adjuvant treatment not 
necessary in the presence of otherwise favourable patient and tumour characteristics? 
According to the UICC/TNM classification these patients should be managed as having pT1-3 
tumours. However, in present study we have shown that patients with tumours with non-
cT4/pT4 skin involvement, but with dermal lymphatic involvement had a particularly dismal 
prognosis similar to that of patients with cT4/pT4 breast cancers. We therefore propose to 
include tumours with clinically occult dermal lymphatic involvement into the UICC/TNM 
cT4/pT4 category and that patients with this type of tumours should thus be treated as those 
with cT4/pT4 breast cancers. 
 
In chapter 3 the prognostic value of the mitotic activity index (MAI) and the volume 
corrected mitotic index (M/V-index) was evaluated and compared with that of the histological 
grade in 477 breast cancer patients not treated with adjuvant systemic therapy and with long-
term follow-up. 
In multivariate survival analyses the MAI and M/V-index showed similar hazard rate ratios 
(HR) compared to histological grade for overall survival (OS) and similar or lower HRs for 
breast cancer specific survival (BCSS). For OS the M/V-index was a slightly more powerful 
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variable than the MAI or histological grade. However, for BCSS histological grade was a 
slightly more powerful variable compared to the MAI or M/V-index. The other independent 
prognostic variables for OS and BCSS were age at diagnosis, tumour size, and number of 
positive lymph nodes. 
It was concluded that long-term OS and BCSS is independently predicted by the classical 
clinicopathologic prognostic factors as used in various guidelines. In the breast cancer patients 
under study, we were not able to demonstrate that the MAI and M/V-index were more 
informative in predicting outcome than histological grade. 
In the Netherlands a differentiated guideline is used greatly based on age, tumour size, 
histological grade, and nodal status. At this moment, little evidence has been published to 
justify replacement of the histological grade by mitotic activity. Most of the published data on 
mitotic indices are single institutional data. 
Mitotic indices are thought to be good quantitative prognostic factors. However, mitotic 
indices suffer from inter- and intra-observer variability just as histological grade does. 
Based on the results presented in chapter 3 and the scarce published data, changing of the 
guidelines for treatment of breast cancer in favour of the mitotic indices in stead of 
histological grade is not recommended. 
 
In chapter 4 a review of the literature was presented concerning the prognostic impact of 
micro-metastases. The reviewed studies had a follow-up of at least 5 years and included more 
than 100 patients before the sentinel node (SN) era. Furthermore, studies in which 
conventionally haematoxylin-eosin (H&E) negative SNs were investigated for occult 
metastases by serial sectioning (SS) and/or immunohistochemistry (IHC) were reviewed. 
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In only one of eight studies, occult metastases were an independent risk factor for reduced 
survival. However, the outcome was dependent on the size of the nodal metastasis. IHC and 
SS as used in the SN procedure induced a shift from pN0 to pN1 (according to UICC/TNM). 
By the thorough pathologic examination of the SN, isolated tumour cells and micro-
metastases were more frequently detected. 
SN biopsy has largely replaced axillary lymph node dissection (ALND) for staging of the 
axilla in breast cancer. Examination of the SN by SS and IHC results into stage migration due 
to the increased detection of micro-metastases. The consequence may be overshooting of 
patients with adjuvant therapy, as the prognostic relevance of (small) micro-metastases and 
isolated tumour cells is yet unclear. 
The prognostic significance of micro-metastases was examined in studies before the SN era 
and SNs initially examined by H&E only. However, the question remains if these data can 
directly be translated to the daily clinical practice when SN procedure is the standard of care 
with SS and IHC. Handling of non-SNs and SNs in the described studies is different from 
SNs nowadays. Usually, in routinely processed lymph nodes, only one or two levels are 
examined with H&E. These levels are cut after cutting into the paraffin block, whereas SNs 
are (usually) serial sectioned with H&E and IHC with careful cutting of the paraffin block. 
This means that, on beforehand, from the paraffin embedded material of non-SNs and 
conventionally processed SNs more tissue is lost than from nowadays SNs. Also, the non-SNs 
and conventionally processed SNs are not routinely examined with IHC. Even by serial 
sectioning of these lymph nodes with IHC one might expect to detect less metastases than in 
present SN techniques. Therefore, studies are needed in which all patients receive a SN 
procedure with SS and IHC to test if the described findings are the same for the patients who 
undergo a SN procedure nowadays. 
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In an ongoing study, the MIRROR (Micro-metastases and Isolated tumour cells: Robust and 
Relevant Or Rubbish?) study the prognostic and predictive significance of isolated tumour 
cells and micro-metastases will be elucidated in a total of 3000 breast cancer patients with 
otherwise good primary tumour characteristics who underwent a SN procedure. This study is 
a nationwide study in the Netherlands including patients with a median follow-up of at least 5 
years. The study population is divided in 3 cohorts, 1000 patients in cohort 1 without tumour 
involvement in the lymph nodes and without adjuvant systemic therapy, 1000 patients in 
cohort 2 with isolated tumour cells or micro-metastases in the lymph nodes and without 
adjuvant systemic therapy, and cohort 3 with isolated tumour cells or micro-metastases and 
adjuvant systemic therapy. By comparing cohort 1 and 2, the prognostic significance of 
isolated tumour cells and micro-metastases will became clear and by comparing cohort 2 and 
3, the predictive significance of adjuvant systemic therapy in case of isolated tumour cells and 
micro-metastases will be elucidated. 
The first results of this study will be available at the end of 2008. 
 
In chapter 5 the pathology protocol which is used to examine the SN was studied in four 
hospitals (A-D) in the eastern part of the Netherlands. In hospitals A, B, and C, three levels of 
the SN were examined pathologically, whereas in hospital D, at least seven additional levels 
were examined. In the absence of apparent metastases with H&E examination, 
immunohistochemical examination was performed in all four hospitals. 
In total, 541 eligible patients were included. In hospital D, with the more intensified 
examination of the SN, more patients were diagnosed with a positive SN as compared with 
the other three hospitals, mainly because of increased detection of isolated tumour cells. This 
led to more completion ALNDs in hospital D (66.3% of patients (P<0.0001)), compared with 
29.0% in the three other hospitals combined. Positive non-SNs were detected in 13.9% of 
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patients in hospital D, compared with 9.7% in hospitals A, B, and C together. That is, in 
52.4% of patients in hospital D, a negative completion axillary lymph node dissection was 
performed, compared with on average 19.3% of patients in hospitals A, B, and C combined. 
In hospital D, the higher number of SN positive cases was largely based on the finding of 
isolated tumour cells. However, the percentage of non-SN positive cases (13.3%) was similar 
to that of hospitals A (12.5%), the hospital in which ALND was routinely performed in case 
of isolated tumour cells in the SN. In both hospitals B and C in only 1 of 4 cases (25%) 
ALND was performed. In hospital A and D the non-SN positive cases were all 
micrometastases (3/6; 50%) or macrometastases (3/6; 50%). Thus, these findings changed the 
classification of the breast cancer from pN0 to pN1. These findings suggest an under-staging 
in the hospitals A-C, especially in the pN0(i-) group. As lymph node status is the most 
powerful prognosticator in breast cancer, the patients in whom the axilla is still in situ but 
containing lymph node micrometastases or macrometastases might not receive an appropriate 
local and adjuvant systemic treatment. This can lead to local or systemic recurrences, which 
might have been prevented if the positive axillary lymph nodes would have been removed at 
first presentation. 
Internationally, there is no consensus on the pathology protocol to be used for examination of 
SNs. At present, therefore, various hospitals use different SN pathology protocols. 
As was shown, differences in SN pathology protocols between hospitals do have a substantial 
effect on SN findings and subsequent surgical treatment strategies and classification of breast 
cancer. Whether additional surgery and upstaging of a part of the breast cancer cases can offer 
better survival for the patients remains to be determined. 
 
In chapter 6-8 the findings of prophylactic mastectomy in high risk patients with or without a 
BRCA mutation were presented and discussed. The lifetime risk of breast cancer in BRCA 
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mutation carriers is 55–85%, and the estimated lifetime risk of breast cancer in the group 
without a BRCA1 or BRCA2 mutation in the presented studies was more than 30%. 
In the whole group of patients in chapter 8 (N=106; 68 BRCA1 mutation carriers, 14 BRCA2 
mutation carriers, and 24 non-BRCA mutation carriers) the prevalence of high-risk lesions 
(atypical lobular hyperplasia (ALH), atypical ductal hyperplasia (ADH), lobular carcinoma in 
situ (LCIS), and ductal carcinoma in situ (DCIS)) was 49%. 
The prevalence of high-risk lesions was equal in women with a BRCA1 or a BRCA2 
mutation, but was higher in non-BRCA mutation carriers; all lesions 43% versus 71%, 
respectively. 
The prevalence of high-risk lesions was correlated with age with a significant higher 
prevalence in the patient group older than 40 years. Again, there was a difference for BRCA 
mutation carriers and non-BRCA mutation carriers; 55% and 80%, respectively. 
It was concluded that women with an autosomal dominant family history for breast cancer, 
with and without a BRCA mutation are prone to develop high-risk epithelial lesions, 
especially over 40 years of age. 
The high prevalence of high risk lesions in women with a BRCA mutation is in line with the 
high chance of developing invasive breast cancer in this patient population, as well as with the 
age of appearance of invasive breast cancer, which is at an approximately 20 years younger 
age than in sporadic breast cancer. For women carrying a BRCA mutation, the risk of breast 
cancer begins to increase before the age of 25 years, with a steep increase after the age of 40 
years. The cumulative risk of developing breast cancer before the age of 40 years is 
approximately 15%, whereas the risk of developing breast cancer before the age of 50 years is 
40-50%. In chapter 6 and chapter 8, all types of high-risk lesions showed a higher prevalence 
in the group of women aged 40 years and older. 
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Frequently high-risk lesions were multifocal/multicentric or bilateral. This may explain the 
high risk of a second primary carcinoma in conservatively treated breasts and the high risk of 
contralateral breast cancer in these patients. 
The lower prevalence of high-risk lesions in women who carried a BRCA mutation may 
indicate a different pathophysiology in the progression of precancerous lesions to invasive 
cancer than in the group without such a mutation. It seems that progression from precancerous 
lesions to invasive carcinoma is faster in women with a BRCA mutation than in non-BRCA 
mutation carriers. 
The high prevalence of DCIS and other high-risk lesions, such as LCIS, ADH, and ALH, in 
the prophylactically removed breasts strongly supports the relevance of prophylactic 
mastectomy in women who are at high hereditary risk for breast cancer. 
 
In chapter 9, the pathological examination of prophylactically removed breasts was described 
in detail. The high prevalence of lesions, like DCIS, LCIS, ADH, and ALH, which were 
described in chapter 6 and chapter 8 may be explained by a careful macroscopic examination 
of the breast specimens combined with specimen radiograms and a large number of excisions. 
The resolution of specimen radiograms is higher than that of mammograms. Therefore, with 
specimen radiography it is possible to detect very small architectural distorsions, densities, or 
tiny microcalcifications. This procedure made it possible to detect normally occult lesions 
such as carcinoma in situ or atypical hyperplasia. 
Also, multifocal, multicentric, and bilateral (in case of bilateral mastectomy) lesions can 
easily be diagnosed. Nevertheless, a substantial number of premalignant high-risk epithelial 
lesions can only be identified by examination of “blind” tissue samples of the breast 
specimen. 
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The described procedure of pathological examination of prophylactically removed breasts 
with specimen radiography is fully digitalized. Comparison with preoperative digital 
radiological diagnostics, like mammography, ultrasound, and MRI is very easy. The 
procedure is therefore very helpful in training residents, radiologists, radiotherapists, and 
pathologists.  
The breast specimens radiography is not only very helpful in evaluating prophylactically 
removed mastectomy specimens, but also for examination specimens removed from patient 
not known with a hereditary predisposition for breast cancer. As is known, multifocal and 
multicentric malignant breast disease is also not rare in these patients. 
In the Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands, the 
described procedure is a routine procedure largely carried out by specially trained technicians. 
The procedure is used for all mastectomy specimens and excisional biopsies/lumpectomies 
with a known or suspected malignancy. 
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Samenvattende discussie 
_____________________________________________ 
 

In hoofdstuk 2 werd de prognostische relevantie geëvalueerd van histopathologische 
huidlokalisatie zonder klinisch T4 (cT4) borstkanker bij 482 patiënten die niet werden 
behandeld met adjuvante systemische therapie en langdurig werden gevolgd, met een mediane 
follow-up van 141 maanden. 
Zeven patiënten (1%) hadden cT4 borstkanker, welke werd bevestigd met histopathologisch 
onderzoek (cT4/pT4). Drieëndertig patiënten (7%) hadden histopathologische huidlokalisatie 
zonder cT4 borstkanker (niet-cT4/pT4 huidlokalisatie). Van deze 33 patiënten hadden er 11 
(33%) lymfvatinvasie in de huid. Bij multivariate analyse bleek borstkanker met niet-cT4/pT4 
huidlokalisatie een onafhankelijke prognostische factor te zijn voor zowel totale overleving 
als borstkanker gerelateerd overleving. Echter, wanneer van de groep patiënten met 
borstkanker met niet-cT4/pT4 huidlokalisatie die patiënten werden verwijderd die 
lymfvatinvasie in de huid toonden, dan bleek de totale en borstkanker gerelateerde overleving 
van de resterende groep patiënten niet te verschillen van de groep patiënten zonder 
huidlokalisatie, maar overeenkomstige tumorkenmerken. Daarentegen was de prognose van 
de patiënten met borstkanker met niet-cT4/pT4 huidlokalisatie, maar met lymfvatinvasie in de 
huid net zo slecht als die van patiënten met cT4/pT4 borstkanker met nagenoeg identieke 
hazard ratios voor borstkanker gerelateerde overleving (respectievelijk 4.73 en 5.91). 
Onder cT4 borstkanker volgens de UICC/TNM classificatie wordt gerekend tumoruitbreiding 
in de borstwand, oedeem (inclusief peau d’orange), satelliethaarden of ulceratie van de huid, 
of inflammatoir borstkanker. Binnen de UICC/TNM classificatie is microscopische, klinisch 
occulte huidlokalisatie zonder cT4 borstkanker geen aparte categorie. Dit type tumor wordt 
ingedeeld in de pT1-3 categorie en wordt expliciet uitgesloten van de pT4 categorie. 
Wij hebben de sterke prognostische betekenis van cT4/pT4 borstkanker, zoals gedefinieerd 
door de UICC/TNM classificatie, bevestigd. Echter, huidlokalisatie zonder cT4 borstkanker, 
maar met lymfvatinvasie in de huid is van gelijke prognostische betekenis. Dit type tumor zou 
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een voorloper kunnen zijn van het volledig ontwikkelde beeld van T4d inflammatoir 
borstkanker, welke gekarakteriseerd wordt door massale lymfvatlokalisatie in de huid, met 
dezelfde slechte prognose. 
Daarentegen hebben patiënten met borstkanker met directe uitbreiding van de tumor in de 
huid of microscopische satelliethaarden in de huid, maar zonder lymfvatinvasie in de huid een 
betere prognose, overeenkomend met patiënten met tumoren zonder huidlokalisatie. 
In de dagelijkse praktijk leidt de bevinding van microscopisch huidlokalisatie zonder cT4 
borstkanker tot veel discussie binnen de mammatumor werkgroep over hoe deze patiënten 
behandeld moeten worden. Bijvoorbeeld, hoe moeten patiënten behandeld worden met kleine 
tumoren dichtbij en met uitbreiding in de huid, of patiënten met microscopische 
lymfvatinvasie in de huid, maar zonder klinisch inflammatoir borstkanker? Moeten deze 
patiënten behandeld worden met locoregionale radiotherapie, adjuvante systemische therapie, 
of beide, of is adjuvante therapie bij anderzijds gunstige patiënt- en tumorkarakteristieken niet 
nodig? Volgens de UICC/TNM classificatie moeten deze patiënten behandeld worden alsof ze 
een pT1-3 borstkanker hebben. Echter, met de huidige studie hebben we aangetoond dat 
patiënten met tumoren met niet-cT4/pT4 huidlokalisatie, maar met lymfvatinvasie in de huid 
een erg slechte prognose hebben, vergelijkbaar met patiënten met cT4/pT4 borstkanker. 
Daarom stellen we voor om tumoren met klinisch occulte lymfvatinvasie in de huid toe te 
voegen aan de UICC/TNM cT4/pT4 categorie en dat patiënten met dit type tumor hetzelfde 
behandeld moeten worden als patiënten met cT4/pT4 borstkanker. 
 
In hoofdstuk 3 werd de prognostische betekenis van de mitotische activiteitsindex (MAI) en 
de volume gecorrigeerde mitotische index (M/V-index) geëvalueerd en vergeleken met de 
histologische graad bij 477 patiënten met borstkanker die niet werden behandeld met 
adjuvante systemische therapie en langdurig werden gevolgd. 
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Bij multivariate analyse toonden de MAI en M/V-index overeenkomstige hazard ratios 
vergeleken met de histologische graad, voor zowel totale overleving als voor borstkanker 
gerelateerde overleving. Voor de totale overleving was de M/V-index een iets sterkere 
variabele dan de MAI en histologische graad. Echter, voor de borstkanker gerelateerde 
overleving was de histologische graad een iets sterkere variabele dan de MAI en M/V-index. 
De andere onafhankelijke prognostische factoren voor totale en borstkanker gerelateerde 
overleving waren de leeftijd bij diagnose, de tumorgrootte en het aantal lymfklieren met 
uitzaaiingen van de borstkanker. 
Geconcludeerd werd dat langdurige totale en borstkanker gerelateerd overleving wordt 
voorspeld door de klassieke prognostische factoren welke gebruikt worden in diverse 
richtlijnen. Met de groep patiënten in deze studie waren we niet in staat om aan te tonen dat 
de MAI en M/V-index beter waren in het voorspellen van de uitkomst dan de histologische 
graad. 
In Nederland wordt een gedifferentieerde richtlijn gebruikt die grotendeels gebaseerd is op 
leeftijd, tumorgrootte, histologische graad en lymfklierstatus. Op dit moment is er weinig 
bewijs gepubliceerd die het rechtvaardigt om de histologische graad te vervangen door de 
mitotische activiteit. De meeste gepubliceerde data over mitotische activiteit zijn data 
afkomstig van één instituut. 
Van de mitotische indices wordt gedacht dat het harde kwantitatieve prognostische factoren 
zijn. Echter, de mitotische indices staan, net als de histologische graad, bloot aan verschillen 
die ontstaan tussen verschillende beoordelaars, maar ook door verschillen die ontstaan 
wanneer dezelfde beoordelaar de bepaling meerdere keren doet. 
Op grond van de resultaten zoals gepresenteerd in hoofdstuk 3 en de schaarse gepubliceerde 
data wordt een verandering van de richtlijn voor behandeling van borstkanker ten voordele 
van de mitotische indices en ten nadele van de histologische graad niet aangeraden. 
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In hoofdstuk 4 werd een literatuuroverzicht gepresenteerd over de prognostische betekenis 
van micrometastasen. De beoordeelde studies hadden een follow-up van ten minste 5 jaar en 
includeerden meer dan 100 patiënten van vóór de schildwachtklier periode. Daarnaast werden 
studies geïncludeerd waarbij schildwachtklieren die bij conventioneel hematoxyline-eosine 
onderzoek negatief waren opnieuw werden onderzocht door het maken van een serie extra 
coupes met een hematoxyline-eosine kleuring (stapserie onderzoek) en/of 
immuunhistochemisch onderzoek. 
Bij slechts 1 van de acht studies waarbij occulte metastasen werden aangetroffen was dit een 
onafhankelijke prognostische factor voor verminderde overleving. Echter, de uitkomst was 
wel afhankelijk van de grootte van de lymfklieruitzaaiing. Het immuunhistochemische 
onderzoek en het stapserie onderzoek zoals gebruikt werd bij de studies met de  
schildwachtklierprocedure leidden tot een verschuiving van pN0 naar pN1 (volgens 
UICC/TNM). 
Door het uitgebreide pathologische onderzoek van de schildwachtklieren werden geïsoleerde 
tumorcellen en micrometastasen vaker gevonden. 
Het schildwachtklieronderzoek heeft de okselklierdissectie voor de stagering van de oksel bij 
borstkanker grotendeels vervangen. Het onderzoek van de schildwachtklier met behulp van 
stapserie onderzoek en immuunhistochemie leidt tot stadiummigratie als gevolg van de 
detectie van micrometastasen. Het gevolg hiervan kan zijn dat teveel patiënten behandeld 
worden met adjuvante systemische therapie, omdat de prognostische relevantie van (kleine) 
micrometastasen en geïsoleerde tumorcellen nog niet is opgehelderd. 
In hoofdstuk 4 werd de prognostische relevantie van micrometastasen bestudeerd in studies 
vóór de schildwachtklier periode en bij schildwachtklieren die aanvankelijk alleen met een 
hematoxyline-eosine kleuring werden onderzocht. Echter, de vraag blijft of deze bevindingen 
direct vertaald kunnen worden naar de huidige dagelijkse praktijk waarbij de 
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schildwachtklierprocedure de standaard behandeling is en stapserie onderzoek en 
immuunhistochemie hiervan een regulier onderdeel zijn. 
Het onderzoek van de niet-schildwachtklieren en schildwachtklieren zoals beschreven in de 
studies verschilt van het onderzoek van de schildwachtklieren zoals dat nu gebeurt. 
Meestal worden lymfklieren in de routinebehandeling onderzocht op slechts 1 of 2 niveaus 
met de hematoxyline-eosine kleuring. Deze niveaus worden verkregen na het insnijden van 
het paraffineblokje. Daarentegen worden schildwachtklieren met stapserie onderzocht met de 
hematoxyline-eosine kleuring en immuunhistochemie waarbij het paraffineblokje voorzichtig 
wordt aangesneden. Dit betekent dat bij het onderzoek van de lymfklieren in de studies bij 
voorbaat al meer weefsel verloren is gegaan dan bij het onderzoek van de huidige 
schildwachtklieren. Tevens werden de lymfklieren in de studies niet routinematig met 
immuunhistochemie onderzocht. Zelfs indien deze lymfklieren wel met stapserie onderzoek 
en immuunhistochemie werden onderzocht mag men ervan uitgaan dat er minder metastasen 
gedetecteerd zouden worden dan bij de huidige gebruikte methodiek. Daarom zijn er studies 
nodig waarbij alle patiënten een schildwachtklierprocedure ondergaan met stapserie 
onderzoek en immuunhistochemie om te kijken of de beschreven bevindingen in hoofdstuk 4 
hetzelfde zijn voor patiënten die de huidige schildwachtklierprocedure ondergaan. 
In een lopende studie, de MIRROR (Micro-metastases and Isolated tumour cells: Robust and 
Relevant Or Rubbish?) studie wordt de prognostische en predictieve relevantie van 
geïsoleerde tumorcellen en micrometastasen onderzocht bij totaal 3000 patiënten met 
borstkanker en anderzijds gunstige primair tumorkenmerken en bij wie een 
schildwachtklierprocedure werd uitgevoerd. 
Deze studie is een landelijk studie in Nederland waarbij patiënten worden geïncludeerd met 
een mediane follow-up van ten minste 5 jaar. De studiepopulatie is verdeeld in 3 cohorten. 
Duizend patiënten in cohort 1 zonder lymfkliermetastasen en zonder adjuvante systemische 
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therapie, 1000 patiënten in cohort 2 met geïsoleerde tumorcellen of micrometastasen in de 
lymfklieren, maar zonder adjuvante systemische therapie en cohort 3 met 1000 patiënten met 
geïsoleerde tumorcellen of micrometastasen in de lymfklieren en behandeld met adjuvante 
systemische therapie. 
Door cohort 1 met cohort 2 te vergelijken kan de prognostische relevantie van geïsoleerde 
tumorcellen en micrometastasen worden achterhaald. Door cohort 2 met cohort 3 te 
vergelijken kan de predictieve relevantie van adjuvante systemische therapie worden 
opgehelderd bij de aanwezigheid van geïsoleerde tumorcellen en micrometastasen. 
De eerste resultaten van deze studie worden eind 2008 verwacht. 
 
In hoofdstuk 5 was het pathologieprotocol dat gebruikt wordt voor het onderzoek van 
schildwachtklieren in 4 ziekenhuizen (A-D) in het oosten van Nederland onderwerp van 
studie. In de ziekenhuizen A, B en C werden 3 niveaus van de schildwachtklier pathologisch 
onderzocht, terwijl in ziekenhuis D ten minste 7 extra niveaus werden onderzocht. Indien er 
bij hematoxyline-eosine onderzoek geen duidelijke metastasen werden aangetroffen, werd in 
alle 4 ziekenhuizen aanvullend immuunhistochemisch onderzoek verricht. 
In totaal werden 541 patiënten geïncludeerd. In ziekenhuis D, met het meer uitgebreide 
onderzoek van de schildwachtklier, werden meer patiënten met een positieve schildwachtklier 
gediagnosticeerd dan in de andere 3 ziekenhuizen, vooral door de detectie van meer 
geïsoleerde tumorcellen. Dit leidde tot meer okselklierdissecties in ziekenhuis D (66,3% van 
de patiënten (P<0.0001)) ten opzichte van 29.0% in de andere drie ziekenhuizen gezamenlijk. 
Positieve niet-schildwachtklieren werden in ziekenhuis D in 13.9% aangetroffen, tegen 9.7% 
in de ziekenhuizen A, B en C gezamenlijk. Dit betekent dat in ziekenhuis D bij 52.4% van de 
patiënten een okselklierdissectie werd verricht waarbij geen metastasen werden aangetroffen, 
tegen gemiddeld 19.3% in de ziekenhuizen A, B en C. 
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Het hogere aantal schildwachtklier positieve gevallen in ziekenhuis D bestond voornamelijk 
uit geïsoleerde tumorcellen. Echter, het percentage niet-schildwachtklier positieve gevallen 
(13.3%) kwam overeen met dat in ziekenhuis A (12.5%), het ziekenhuis waar routinematig 
een okselklierdissectie werd uitgevoerd bij de aanwezigheid van geïsoleerde tumorcellen in de 
schildwachtklier. In beide ziekenhuizen B en C werd slechts in 1 van 4 gevallen (25%) een 
okselklierdissectie verricht. In de ziekenhuizen A en D waren de niet-schildwachtklier 
positieve gevallen allen micrometastasen (3/6; 50%) of macrometastasen (3/6; 50%). 
Hierdoor veranderde de classificatie van de borstkanker van pN0 in pN1. Deze bevindingen 
suggereren een onderstagering in de ziekenhuizen A-C, voornamelijk in de pN0(i-) groep. 
Omdat de lymfklierstatus de sterkste prognostische factor is bij borstkanker, bestaat de 
mogelijkheid dat die patiënten waarbij er in de oksel nog lymfklieren aanwezig zijn met 
micrometastasen of macrometastasen niet de adequate locale en adjuvante systemische 
therapie ontvangen. Dit kan leiden tot locale en systemische recidieven die voorkomen 
hadden kunnen worden indien de positieve oksellymfklieren in eerste instantie al verwijderd 
waren. 
Internationaal is er geen consensus over welk pathologieprotocol gebruikt moet worden voor 
het onderzoek van de schildwachtklieren. Daarom worden er in verschillende ziekenhuizen 
verschillende pathologieprotocollen gebruikt. 
Zoals werd aangetoond in hoofdstuk 5, hebben verschillende pathologieprotocollen voor het 
onderzoek van schildwachtklieren een substantieel effect op de uitslag van het 
schildwachtklieronderzoek en de vervolgens uitgevoerde chirurgische ingrepen en 
classificatie van de borstkanker. Of additionele chirurgie en daarmee een hoger stadium voor 
een deel van de borstkankergevallen zal leiden tot een betere overleving moet nog worden 
aangetoond. 
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In hoofdstuk 6-8 werden de bevindingen van preventief verwijderde borsten bij hoogrisico 
patiënten gepresenteerd en bediscussieerd. Het risico op borstkanker bij BRCA 
mutatiedraagsters is tijdens het leven 55-85% en het geschatte risico op borstkanker bij de 
groep zonder een BRCA1 of BRCA2 mutatie was in de besproken studies meer dan 30%. 
In de gehele onderzochte groep van patiënten in hoofdstuk 8 (N=106; 68 BRCA1 
mutatiedraagsters, 14 BRCA2 mutatiedraagsters en 24 patiënten zonder een BRCA mutatie) 
was de prevalentie van hoogrisico laesies (atypische lobulaire hyperplasie (ALH), atypische 
ductale hyperplasie (ADH), lobulair carcinoma in situ (LCIS) en ductaal carcinoma in situ 
(DCIS)) 49%. 
De prevalentie van hoogrisico laesies was gelijk voor de vrouwen met een BRCA1 of een 
BRCA2 mutatie, maar was hoger bij de vrouwen zonder een BRCA mutatie; alle laesies 
respectievelijk 43% versus 71%. 
Het voorkomen van hoogrisico laesies was gerelateerd aan leeftijd, met een significant hogere 
prevalentie in de patiëntengroep ouder dan 40 jaar. Ook hierbij was er een verschil tussen de 
BRCA mutatiedraagsters en de niet-mutatiedraagsters, respectievelijk 55% en 80%. 
Er werd geconcludeerd dat vrouwen met een autosomaal dominant overervende 
familiehistorie voor borstkanker vatbaar zijn voor het ontwikkelen van hoogrisico epitheliale 
laesies, vooral na de leeftijd van 40 jaar. 
De hoge prevalentie van hoogrisico laesies bij vrouwen met een BRCA mutatie komt overeen 
met de hoge kans op de ontwikkeling van borstkanker in deze patiëntenpopulatie. Ook komt 
dit overeen met de leeftijd waarop de borstkanker optreedt, die ongeveer 20 jaar jonger is dan 
bij vrouwen met de zogenaamde sporadische borstkanker. Voor vrouwen met een BRCA 
mutatie begint het risico om borstkanker te krijgen te stijgen voor de leeftijd van 25 jaar, met 
een sterke stijging na de leeftijd van 40 jaar. Het cumulatieve risico om borstkanker te krijgen 
voor de leeftijd van 40 jaar is ongeveer 15%, terwijl dit voor de leeftijd van 50 jaar 40-50% is. 
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In hoofdstuk 6 en hoofdstuk 8 toonden alle hoogrisico laesies een hogere prevalentie in de 
groep vrouwen van 40 jaar en ouder. 
Regelmatig waren de hoogrisico laesies multifocaal/multicentrisch of bilateraal. Dit kan het 
hoge risico verklaren bij deze patiënten op het krijgen van een tweede primaire borstkanker in 
de borstsparend behandelde borst en het hoge risico op het krijgen van een borstkanker in de 
andere borst. 
De lagere prevalentie van hoogrisico laesies in vrouwen met een BRCA mutatie kan er op 
wijzen dat er hier sprake is van een andere pathofysiologie bij de progressie van premaligne 
laesies naar een invasief carcinoom dan bij vrouwen zonder deze mutatie. Het lijkt er op dat 
de progressie van een premaligne laesie bij vrouwen met een BRCA mutatie sneller gaat dan 
bij vrouwen zonder een BRCA mutatie. 
De hoge prevalentie van DCIS en andere hoogrisico laesies, zoals LCIS, ADH en ALH in 
preventief verwijderde borsten ondersteunt in hoge mate de relevantie van preventieve 
verwijdering van de borsten bij vrouwen met een hoog familiair risico op het krijgen van 
borstkanker. 
 
In hoofdstuk 9 werd het pathologische onderzoek van de preventief verwijderde borsten in 
detail beschreven. De hoge prevalentie van laesies zoals DCIS, LCIS, ADH en ALH, zoals 
beschreven in hoofdstuk 6 en hoofdstuk 8, kan worden verklaard door het nauwkeurige 
macroscopische onderzoek van de borstpreparaten, in combinatie met specimenradiografie en 
het grote aantal excisies. 
De resolutie van specimenradiogrammen is groter dan die van mammografieën. Daarom is het 
mogelijk om met specimenradiografie erg kleine architecturele verstoringen, densiteiten of 
kleine microcalcificaties te detecteren. Met deze procedure was het mogelijk om gewoonlijk 
occulte laesies zoals carcinoom is situ of atypische hyperplasie te detecteren. 
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Tevens kunnen multifocale, multicentrische en bilaterale (in geval van bilaterale 
borstverwijdering) laesies worden gediagnosticeerd. Toch kon een substantieel deels van de 
premaligne hoogrisico epitheliale laesies alleen worden gevonden door onderzoek van “blind” 
gesamplede weefselfragmenten van de borstpreparaten. 
De in hoofdstuk 9 beschreven procedure voor het pathologische onderzoek van preventief 
verwijderde borsten is volledig gedigitaliseerd. Hierdoor is vergelijking met preoperatieve 
radiologische beeldvorming zoals mammografie, echografie en MRI erg gemakkelijk. De 
procedure kan goed gebruikt worden voor de opleiding van artsen in opleiding tot medisch 
specialist, radiologen, radiotherapeuten en pathologen. 
Het onderzoek van borstpreparaten met specimenradiografie is niet alleen bijzonder nuttig 
voor onderzoek van preventief verwijderde borsten, maar ook voor onderzoek van 
borstpreparaten die verwijderd zijn bij patiënten zonder een familiaire vatbaarheid voor 
borstkanker. Zoals bekend is, is het optreden van multifocale of multicentrische kwaadaardige 
ziekte bij deze patiënten ook niet zeldzaam. 
In het Radboud Universiteit Nijmegen Medisch Centrum, Nijmegen, Nederland, is de 
beschreven procedure een routinematig uitgevoerde procedure en wordt grotendeels 
uitgevoerd door speciaal hiervoor opgeleide medisch analisten. De procedure wordt gebruikt 
voor borstamputaties en excisies met een bekende kwaadaardigheid of een verdenking hierop. 
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Dankwoord 
_____________________________________________ 
 

Voordat ik iedereen wil bedanken voor hun bijdrage aan mijn proefschrift wil ik nog een 
aantal woorden wijden aan het tot stand komen hiervan.  
Al snel tijdens mijn opleiding tot patholoog ontwikkelde zich een grote interesse voor de 
mammapathologie. Deze werd nog extra gestimuleerd door Roland Holland. Na afronding 
van de opleiding tot patholoog kon ik de mammapathologie van Roland overnemen. 
Aangezien ik graag in de academie wilde blijven werden er al snel plannen gemaakt om 
promotieonderzoek te doen in de mammapathologie. Het onderzoek moest echter gebeuren 
naast mijn patiëntenzorgtaken, onderwijstaken en opleidingstaken. Dit bleek een hele klus, 
mede doordat er in de afgelopen jaren binnen Blok-1 tweemaal gedurende langere tijd een 
onderbezetting van pathologen was. Ik ben dan ook bijzonder blij dat het uiteindelijk toch 
gelukt is mijn proefschrift af te ronden. Dit was echter niet mogelijk zonder de bijdragen van 
velen. 
 
Beste Roland, als eerste promotor van mijn proefschrift wil ik je hartelijk bedanken voor je 
niet aflatende inspanningen. We hebben zeer regelmatig pittige discussies gehad over de 
richting waarin mijn proefschrift moest gaan. Meestal kwamen we daar goed uit, maar ik ben 
blij dat ik toch af en toe mijn “poot” heb stijf gehouden. 
Ondanks mijn uitstapjes naar toch ook zo leuke onderzoekjes heb je mij steeds op het rechte 
pad gehouden. Hierbij was je altijd zeer gemotiveerd, betrokken en deskundig. Zoals je weet 
heb ik je kritische houding soms wel eens verfoeid, maar ik moet bekennen dat het resultaat 
altijd beter werd. Zonder jou was dit proefschrift er in de huidige vorm niet geweest. 
Ik heb je inbreng zeer gewaardeerd en prijs mij bijzonder bevoorrecht om met jou samen te 
hebben gewerkt en niet alleen in het kader van mijn proefschrift. Je hebt mij als een echte 
coach de mammapathologie meester laten maken. 
Ik vind het erg leuk dat je mij gevraagd hebt om samen met jou alweer een nieuwe studie te 
gaan doen. Je bevestigt hier maar weer mee dat het woord “pensioen” in jouw woordenboek 
niet voorkomt. 
 
Beste André, als tweede promotor wil ik je bedanken voor je zeer gewaardeerde inbreng. 
Verscheidene malen hebben we zeer nuttige discussies gevoerd en heb je mij wegwijs 
gemaakt in de statistiek. Je was een onmisbare schakel in het onderzoekstraject waarbij je met 
je relativerende manier van denken mij op het goede spoor hield. Je inspanningen aan het toch 
moeilijke eind van de rit heb ik zeer gewaardeerd. Ik hoop dat we in de toekomst nog vele 
zaken samen zullen uitvoeren. 
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Beste Vivianne, jij hebt je als derde promotor danig van je taak gekweten. Ik waardeer je 
snelle, adequate, deskundigheid en “to the point” benadering en wil je hiervoor hartelijk 
bedanken. Ondanks dat je nu in Maastricht zit zijn er nog verschillende zaken die we samen 
tot een goed eind moeten brengen en dat doet mij deugd. 
 
Ook wil ik alle medeauteurs van de vele al gepubliceerde en enkele hopelijk bijna 
gepubliceerde artikelen bedanken voor hun bijdragen. Jullie staan niet voor niets bij de 
artikelen en ik wil jullie dan ook hartelijk bedanken voor jullie onmisbare inbreng. 
In het kader hiervan wil ik Nicoline Hoogerbrugge speciaal bedanken. 
Beste Nicoline, jij kwam met het idee om de histomorfologische kenmerken van het 
mammaweefsel bij hoogrisico patiënten uit te zoeken. Dit heeft geleid tot een aantal zeer 
goede publicaties en een hoofdstuk in een boek. Deze publicaties maken een relevant 
onderdeel uit van mijn proefschrift. Zonder jouw inbreng was mijn proefschrift niet zo fraai 
geworden. Ik wil je voor je enthousiasme, motivatie en grote betrokkenheid hartelijk 
bedanken. Ik heb onze samenwerking altijd zeer plezierig gevonden en hoop dat we nog vele 
zaken samen zullen doen. 
 
Zonder het enthousiasme van de medewerkers van de afdeling Epidemiologie en Biostatistiek 
was de statistische onderbouwing van mijn proefschrift niet zo solide geweest. 
Erik Brummelkamp; beste Erik, jou zeer nauwkeurige beheer van de database en de invoer 
van duizenden data heb ik zeer gewaardeerd. Ik wil je bedanken voor je onmisbare bijdrage 
aan mijn proefschrift. 
Huub Straatman; beste Huub, je hebt mij veel statistiek bijgebracht en je hebt enorm veel 
analyses voor mij uitgevoerd. Je hebt mij hierbij steeds bijgestuurd indien ik dreigde af te 
drijven. Door je deskundigheid en betrokkenheid bij mijn onderzoek heb je mij gestimuleerd 
en gemotiveerd. Mijn hartelijke dank hiervoor. 
Wim Lemmens; beste Wim, na het vertrek van Huub heb jij naadloos zijn functie in mijn 
promotieonderzoek overgenomen. Het was of je er vanaf het begin al bij was geweest. Ik wil 
je bedanken voor je snelle en deskundige inbreng in mijn proefschrift. 
 
De medewerkers van het Landelijk Referentie Centrum voor bevolkingsonderzoek op 
Borstkanker (LRCB). 
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Beste allemaal en vooral de secretaresses. Jullie hebben mij zeer goed geholpen met het 
opzoeken van alle dossiers die ik nodig had voor mijn onderzoek. Mijn hartelijke dank 
hiervoor. 
 
De medewerkers van de afdeling Histologie hebben de basis gelegd voor het tot stand komen 
van mijn proefschrift. 
Beste allemaal, nu nog werkzaam op de afdeling en diegenen die inmiddels naar elders zijn 
gegaan, ik wil jullie bedanken voor al die paraffineblokjes die jullie voor mij uit het archief 
hebben opgesnord, voor al die coupes die jullie voor mij hebben gesneden en gekleurd en het 
enthousiasme waarmee jullie dat steeds weer deden. Bedankt! Ik hoop onze altijd plezierige 
samenwerking nog vele jaren voort te zetten. 
 
Ook anderen binnen de afdeling Pathologie hebben een bijdrage geleverd aan mijn 
proefschrift. Ik wil de medewerkers van het patiëntenzorgsecretariaat, de afdeling 
immuunhistochemie en in situ hybridisatie en de obductieafdeling (Wim Janssen en Roel 
Westerhoff (†)) bedanken voor hun inzet. 
 
Collegae pathologen uit Den Bosch, Jan Broekman, Hans van der Linden en Hans Meijer; 
Beste Jan, Hans en Hans, bedankt voor het halve jaar dat jullie mijn patiëntenzorgtaken 
hebben waargenomen zodat ik een extra impuls kon geven aan mijn promotieonderzoek. 
 
Collegae pathologen Blok-1, Hans Bulten, Annemarie Grefte, Ton Hanselaar, Rina Aliredjo, 
Monika Looijen-Salamon en Uta Flucke. 
Beste allemaal, het was niet altijd gemakkelijk om de patiëntenzorg draaiende te houden, 
maar we hebben het toch steeds weer gered. 
Beste Hans en Annemarie, ik wil jullie bedanken voor jullie flexibiliteit ten aanzien van de 
patiëntenzorg de afgelopen jaren zodat ik zo nu en dan meer tijd kon vrijmaken voor mijn 
promotieonderzoek. 
Ik hoop, Hans, Annemarie, Monika en Uta, dat we samen nog een hele tijd zo door mogen 
gaan. 
Iris Nagtegaal; beste Iris, uiteraard hoor jij nu ook sinds kort bij Blok-1 en ik hoop dat onze 
samenwerking zeer vruchtbaar zal zijn. 
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Beste collegae pathologen van Blok-2 en Blok-3. Ik wil jullie bedanken voor jullie interesse 
in mijn vorderingen. Meerdere van jullie hebben een bijdrage geleverd door af en toe mijn 
patiëntenzorgtaken, vooral wat betreft de obductiepathologie, waar te nemen. Ik wil jullie 
hiervoor hartelijk bedanken. 
 
Voormalig hoofd van de afdeling Pathologie Dirk Ruiter en huidig hoofd van de afdeling 
Pathologie Han van Krieken. 
Beste Dirk en Han, ik wil jullie bedanken voor het faciliteren van mijn promotieonderzoek op 
de afdeling Pathologie van het UMC Sint Radboud. 
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Niemand kan zonder familie die je steunt en motiveert, ook als het weer eens niet meezit. 
 
Beste Pa en Ma, jullie hebben mij altijd gesteund en gezorgd dat ik datgene kon doen wat ik 
nodig vond om arts en later patholoog te worden. Ik wil jullie daarvoor hartelijk bedanken en 
ik hoop dat we samen nog vele leuke dingen zullen meemaken. 
 
Beste Ab, Yuri, Sasha, Bert, Sterre, Lennart, Isabelle en Noortje, jullie hebben altijd met 
interesse mijn vorderingen gevolgd en mij gesteund, bedankt hiervoor. 
 
Beste schoonpapa en schoonmama, u bent altijd geïnteresseerd en betrokken geweest bij mijn 
activiteiten als schoonzoon van uw jongste dochter. Ik heb dat zeer gewaardeerd en wil u daar 
hartelijk voor bedanken. 
 
Ook wil ik alle andere familieleden, vrienden en bekenden bedanken voor hun interesse en 
steun bij het tot stand komen van mijn proefschrift. 
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Beste / lieve Tim en Anita, jullie hebben mij hoop ik niet te vaak als vader gemist, al moet ik 
natuurlijk toegeven dat ik erg veel heb gewerkt. Anita zei niet voor niets al heel jong “papa 
wèke" als ik op mijn fiets stapte om naar mijn werk te gaan. 
Ik ben er heel trots op dat jij, Anita, nu wiskunde studeert aan de Radboud Universiteit 
Nijmegen en dat jij, Tim, al weer in de 5de klas van het VWO zit. 
Ik heb er alle vertrouwen in dat jullie een goede toekomst tegemoet gaan. Na mijn promotie 
zal ik meer tijd hebben om andere dingen te doen dan mijn werk en jullie mogen dan echt een 
deel van die tijd opeisen! 
 
Lieve Gerda, het is de afgelopen jaren niet gemakkelijk geweest. Maar, zonder jouw steun en 
geduld had ik het echt niet gered. Nu de promotie er eindelijk opzit zullen we zeker meer tijd 
voor elkaar hebben. Graag wil ik allerlei dingen samen met je gaan doen zonder die niet 
aflatende druk van mijn werk op mijn schouders. Ik hoop dat we samen nog zeer vele 
gelukkige en liefdevolle jaren zullen meemaken. 
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Curriculum Vitae 
_____________________________________________ 
 

Peter Bult werd op 11 februari 1963 in Leiden geboren. Zijn eerste tien levensjaren bracht hij 
door in Vegelinsoord, Friesland, waar hij ook naar de lagere school ging. Vervolgens woonde 
hij 5 jaar in Nijkerk en ging daar naar de lagere school en later naar Amersfoort naar de 
middelbare school. Daarna verhuisde hij naar Haren, Groningen, en volgde de rest van de 
middelbare school aan het Zernike College te Groningen alwaar hij in 1981 zijn VWO 
diploma haalde. Omdat hij uitgeloot werd voor de studie geneeskunde, ging hij (samen met 
zijn tweelingbroer Ab) een jaar biologie studeren in het Biologisch Centrum te Haren. Omdat 
hij het jaar daarop werd ingeloot voor de studie geneeskunde, ging hij alsnog geneeskunde 
studeren en wel aan de Universiteit van Groningen. In 1986 behaalde hij zijn 
doctoraalexamen. Vervolgens liep hij het grootste gedeelte van zijn coschappen in Ziekenhuis 
de Weezenlanden te Zwolle. In 1989 studeerde hij af als basisarts. Datzelfde jaar werd hij 
aangenomen voor de opleiding voor patholoog in het UMC Sint Radboud. Op 1 december 
1994 werd deze opleiding met succes afgerond en werd hij geregistreerd als patholoog. 
Gezien zijn grote interesse voor de mammapathologie en het vertrek van Roland Holland naar 
het Landelijk Referentiecentrum voor Bevolkingsonderzoek op Borstkanker nam hij de 
mammapathologie van Roland Holland in het UMC Sint Radboud over. Na 5 jaar nagenoeg 
alleen de mammapathologie te hebben gedaan werd in 1999 besloten om te reorganiseren en 
maakt hij sindsdien deel uit van Blok-1 met de huidige collegae Hans Bulten, Annemarie 
Grefte, Monika Looijen-Salamon, Uta Flucke en Iris Nagtegaal. Zij zijn gezamenlijk 
verantwoordelijk voor de longpathologie, gynaecopathologie, cytopathologie en 
mammapathologie. 
Peter is lid van de European Society of Mastology (EUSOMA), lid van de Nederlandse 
Vereniging voor Pathologie (NVVP), lid van de IKO mammatumor werkgroep, lid van de 
IKO werkgroep Pathologie en secretaris van de mammatumor werkgroep van het UMC Sint 
Radboud. 
Hij trouwde op 23 juni 1989 met Gerda Pol en kreeg samen met haar twee kinderen, Anita 
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